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Abstract 
 
Haemoglobinopathies are inherited disorders, typically detected during neonatal healthcare 
screening programmes. Haemoglobinopathies are characterised by either a reduction in the 
synthesis of the globin chains or by point mutations in the globin gene often leading to a 
single amino acid substitution in the globin chain. Current screening techniques analyse 
samples from resolubilised dried blood spots (DBS) by HPLC and/or isoelectric focusing. 
These methods are characterised by lengthy sample preparation and/or ambiguous variant 
determination. Further analysis is required for unequivocal diagnosis. The work presented 
here describes a method for the unambiguous diagnosis of haemoglobin variants in 
neonatal DBS samples using a surface sampling technique called liquid extraction surface 
analysis (LESA) coupled with high resolution top-down mass spectrometry. LESA allows 
DBS samples to be sampled directly and the material recovered to be directly 
electrosprayed into a mass spectrometer. Both the sampling and MS/MS (CID/ETD) 
parameters were optimised to yield maximum globin chain sequence coverage (up to 81 
%) allowing for the unambiguous diagnosis of common Hb variants such as HbS and so-
called unknown variants (variants unable to be diagnosed during the standard screening 
protocol). The LESA sampling technique has also successfully been applied to study Hb 
non-covalent interactions.      
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Chapter 1: Introduction 
 
Overview 
 
Abnormalities of haemoglobin, haemoglobinopathies, are the most common type of 
inherited disorder. Haemoglobinopathies including HbS which is responsible for sickle cell 
disease are typically detected during population wide neonatal healthcare screening 
programmes. Current screening techniques analyse samples from resolubilised dried blood 
spots (DBS) by HPLC and/or isoelectric focusing. These methods are characterised by 
lengthy sample preparation and/or ambiguous variant determination. Further analysis by 
either DNA sequencing or mass spectrometry (MS) analysis is required for a definitive 
diagnosis. 
Tandem mass spectrometry (MS/MS) is the standard technique used in newborn screening 
for inherited metabolic disorders such as phenylketonuria. For convenience, it would be 
advantageous to use the same technique to screen Hb variants as well. Mass spectrometry 
accurately determines the m/z of globin chains, pinpoint the precise location of a variant 
without the need to perform any further confirmatory analysis. For this reason MS has 
been studied has an alternative to the current screening method. However, mass 
spectrometery-based screening techniquuies have been typically categorised by lengthy 
sample preparation (including resolubilisation of the dried blood spot (DBS), tryptic 
digests, removal of salts from the sample and HPLC-MS coupled runs) and often the 
inability to diagnose Hb variants with very small mass shift.
2 
 
The aim of the work presented in this thesis is to assess the viability of liquid extraction 
surface analysis (LESA) of DBS coupled with top-down mass spectrometry for the 
diagnosis of a variety of Hb variants in neonatal samples.   
1.1 Mass Spectrometry 
 
The origin of mass spectrometry (MS) as an analytical technique occurred over a century 
ago when J.J. Thomson built an apparatus that could measure e/m (charge to mass ratio) of 
an electron. Two years later, he developed an instrument that could simultaneously 
measure e/m and e from which the mass of an electron could be determined and for this 
discovery he was awarded the Nobel Prize in Physics in 1906 [1]. In 1912 Thomson along 
with F.W. Aston introduced what is widely acknowledged as the first mass spectrometer 
and which could measure the mass of charged molecules [2]. Since then biological mass 
spectrometry has undergone a revolution, principally due to the development of the soft 
ionisation techniques electrospray ionisation (ESI) [3] and matrix-assisted laser desorption 
ionisation (MALDI) [4]. These developments removed the restrictions to the molecular 
weight and type of samples that could be analysed, making MS the technique of choice 
across a variety of disciplines. 
Mass spectrometers consist of three fundamental components: an ion source, a mass 
analyser and a detector. Ions are separated according to their mass to charge ratio (m/z) by 
measuring the response of an ion’s trajectory to electric and/or magnetic fields under 
vacuum [5].  
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1.2 Ionisation  
 
In electron impact/electron ionisation (EI), a beam of electrons are formed from a heated 
metallic filament, accelerated by an electric field and collided with a vaporised sample 
causing electron expulsion from the analytes and the subsequent formation of positively 
charged radical cations M
+∙ [6]. EI is an energetic process responsible for extensive and 
reproducible in-source fragmentation. This is advantageous in structural elucidation and 
compound identification studies where comparisons are made with reference spectra, 
however, due to the excessive fragmentation the molecular ion is often absent rendering 
the technique unsuitable for molecular weight determination [7]. Chemical ionisation is an 
alternative ionisation technique in which ions are produced through the collision of the 
analyte molecules (added at low pressure) with reaction gas molecules [8]. Fast atom 
bombardment (FAB) is a technique that was developed in 1981 [9] with the aim of 
overcoming some of the problems associated with the ionisation of biological samples, 
namely their non- volatility and large molecular weights. The process involves the 
interaction of the sample dissolved in a non- volatile liquid matrix such as glycerol with a 
high intensity molecular beam of a neutral gas (argon). Energetic particles hit the sample 
solution producing a spluttering effect (momentum transfer from Ar ions to the target 
sample) which ejects positively and negatively charged ions from the solution [10]. The 
technique allows for the analysis of thermally labile biological molecules up to about 25, 
000 Da producing mainly singly charged ions which places limitation on the mass analyser 
that can be used [11].  
Matrix- assisted laser desorption ionisation (MALDI) was established in the late 1980s by 
Karas and Hillenkamp [4] and Tanaka [12]. For the first time, it allowed for the 
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measurement of intact proteins larger than 25,000 Da [13]. It is also a soft ionisation 
technique meaning the process itself results in little or no fragmentation. The key feature in 
the MALDI ion generation process is the presence of an organic matrix which is present in 
excess with comparison to the sample. The sample is dissolved in the matrix solvent. The 
mixture is dried and the matrix which strongly absorbs (N2) laser wavelengths, is co-
crystallised with the sample. The analyte molecules are completely separated from one 
another by the matrix molecules. Under vacuum, irradiation of the crystalline sample 
causes the crystals to heat up rapidly due to the excitation of the matrix molecules which 
causes an accumulation of energy. This heating causes sublimation of the crystal surface 
and expands the matrix into gas phase along with the analyte into the expanding matrix 
plume.  
1.2.1 Electrospray ionisation  
 
Electrospray ionisation (ESI) was originally proposed in the 1960s by Malcolm Dole [14] 
and was developed further by John Fenn [15] for which he was awarded a Noble prize in 
2002. An ESI source creates ions through the nebulization of a solution phase sample into 
electrically charged droplets from which ions are released. A typical ESI solution suitable 
for protein/peptide analysis consists of water with the addition of an organic solvent which 
aids the ESI process (increases ionisation efficiency) as it decreases the surface tension. In 
positive mode formic acid is also added for protonation [16].  
The process begins by the mechanical injection of a solution through a stainless steel 
needle or capillary under atmosphere pressure at a flow rate of between 1 and 20 μl/min. In 
positive mode electrospray a high voltage of 3-6 kV is applied. The resulting electric field 
leads to positive charge accumulation at the tip. The repulsion between the positive ions 
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accumulated at the tip overcomes surface tension causing an expansion of the emerging 
liquid [17, 18] forming a Taylor cone [19]. In the presence of a suitably high electric field 
a fine jet arises from the cone which then breaks into small charged droplets [20]. See 
Figure 1.1. 
At ambient temperature the charged droplet travels towards the counter electrode during 
which the droplet decreases in size due to solvent evaporation. The charge density of each 
droplet increases until the Rayleigh limit is reached. Coulomb repulsion between charges 
overcomes surface tension breaking the droplet apart (Coulomb fission) producing smaller 
daughter droplets. This sequence of events continues to repeat itself causing fission of the 
daughter droplets formed [21], producing very small, highly charged droplets.  
Two mechanisms have been proposed to describe how gas-phase ions are formed from 
these small highly charged droplets. The first mechanism, termed charged residue model 
(CRM), was suggested by Dole [14].  It states that the gas phase ions of globular proteins 
are produced from very small droplets that only contain one macromolecule, so called 
ultimate droplets.  
As the ultimate droplet completely evaporates  the small ions on the surface of the droplet 
transfer to the macromolecule, providing the macromolecule with a charge [22].  The 
second mechanism is termed ion evaporation model (IEM) and was proposed by Iribarne 
and Thomson [23] whose studies were conducted on small analytes. The IEM proposes 
that direct ion emission occurs when an electric field at the surface of the droplet with a 
radius of 10 nM or less has become suitably high. Ion evaporation in these droplets is 
faster than Coulombic fission. An assumption is made that the evaporating ion is a charge 
located at the surface of the droplet. The emitted ion is repelled by the remaining charges 
on the droplet pushing the ion into the ambient gas forming a gas-phase ion [20, 24].  
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Figure 1.1. The electrospray ionisation process showing the formation of small highly 
charged droplets.   
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ESI is an effective so-called soft ionisation technique because the transfer of analyte ions 
from the solution to the gas phase is a non-energetic process therefore the structure of 
analyte ions remains intact (no fragmentation). ESI can produce multiply charged ions of 
biomolecules with large molecular masses due to the increased amount of proton accepting 
(or realising) sites. This is advantageous as it means mass analyzers with a relatively small 
m/z range (up to m/z 3000) are capable of accurately determining the mass of large intact 
proteins [16]. Reduction in the efficiency of the ESI process is caused by high sample 
concentration (above 10
-5
 M) [25] and ion suppression (which is produced by the presence 
of salts/drugs or molecules with larger masses in the ESI solution that produce a greater 
signal than the analyte of interest which is less readily ionised) [26]. The development of 
nanoelectrospray helped alleviate some of these issues, subsequently making the technique 
even more widely used. 
1.2.2 Nanoelectrospray  
Nanoelectrospray (nano-ESI) uses a smaller capillary (often made of fused silica) with an 
inner diameter of approximately 1 μm resulting in the formation of smaller droplets. The 
smaller droplet size is responsible for the reduction in contaminants such as salt observed 
during nano-ESI. The initial droplets are often 1000 times smaller than the initial droplets 
formed by standard ESI reducing the number of solvent evaporation (which would 
increase the concentration of the salt/analyte) and Coulombic fission steps required for the 
generation of the ions, consequently reducing the concentration of the contaminants and 
increasing  the sensitivity of the analytes [27]. In ESI analyte sample flow rate through a 
capillary is typically a few μl/min. The application of nano-ESI, with flow rates of nl/min, 
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reduces sample consumption meaning very low sample volumes are sufficient for analysis 
[28]. Henion et al. [29, 30] have developed an automated nano-ESI system for sample 
infusion. It allows for automated high throughput sample analysis with increased spray 
stability. A robotic probe (Triversa NanoMate) controlled by ChipSoft (Advion) software 
picks up a disposable pipette tip to collect the sample from a well of a standard 96-well 
plate and then positions the pipette tip containing the sample flush with the inlet of ESI 
chip (which is composed of 400 silica based nozzles/capillaries). A spray voltage (kV) and 
nitrogen gas pressure (psi) is applied to the sample in the tip which initiates the nano-ESI 
process. Once sample infusion and analysis is complete the tip is automatically discarded. 
The next sample to be analysed uses a fresh tip and nozzle. The system of one tip and one 
nozzle per sample eliminates sample carry over.    
1.2.3 Desorption electrospray ionisation  
 
In 2004 Cooks et al. introduced an alternative ambient ionisation technique desorption 
electrospray ionisation (DESI) [31]. Ionized solvent droplets created by the electrospray 
ionization (ESI) source are directed at a sample surface of interest. The charged solvent ion 
droplets from ESI source impact with the sample surface. The ions bounce off the surface 
and are transported to the mass spectrometer via the inlet capillary of an atmosphere 
pressure ion transfer line. The precise mechanism is not fully known but is believed to 
occur because the initial droplets that have been electrosprayed onto the sample pre-wet 
the surface, causing surface analytes to dissolve in a localised solvent layer. Subsequent 
droplets impact with and disturb this solvent layer emitting secondary droplets which 
contain dissolved analytes from the sample surface. Therefore analyte desorption occurs 
due to the momentum transfer from charged droplets that are the ionised by ESI [32]. 
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DESI produces similar mass spectra to those of ESI. This technique has been used in a 
number of applications such as: in vivo sampling of living tissue surfaces, imaging to 
determine the spatial distribution of compounds across a sample surface, such as a 
fingerprint [33]. The development of this technique has triggered interest into a range of 
techniques know as ambient surface sample techniques (ionization occurs at atmosphere 
pressure) and their associated ionization techniques [34].  
1.2.4 Liquid extraction surface analysis  
 
The development of liquid microjunction-surface sampling probe (LMJ-SSP) latterly 
termed liquid extraction surface analysis (LESA) (Advion Biosciences) is a technique that 
has reported applications on a wide variety of samples including drugs captured in solid 
phase extraction cards and compounds such as metabolites from thin tissue sections [35]. It 
is performed using a combined surface sampling probe and an electrospray emitter, such as 
the Advion Triversa Nanomate [29]. A key feature of liquid extraction surface sampling is 
the formation of the probe-to-surface liquid microjunction. A robotic probe (solvent flow 
channel) is positioned an appropriate distance from the sample surface, the ESI solvent is 
dispensed on the sample surface and a wall-less liquid microjunction is formed by 
dispensing the liquid (electrospray solvent) from the sample extraction/dispensing end of 
the probe and onto the sample surface. There is often a small delay time of a few seconds 
where the LMJ is maintained allowing for species on the surface dissolved by the 
electrospray solvent are drawn back into the probe. The surface analytes are then 
electrosprayed into a mass spectrometer. The technique can theoretically be performed 
with any probe capable of both dispensing and recovering solution from the sample 
surface. LESA has been investigated has a tool in large scale proteomic studies in recent 
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work by Quanico et al. [36]. It describes a protocol consisting of a direct on tissue digest, 
followed by LESA and instead of direct sampling into a mass spectrometer; the extracted 
sample is collected and then subjected nanoLC-MS/MS. This allowed for the identification 
of 1500 proteins.    
1.3  Mass analysers   
 
There are five major types of mass analyser: quadrupole, time-of-flight (TOF), ion trap 
(IT), Fourier transform ion cyclotron resonance (FT-ICR) and orbitrap analysers. Each of 
the analysers has different characteristics regarding mass accuracy, m/z range, sensitivity 
and scanning speed. To take advantage of their differing characteristics often multiple 
analysers are coupled together to create hybrid instruments such as a quadrupole-TOF or 
ion trap-FT-ICR [37]. The mass analysers used in this work are presented below.  
1.3.1 Ion traps  
 
An ion trap uses an oscillating electric field to store ions and a radio frequency (RF) 
quadrupolar field to trap ions in either two dimensions (linear ion trap) or three dimensions 
(quadrupole ion trap). Quadrupole ion traps (QIT), known as Paul traps, consist of a 
central ring electrode positioned between two ellipsoid end cap electrodes. The upper cap 
electrode has an inlet to allow ions to enter the trap from the source and the lower cap 
electrode has an inlet to allow ions to exit trap and reach the detector, figure 1.2. Inside the 
trap, ion repulsion results in an expansion of its trajectory. Helium gas (10
-3
 Torr) present 
in the trap eliminates the ions’ excess kinetic energy preventing ion escape through 
trajectory expansion directing the ions towards the centre of the trap, trapping the ions in 
the presence of RF potential [38, 39]. Ions are ejected sequentially from the QIT by the 
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linearly ramping the amplitude of the RF potential that is applied to an electrode. Ions of 
the same species are ejected from the trap at specific RF amplitude, the m/z ratio for the 
ion species is determined from initial amplitude and ramping rate [40].  
In contrast a linear ion trap (LIT) on is made up of four parallel electrode rods with 
opposite electrodes possessing the same polarity. A quadrupolar field (RF) is used to trap 
ions radially and an electric field applied to the tip of the rods to trap ions axially. Ions are 
trapped along the z axis through the centre of rods when a balanced dipolar RF potential is 
applied to opposing rod pairs. Simultaneous ion oscillation in the xy plane occurs is due to 
the application of a RF voltage. Inside the LIT the ions collide with inert buffer gas with 
the purpose of reducing the ions’ kinetic energy and the DC voltage applied to the tip of 
the rods contribute to containing the ions inside the trap [41, 42]. Ions are either ejected 
axially following the presence of a so-called fringe field produced by applying an AC 
voltage between the rods and an exit lens [43] or by radial (perpendicular) ejection through 
application of an AC current to opposing rods with slots cut into them. The advantages of a 
LIT over a QIT include a greater ion trapping capacity and ejection efficiency [39].  
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Figure 1.2 Schematic of a 3D ion trap. 
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1.3.2 The orbitrap 
 
The recently developed orbitrap mass analyser is an electrostatic ion trap that utilizes an 
electrostatic field for ion trapping. It does not require RF or magnetic fields and uses 
Fourier transform to obtain mass spectra. It was originally proposed by Makarov in 1996 
[44]. The orbitrap, figure 1.3 consists of a thin-wire central electrode and an electrically 
isolated barrel- like outer cylindrical electrode. Ions are injected tangentially into the 
orbitrap after the voltage on the central electrode has been switched on but before the 
electrode has reached its target voltage. As a consequence the ions undergo what is known 
as electrodynamic squeezing because of the increase in electric field strength. Ions are 
squeezed towards the central electrode, responding with a reduction in the rotational radius 
which prevents unwanted collisions with the outer electrode. This initiates the ion packet’s 
oscillation along the z axis without the need for any additional excitation. Once the voltage 
incline ceases ion packet trajectories become a stable spiral. The ions all have the same 
amplitude but ions of different m/z ratios will oscillate along the z axis at a specific 
frequency [45, 46].  
 The direct current (DC) voltage is applied between the two axially symmetric inner and 
outer electrodes which creates an electrostatic potential. See equation 1.    
 (   )  
 
  
 (   
  
 
)  
 
 
 (  )
   (
 
  
)     
Equation 1 
In the equation r and z are cylindrical coordinates z = 0 is the axis of symmetry of the 
field, k is the field curvature, C is a constant and Rm is the characteristic radius [45].  
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The voltage gradient z (in the horizontal direction through the orbitrap) is defined in 
equation 2. 
 
  (   )
  
    
Equation 2 
An ion with a mass m and overall charge q=ze accelerates along the z axis as a 
consequence of the force induced by the electric field. This electric force –qkz is equal to 
mass times acceleration i.e m(d
2
Z/dt
2
). 
    
   
   
 
 
    
Equation 3 
Ion motion along the z axis is described as a harmonic oscillation, see equation 4, 
independent of both r and φ (φ is the angular coordinate). Ez is the energy characteristic in 
the z direction.  
    (
 
 
) (
   
  
)2 
Equation 4 
The solution to equation 3 is  
 ( )            √           
Equation 5 
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Whereby  
   √(
 
 
)   
Equation 6 
The information shown in equation 6 shows frequency of axial oscillations is proportional 
to the m/q ratio independent of the kinetic energy of the injected ions. Detection of the ions 
requires a signal voltage that is induced by the oscillations of the ions. The signal (the 
image current) is detected by the Orbitrap analyser’s outer electrodes. The ions are 
observed for a time period, often several seconds. This time domain signal (transient) is 
composed of sinusoids of the frequencies of the measured ions at intensities corresponding 
to the amount of the molecular species in the sample  [39, 47]. The acquired image 
signal/transient is converted from the time domain into a frequency spectrum by applying a 
fast Fourier transform algorithm [48]. The frequency components are then calibrated 
andsubsequently converted into a mass spectrum [49, 50].  
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Figure 1.3 A schematic of an Orbitrap Velos mass spectrometer used in this work. 
(Thermo Scientfic).  
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Figure 1.4. (Left) A schematic of a time domain frequency transient and (right) a mass 
spectrum. 
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1.4 Tandem Mass Spectrometry      
 
Tandem mass spectrometry (MS/MS) is the process in which an ion is characterised 
according to its fragments. Following generation in an ion source (e.g. by ESI) an ion is 
selected in MS
1
 then fragmented, then product ions are analysed in MS
2
 [51]. The 
fragmented ions are displayed as a mass spectrum [52].  
1.4.1 Collision induced dissociation 
 
Collision induced dissociation (CID) also known as collisional activated dissociation 
(CAD) was first described by McLafferty [53] and Jennings [54]. CID involves the 
collision of the ion with non-reactive gas molecules such as helium or nitrogen [55]. Upon 
collision, a portion of the ion’s kinetic energy is converted into internal vibrational energy. 
This is termed the activation/ excitation stage. The resultant bond breakage is known as the 
dissociation stage. CID is a slow activation method where the activation stage is longer 
than the dissociation stage. The slow activation stage involves multiple discrete reactions 
that give time for other processes to occur, including deactivation events. Competition 
between activation and de-activation events results in distribution of internal energy 
throughout the ion causing cleavage of the most labile bonds. In peptides, this tends to be 
the amide N–CO bond [56, 57] resulting in a series of N-terminal b and C-terminal y 
fragment ions [58], see figure 1.5. During CID the most labile bond is preferentially 
cleaved [59].  
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Figure 1.5. Schematic of the b and y fragment ions  formed by collision induced 
dissociation. 
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1.4.2 Electron capture dissociation   
  
 Electron capture dissociation (ECD) was developed by Zubarev et al. in 1998 [60]. 
Multiply charged peptide ions are irradiated with a beam of low energy electrons (< 0.2 
eV) dispensed by a cathode. The result is electron capture (e
-
 ) by the multiply charged ion 
producing a radical charge-reduced species which then dissociates [39]. Peptide 
fragmentation occurs along the backbone N-Cα bond producing a series of informative N-
terminal c and C-terminal z
 
fragment ions. During the fragmentation process transfer of a 
hydrogen atom often occurs leading to the formation of additional fragments c
• 
and z 
fragment ions (figure 1.5) [57, 61]. In contrast to CID the most labile bond is not the 
favoured site of fragmentation. One advantage of this behaviour is that it results in the 
retention of post-translational modifications and therefore the ability to determine the site 
of modification [62].  
The precise mechanism of the production of fragment ions by ECD is subject to much 
debate. Two proposed mechanisms, the Cornell mechanism [60] and the Utah-Washington 
mechanism [63, 64] are considered the most likely candidates. The Cornell mechanism 
states that following electron capture to high-n Rydberg state, the electron is localized to 
protonation site forming a hypervalent radical. Transfer of a hydrogen atom from a –NH3
+
 
group to an amide oxygen results in the cleavage of the nearby N-Cα bond [65]. The Utah-
Washington mechanism proposes that following its capture an electron is localised to the 
amide π* orbital increasing the amide bond’s basicity. This results in proton abstraction 
from a proximal amino acid side site resulting in the formation of an aminoketyl radical 
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that undergoes dissociation by cleavage of the [64, 66]. The beam of low energy electrons 
used in ECD require a high vacuum therefore standard ion trap vacuum is insufficient 
limiting ECD to mainly FT-ICR mass analysers [16]. 
      
1.4.3 Electron transfer dissociation   
 
Electron transfer dissociation (ETD), first described in 2004 by Syka et al. [67], is an 
ECD- like dissociation technique suitable for use in instruments with reduced vacuum 
specifications, such as an ion trap [68]. In this work ETD has been performed on a Thermo 
Scientific LTQ Orbitrap Velos. The multiply charged analyte ions are injected into the 
linear trap for precursor cation isolation [69]. The ETD reagent radical anions (e.g 
anthracene) are generated in the CI source and are transferred into the linear trap via RF-
only ion guides (transfer multipoles), the gas-filled HCD collision cell, and the C-Trap. 
The reagent ions pass a quadrupole mass filter between C-Trap and linear trap. Like ECD 
the initial capture of an electron by a multiply charged ion occurs at an amide carbonyl 
group that is hydrogen bonded to a protonated basic amino acid side chain. The radical 
anion then abstracts a proton and generates an amino-ketal radical site which triggers 
dissociation into a series of ECD analogous c and z type fragment ions. The resulting 
product ions are analyzed in either the linear ion trap or when an increase in mass 
resolution and accuracy is required, in the orbitrap [70]. 
1.5 Mass spectrometry-based proteomics  
 
In the post-genomic era DNA sequence information has been collected for entire genomes, 
including the human genome [71, 72]. However defining the function of each protein 
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encoded by the genes is more challenging. The human proteome is diverse and complex. 
The same protein may have several different functions, alter in disease state and undergo 
dynamic post-translation modifications. A conservative estimate put the total number of 
proteins between 60,000 and 70,000 but including post-translational modifications the 
number could reach 700,000 [16]. Changes in the composition of proteins may yield 
disease pathology information and biomarker discovery. Proteomics is the global analysis 
of all the proteins in a cell, tissue or organism. The analysis of complex protein-laden 
samples by mass spectrometry has become the method of choice [37]. The vast majority of 
proteomic experiments are completed using a bottom-up proteomic work flow. 
1.5.1 Bottom-up proteomics  
 
Bottom-up proteomics is the established high-throughput method used in protein 
identification. In a gel based approach, proteins in complex biological samples are often 
separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) or 
2-dimensional gel electrophoresis (2D-GE). The gel is stained with either coomassie 
brilliant blue [73] or silver staining [74] to locate the proteins. Bands are cut out, the gel 
digested with an enzyme (e.g. trypsin), producing numerous short peptides. The short 
peptides are separated by online reverse phased high-pressure liquid chromatography 
(HPLC) MS and MS/MS (CID) analysis. Removal of containments such as detergents, 
staining and salts by dialysis an important step in the preparation of complex biological 
samples such as plasma or urine for MS analysis [75]. Very complex samples such as 
whole cell lysates often require an extra separation step (2D LCMS/MS), strong cation 
exchange (SCX) chromatography, prior to online HPLC [76]. The obtained CID spectra 
are searched against protein databases such as MASCOT [77] and SEQUEST [78] which 
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contains lists of peptides generated by in-silico digestion of known proteins. A probability 
score, based on sequence coverage obtained and mass accuracy is given for each 
peptide/protein identified to assess the likelihood of its presence in the sample. An 
alternative non-gel based approach involves the digestion of a mixture of proteins in a 
solution. This is often coupled with peptide labelling techniques such as isotope-coded 
affinity tag (ICAT) [79] or stable isotope labelling by amino acids in cell culture (SILAC) 
[80] to study protein expression [81].   
1.5.2 Top-down proteomics  
 
Top-down proteomics is the measurement of the molecular weight of intact protein ions 
and direct fragmentation of gas-phase protein ions [82]. Top-down proteomics is often 
performed with ESI which produces intact multiply charged gas-phase ions coupled with 
high-resolution mass spectrometers. The high mass accuracy is vital for the accurate 
assignment of large multiply charged intact protein ions [46]. Top-down proteomics 
usually involves the isolation of a single protein or small number of proteins from a protein 
rich complex sample. The protein sample is then either further separated by online reverse 
phase HPLC or directly infused into the mass spectrometer [83]. Top-down methodology 
[84, 85] removes the need for lengthy proteolysis and addresses the problems of 
‘information loss’ inherent in bottom-up approaches [86]. There is no loss of regions of the 
protein due to poor ionisation or confusion due to the presence of isomeric peptides.  
The potential of top-down proteomics was first demonstrated by Loo et al. [87] in 1990 
where intact multiply charged bovine ribonuclease A (14 kDa) was fragmented by CID 
resulting in a series of sequence specific product ions. The same group demonstrated top-
down MS with a significantly larger intact protein serum albumin (66 kDa) from a variety 
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of species including bovine and human. However, sequence assignment is restricted to the 
first 30 amino acid residues of the N-terminus and first 10 of the C-terminus due to the 
limited m/z range and sensitivity of the mass analyser used [88]. Top-down proteomics 
results in the generation of complex spectra that requires lengthy manual interpretation.  
Extensive work led by Kelleher et al. since 1996 [89] focuses on the development of a 
suitable database capable of identifying intact proteins by matching MS/MS against 
sequence databases to aid with spectra interpretation. MS/MS spectra of intact bovine 
ubiquitin (8.6 kDa), human muscle creatine kinase (43 kDa), bovine carbonic anhydrase B 
(29 kDa) and chicken cyctochrome C (12 kDa) where trialled in the study. Results showed 
identification of proteins from intact MS/MS data was possible. It also showed the 
importance of high resolution (high mass accuracy) Fourier transform mass spectrometry 
(FTMS) data for such identifications. The study demonstrated the effectiveness of the web-
based ProSight PTM software for the automatic identification of single proteins and 
protein mixtures including those with post translational modifications [90, 91] from top-
down MS and MS/MS spectra. Currently ProSight PTM is viewed as the most effective 
software available for the analysis of top-down data [92]. 
1.6 Haemoglobin and its variants 
 
Adult haemoglobin (HbA) exists as a tetramer of non-covalently bound globin chains, 
consisting of two α- and two β- subunits each containing a single oxygen binding heme B 
complex with an iron atom at its core (Figure 1.6). HbA has a total molecular weight of 68 
000 Da. Foetal haemoglobin (HbF), with its increased oxygen affinity, is composed of two 
α and two γ subunits (α2γ2). The gamma subunits are homologous to the β chain, differing 
by 39 amino acids. Foetal haemoglobin is usually present in the blood until six months 
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after birth. The γ subunits comprise of one Aγ and one Gγ which corresponds to the amino 
acid at position 136 in the globin chains
 
(
Aγ an alanine and Gγ a glycine) [93].  
Abnormalities of haemoglobin, haemoglobinopathies, are the most common single gene 
recessive disorder with approximately 269 million carriers worldwide [94]. 
Haemoglobinoapthies are classified into two major types; Thalassemias which are 
characterised by a reduction in the synthesis of the globin chains and structural 
haemoglobin variants which are caused by point mutations in the globin gene typically 
leading to a single amino acid substitution in the globin chain. There are over 1000 Hb 
variants [95] classified and in the majority of cases occur on the β chain are clinically 
silent. The most well-known structural Hb variant is the sickle variant, HbS [96].  
In the 1950s Ingram was the first to demonstrate that HbA differed from HbS by just a 
single amino acid substitution, a glutamic acid for a valine [97] (Δm -29.9745 Da) which is 
a consequence of a single substitution (GTG for GAG) on the sixth codon of the β globin 
chain. The heterozygous inheritance of the sickle variant (HbAS), sickle trait/ carrier 
results in mild complications. The phenotypic consequences of inheriting HbS variant in 
homozygous form is sickle cell disease (SCD) with all the serious clinical complications 
associated with the disease [98]. Sickle cell disease affects the oxygen-carrying capacity of 
red blood cells. Patients with sickle cell disease experience reduced life spans [99] and 
15% of young children with sickle cell disease die due to acute infections and other sickle-
related complications. The rapid detection of sickle cell disease dramatically reduces 
mortality rates [100]. Clinical complications include vaso-occlusion, caused by the 
characteristic sickle-shaped red blood cells obstructing blood vessels leading to ischemic 
damage. An increase in the risk of infections especially in infants is caused by infarction of 
the spleen and the subsequent decrease in splenic function, is also observed [101]. There is 
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no cure for SCD. Some studies suggest that penicillin prophylaxis reduces the rate of 
infections and mortality rate in infants from infection related complications [102, 103].  
Another sickling disorder, sickle cell haemoglobin C (HbSC) disease is caused by the 
inheritance of HbS from one parent and HbC (substitution of a glutamic acid to lysine, also 
at position 6 on the β chain Δm = -0.9476 Da) from another. The phenotype for the HbSC 
variant is variable, it is generally expressed as a milder form of sickle cell anaemia 
requiring medical intervention and careful monitoring although in some cases it can be 
equally/more severe than HbSS [104-106]. Patients with SCD experience reduced life-
spans, typically mid 40s [107]. Rapid diagnosis during newborn blood screening 
programmes which allow for the implementation of a suitable healthcare strategy has been 
credited with the ability to reduce childhood mortality in SCD and SCD-related disorders 
[108, 109]. Haemoglobin C disorder requires both abnormal genes, HbCC (homozygote), 
whereas trait, HbAC (heterozygote), is asymptomatic. Symptoms of the disease state 
include mild/ moderate anaemia and haemolysis [110].  
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Figure 1.6. The structure of haemoglobin. The red ribbons represent the α- globin chains, 
blue ribbons represent β- globin chains and the green represent the heme groups. Image 
courtesy of PDB and PDB ENZYME. 
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The haemoglobin D variant is a caused by a mutation on the β chain at position 121 
(glutamic acid for a glutamine), also resulting in a mass shift of less than -1Da (Δm = 
0.9840 Da). Haemoglobin D (HbAD) trait (heterozygote) again causes no clinical 
manifestations but if co-inherited with sickle (HbSD) causes considerable sickle-like 
health problems. In its homozygous state HbD causes haemoglobin D disease which 
manifests as mild to moderate anaemia [111, 112]. 
HbE is another common variant occurring on the β chain position 26, a glutamic acid 
substituted for a lysine, resulting in a mass shift of Δm 0. 9476 Da. HbE inherited in 
homozygous or heterozygous form is asymptomatic, however inherited in combination 
with β thalassemia (HbE/β thalassemia) can result in severe anaemia [113]. Hb variants 
with significant clinical outcomes, such as homozygous sickle cell disease, have a 
prevalence rate of 1 in 2000 births [114]
,
[115]. Over a two year screening period 17,000 
carriers (heterozygous for Hb variants) were identified from almost 1.2 million infants 
[115]. 
 
1.7 Newborn screening 
  
Annually the UK newborn screening programme screens ~700 000 neonates for five 
genetic disorders; PKU, congenital hypothyroidism (CHT), cystic fibrosis (CF), medium 
chain acyl-CoA dehydrogenase deficiency (MCADD) and sickle cell disease (SCD)[116]. 
SCD has the highest prevalence of all the disorders screened for by the NHS in England 
with a rate of 1 in 2000 [117]. The term SCD refers to a set of disorders characterized by 
the inheritance of the structural variant haemoglobin S (HbS). SCD also includes 
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compound heterozygotes disorders whereby one HbS variant has been co-inherited with 
another haemoglobinopathy for example HbC, HbE or HbD Punjab/ Los Angeles [118]. 
Clinical significance of these compound heterozygote variants differ. For example HbSE 
syndrome is uncommon and the vast majority of patients experience no sickle-like 
symptoms. Rarely symptoms may develop requiring medical assistance [119]. The 
compound heterozygotes HbSD- Punjab/ Los Angeles and the rare HbSO-Arab (β121 
Glu→Lys Δm -0.9476 Da) phenotypes are severe with a similar pathology to HbSS [120]. 
Neonatal screening for the sickle variant allows for early detection, appropriate genetic 
counselling and treatment to reduce deaths from sickle related complications [121, 122]. 
As well as screening for the sickle variant the NHS newborn screening programme 
requires that methods used in the screening process must be able to reliably detect the 
following clinically significant structural haemoglobin variants:  HbC, HbD Punjab/ Los 
Angeles, HbE and HbO-Arab [123]. Inheritance of these variants (without HbS) in either 
heterozygous or homozygous state is usually clinically benign.  
The current screening protocol for haemoglobinopathies uses blood samples collected by 
midwives via heel prick onto standard NHS Guthrie (dried blood spot) cards from neonates 
between 5-8 days old. The initial labour intensive stage in the screening process involves 
manually punching out small discs (approx. 3 mm in diameter) from the dried blood card 
and eluting the sample for around 30 mins [124]. The samples are usually analysed by 
cation exchange high-performance liquid chromatography (ceHPLC) and/or isoelectric 
focusing (IEF) [125]. IEF results are interpreted by comparison with known standards. 
Samples that merge or are insufficiently focused require repeating [126] and IEF is unable 
to separate some Hb variants [127]. ceHPLC detects Hb variants by comparing the 
characteristic retention time of HbA to any deviations from the retention time, 
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problematically some variants co-elute [128]. Separation of Hb variants has also recently 
been reported using a technique called capillary electrophoresis (CEP) [129, 130]. These 
methods involve lengthy sample preparation and identification of an Hb variant these 
methods are presumptive. Conclusive diagnosis of an Hb variant can only be determined 
by second line testing with DNA analysis (sequencing) or amino acid analysis (mass 
spectrometry) [131].    
 
1.8  Mass spectrometry and haemoglobin variant analysis  
 
Tandem mass spectrometry (MS/MS) is now the standard method for PKU and MCADD 
screening in the newborn dried blood spot screening programmes [132]. Logically also 
using this technique as first line test to screen for haemoglobinopathies without the need to 
perform any further confirmatory analysis would reduce work flow in newborn screening 
laboratories. MS/MS is able to diagnose Hb structural variants accurately measuring the 
monoistopic mass of intact globin, digested or fragmented peptide chains 
Analysis of Hb and variant globin chains by mass spectrometry was first described in 1981 
by Wada et al. [133] using field desorption ionisation. Whole blood samples were purified 
by chromatography and the heme groups removed by addition of acetone. The globin 
chains were separated by further chromatography and a trypsin digest was performed to 
yield a series of sequence informative shorter peptide chains. Detection of Hb variants 
with large mass shifts on both the α-globin (Hb Boston α58 His→Tyr, Δm + 26.0044 Da) 
and the β-globin (HbS and Hb Genova (β28 Leu → Pro, Δm -16.1066 Da) was  
demostrated.  
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In the early 1990s, Witkowska and co-workers [134, 135] applied a combination of 
electrospray ionisation (ESI), liquid secondary ion mass spectrometry (LSIMS) [136] 
ionisation and tandem mass spectrometry (MS/MS) to the analysis of haemoglobin 
variants in whole blood samples. Sample preparation was a lengthy process, it involved the 
lysis of red blood cells combined with two separate chromatography steps and 
aminoethylation of cysteine residues and an overnight trypsin digestion. ESI of the intact 
globin chains enabled preliminary detection of the Hb variants. Data were collected by use 
of a low resolution quadrupole mass spectrometer. The results suggested that variants 
separated by greater than 14 Da could be diagnosed from examination of the intact globin 
molecule. For mass shifts < 14 Da, and to determine the site of the substitution, HPLC 
fractionation followed by LSIMS analysis of the tryptic peptides by CID was performed 
[53, 54].  
Wild et al. [137] described a two-stage protocol for identifying Hb variants using  
electrospray ionization mass spectrometry. The procedure used a 1 in 50 fold dilution of 
whole blood which was then de-salted. In the first step, the intact globin chains are 
analysed and the variant containing globin chain was identified by a difference in the 
expected molecular weight. These researchers suggested that the minimum variant mass 
shift that could be observed in this step was ~6 Da. In the second step, the diluted whole 
blood sample was subjected to a 12-15 hr tryptic digestion. The resulting peptides were 
analysed by ESI-MS to identify the variant-containing peptide, which was subsequently 
analysed by MS/MS to identify the precise location of amino acid substitution.  
In 2001, Rai et al. applied a similar approach [138]. Seventy blood samples from patients 
exhibiting unexplained erythrocytosis, but which had behaved normally in IEF and HPLC 
analyses, were analysed using mass spectrometry of the intact globins, followed by 
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MS/MS of the tryptic peptides where indicated. Three samples were diagnosed as Hb 
variants. In two cases, Hb Olympia (β20 Val→Met, Δm +31.9721 Da) was identified. The 
third variant was identified as Hb Coimbra/Ingelheim (β99 Asp→Glu, Δm +14.0157 Da). 
The study was successful in demonstrating the advantages of mass spectrometry over the 
standard screening methods, HPLC and IEF. In 2003, Rai et al. showed that provided the 
variant was present in abundance >10%, variants of mass shifts between 1 and 4 Da could 
be detected by use of quadrupole instrumentation [139]. 
The approaches described above, however, are not suitable for large-scale population 
screening. In 2005, Daniel et al. [140] proposed a high-throughput MS/MS approach based 
on multiple reaction monitoring (MRM) and pseudo-MRM. In screening programmes, it is 
not necessary to identify all haemoglobin variants but simply those which are clinically 
significant. Those defined variants display characteristic tryptic peptides: For example, to 
confirm the HbS variant, it is sufficient to identify and sequence by MS/MS the [1-8] 
tryptic peptide which contains the Glu→Val substitution at position 6. The nature of the 
variant (homozygous or heterozygous) can be determined by concomitant analysis of the 
wild-type tryptic peptide. Daniel and co-workers [140] analysed 200 whole blood samples 
on a triple quadrupole mass spectrometer. The peptides of interest were sequentially 
isolated in the first quadrupole (MS1), subjected to collision induced dissociation (CID) 
MS/MS in the second quadrupole and the fragment ions detected in the third quadrupole 
(MS2). A series of pre-determined product and parent ion scans ((pseudo)MRM 
transitions) allow for the rapid identification of abnormal haemoglobins. Sample 
preparation time was ~30 mins but the total mass spectrometry acquisition time was 60 s.  
Boemer et al. [141] applied the MRM approach to the detection of HbS, HbC, HbE and β-
thalassemia in dried blood spot eluates and compared the results with those obtained from 
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isoelectric focusing. No discrepancies between the two techniques were observed in over 
2000 samples thus demonstrating the reliability of the mass spectrometry-based approach. 
The approach was subsequently adopted by the neonatal screening programme of the 
French Community of Belgium [142]. Scherl and co-workers [143] have recently 
developed an MRM-based approach for the analysis of intact globin chains from HbS and 
HbC variants. The method utilises electron transfer dissociation (ETD) [67] for fragment 
ion generation. The advantage of this approach is that it negates the requirement for trypsin 
digestion of the sample. 
Therefore an ideal technique for accurate identification of Hb variants would comprise of 
high resolution data with minimal sample preparation. The work presented here fulfils both 
these criteria coupling high resolution top-down mass spectrometry with liquid extraction 
surface analysis (LESA) of DBS to eliminate the need for any sample preparation.  
1.9 Aims and objectives  
 
Then initial aim of this work was to determine if direct surface sampling (LESA) of dried 
blood spots (DBS) coupled with high resolution mass spectrometry could be used and 
subsequently optimised for the extraction/analysis of normal adult haemoglobin (see 
chapter 3). The technique’s suitability would then be investigated as an alternative to the 
current Hb variant screening protocol (ce-HPLC and/or IEF) for diagnosis of common 
structural Hb variants including  HbS and HbD using clinical neonatal DBS samples (see 
chapter 4). 
After establishing that the direct surface sampling technique was suitable for the diagnosis 
of common Hb variants in neonates the robustness of the techniques was probed by 
attempting to diagnose six unknown Hb variants. The current Hb screening protocol 
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employed in a clinincal laboratory showed the presence of a variant was suspected in the 
six samples but a diagnosis could not be made (see chapter 5). A subsequent aim of the 
project was to investigate an appropriate method for the analysis of the complex MS/MS 
spectra generated from top-down analysis of the globin chains. Manual analysis of mass 
spectra was compared with analysis completed with the freely available ProSight PTM 
data analysis software (see chapter 5).        
Chapter 6 aims to investigate the suitability of LESA of dried blood as a technique to 
probe Hb non-covalent interactions.   
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 General Reagents   
 
HPLC grade water (J. T. Baker, Deventer, The Netherlands)  
Methanol (J. T. Baker, Deventer, The Netherlands) 
Formic acid (Sigma-Aldrich Company Ltd., Dorset, UK) 
Ammonium acetate (Fisher Scientific, Loughborough, UK.) 
Drabkin’s reagent (Sigma-Aldrich Company Ltd., Dorset, UK) 
Haemoglobin standard (200 g/L) for spectrophotometry based quantitative assay (Stanbio 
Laboratory, Boerne, Texas, USA) 
30 % (w/v) Brij 35 Solution (Sigma-Aldrich Company Ltd., Dorset, UK) 
Human haemoglobin lyophilized powder  (Sigma-Aldrich Company Ltd., Dorset, UK) 
 m-nitrobenzyl alcohol  (received from Dr  Malgorzata Kaczorowska) 
 
2.1.2 Adult dried blood spots 
 
Blood samples were taken from volunteers by either finger prick or by venipuncture 
carried out by a trained phlebotomist using syringes or BD vacutainer system® (BD, 
Oxford, UK) without the presence of an anticoagulant. The blood was either directly 
dispensed from finger prick or 20 μl of blood pipetted (Gilson Scientific Ltd, Bedfordshire, 
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UK) from the sample collected by venepuncture onto the standard NHS blood spot 
(Guthrie) cards, Ahlstrom grade 226 filter paper (ID Biological Systems, Greenville, South 
Carolina, USA).  
2.1.3 Neonatal dried blood spots  
 
Blood was collected by midwives from neonates 5-8 days after birth via heel prick onto 
standard NHS blood spot cards (ID Biological Systems). Anonoymized dried blood spots 
(DBS) were supplied by Birmingham Children’s Hospital in accordance with the Code of 
Practice for the Retention and Storage of Residual spots [144] All samples have previously 
undergone analysis by the standard NHS screening protocols using cation exchange liquid 
chromatography and isoelectric focusing. The dried blood spots were stored at -20 ºC with 
1 g desiccant packets (Whatman International Ltd, Kent, UK).   
 2.2 Methods  
2.2.1 Surface Sampling 
 
Dried blood spots were placed onto the Advion LESA (Liquid Extraction Surface 
Analysis) universal plate adapter (Advion, Ithaca, NY, USA) and an image of the DBS 
was acquired using an Epson Perfection V300 photo scanner. Using the LESA Points 
software (Advion), the precise location of the DBS to be samples was selected using the 
scanned image. The universal plate adapter was placed into the Triversa Nanomate chip-
based electrospray device (Advion) shown in figure 2.1a.   
Sample analysis was performed using the LESA feature of the Triversa Nanomate 
ChipSoft Manager software. This platform was used to set the parameters for the surface 
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sampling routine based on robotic arm movements (X,Y,Z) of the nanomate probe. The 
method described here was optimised in chapter 3. The routine begins with the Nanomate 
probe collecting a conductive tip, which is used for sample recovery and delivery, from the 
tip rack. The tip then moved to a solvent well containing the electrospray/extraction 
solution and collects 7 μl of the solution (figure 2.1b). The robotic arm relocates to a 
predetermined position above the surface of the DBS and the tip is lowered towards the 
surface of the DBS leaving a gap between the sample surface and the tip. Six μl of the 
electrospray solution is dispensed onto the DBS forming the sample surface to tip liquid 
microjuction (LMJ) (figure 2.2a). The LMJ is maintained for 5 seconds and then 5 μl is 
reaspirated (figure 2.2b) and introduced via nanoelectrospray into the mass spectrometer.    
The advance user interface (AUI) of the ChipSoft software (Advion) was used instead of 
LESA for the direct surface sampling in some cases, for example when following surface 
sampling the sample was collected instead of immediately electrosprayed into the mass 
spectrometer. The sampling parameters remain the same but the DBS was mounted onto a 
96 well microtiter plate (Thermo Scientific, Leicestershire, UK) instead of the universal 
plate adapter and the ESI solvent is picked up from a well on the microtiter plate opposed 
to the separate solvent well. Also sampling location could not be determined using a 
combination of the LESA points software and a scanner, so sampling location was 
determined by a more rudimentary method of employing  a ‘dry’ test run where a location 
co-ordinate (estimated by eye) would be inputted into the AUI and the surface sampling 
routine would be executed (without any solvent or picking up the sample) to ensure an 
accurate location co-ordinate had been established before sampling could occur.   
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Figure 2.1. (Left) LESA apparatus and (right) aspiration of ESI solvent from the solvent 
well.  
              
Figure 2.2 (Left) The formation of a liquid microjuction and (right) the reaspiration of the 
solvent.                      
LESA universal 
plate adapter  
DBS 
Robotic arm 
Tips 
Solvent well 
LMJ 
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2.2.2 Mass Spectrometry 
 
All samples were analysed using the ThermoFisher Scientific Orbitrap Velos ETD 
(ThermoFisher Scientific, Bremen, Germany). Samples were introduced at a flow rate of ~ 
80 nl/min with as gas pressure of 0.5 psi, a tip voltage of 1.75 kV and a capillary 
temperature of 250 ºC. MS data collected in full MS mode (m/z 600-2000) and in selected 
ion monitoring (SIM) mode (m/z 1055-1090) at a resolution of 100,000 at m/z 400. Each 
scan comprises 30 co-added microscans. Automatic gain control (AGC) target was 1 x 10
6 
with a
 
maximum fill time of 2 seconds. Collision induced dissociation (CID) was 
performed in the ion trap and the fragment ions detected in the orbitrap with a resolution of 
100,000 at m/z 400. The isolation window was 8-10 Th and the AGC target for CID was 1 
x 10
6 
with a
 
maximum fill time of 2 seconds. CID experiments were performed with 
helium gas at a normalized collision energy of 30 %. Each CID scan comprises 30 co-
added microscans. Electron transfer dissociation (ETD) was performed in the ion trap and 
the fragments detected in the orbitrap with a resolution of 100,000 at m/z 400. The 
isolation width was 10 Th. The AGC target for ETD was 1 x 10
6 
with a
 
maximum fill time 
of 2 seconds. The reagent ion (fluroranthene ion) AGC target was 1 x 10
5 
with a
 
maximum 
fill time of 1 second. ETD activation time was 20 ms. Each ETD scan comprises 30 co-
added microscans.  
2.3 Data Analysis  
2.3.1 Mass spectral analysis 
 
The acquired spectra were analysed using Xcalibur 2.10 software (ThermoFisher 
Scientific). For the SIM mode mass spectra the Xtract program (44 % fit factor, 25 % 
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reminder, signal/noise threshold 2:1) was used to calculate the singly charge deconvoluted 
monoisotopic masses and their relative intensities (Arbitray units, AU). The program 
calculates the monoisotopic masses as the sum of all charge weighted isotope pattern 
contributions. See equation 7 below.  
 
IntNorm An = ∑ Int An
m+
 / m 
Equation 7  
Where An are the isotopes A0 (monoisotopic), A1, A2….An, m is the charge of the ion 
IntNorm is the normalized intensity, and n is the ion (A0 = M, A1 = M+1, An = M+n). 
 
The deconvoluted singly charged monoisotopic masses are calculated as the sum of all 
contributing isotope intensities see equation 8. 
 
IntNormmonoiso = ∑ IntNorm An 
Equation 8  
 
 
2.3.2 Manual MS/MS Fragment Assignment 
 
For manually assigned MS/MS spectra experimentally measured singly and multiply 
charged CID or ETD m/z values were compared with the theoretical m/z values (fragment 
tolerance Δ 10 ppm) that were calculated in Protein Prospector 
(http://prospector.uscf.edu/prospector/mshome.htm). Fragment ion maps were then 
generated manually, displaying globin chain sequence coverage.   
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2.3.3 Automated MS/MS Fragment Assignment 
 
For automated analysis the MS/MS spectra were first deconvoluted using the Xtract 
program as described in section 2.3.1. The generated list of singly charged CID/ETD 
fragment ions was then copied and pasted into an excel spreadsheet. Using the web based 
program ProsightPTM [145] in single protein mode the fragment ion list was the pasted 
into ProsightPTM from excel. The amino acid sequence of the globin chains and the intact 
mass of the globin chain (determined from Xtracted SIM spectrum) was also inputted into 
the program. A list of observed fragment ions (fragment tolerance Δ 10 ppm) along with 
an fragment ion map are automatically generated.    
 
2.4. Quantitative analysis of whole blood  
2.4.1 Preparation of reagents 
 
In order to determine the concentration of Hb in whole blood samples, internationally 
recommended cyanmethemoglobin technique was used [146].  The method employs the 
use of Drabkin’s reagent [147] (Sigma-Aldrich Company Ltd) which contains sodium 
bicarbonate, potassium ferricyanide and potassium cyanide. A single vial of the dry 
Drabkin’s reagent is reconstituted with 1 L of water with the addition of 0.5 ml of the 
surfactant 30 % Brij 35 Solution (Polyoxyethylene (23) lauryl ether)  (Sigma-Aldrich 
Company Ltd) which reduces any turbidity caused by the addition of erythrocytes. The 
reconstituted Drabkin’s reagent is stable at room temperature for approximately six months 
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when stored in an amber glass bottle and sheltered from light. Drabkin’s reagent oxidizes 
all forms of haemoglobin excluding sulfhemoglobin to methemoglobin in the presence of 
alkaline potassium cyanide. The methemoglobin reacts with the potassium cyanide to form 
cyanmethemoglobin which has peak absorption at 540 nm. The absorption intensity 
measured is proportional to the total haemoglobin concentration.  
2.4.2 Calibration Curve   
 
The cyanmethemoglobin standard haemoglobin solution 200 g/L (Stanbio Laboratory) was 
subsequently diluted with reconstituted Drabkin’s reagent to create a series of five working 
standards with Hb concentrations of 0, 5, 100, 150 and 200 g/L. Each of these solutions 
(n=3) were pipetted into plastic semi-micro cuvettes (10 x 4 x 45 mm) (Sarstedt AG & 
Co., Numbrecht, Germany) with an optical path of 10 mm. Using a Camspec M501 single 
beam scanning UV/visible spectrometer (Spectronic Camspec Ltd, Leeds, UK) the 
absorbance (ABS) of solutions were measured at wavelength 540 nm with the 
spectrophotometer blanked against cuvette containing Drabkin’s reagent between each 
absorbance reading. Results were plotted on a graph in excel where the linear relationship 
between Hb concentration and absorbance, the coefficient of determination (R
2
)
 
is 
calculated.  The equation for the plotted line was determined. 
The relationship between absorbance and the concentration of a solution  can be described 
in the Beer-Lambert law see equation 9.  
        
Equation 9  
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(Where absorbance = ABS, molar absorptivity (coefficient) = ε , path length in cm (b) and 
molar concentration = c)    
2.4.3 Determination of whole blood Hb concentration  
 
Adult whole blood samples from a number of healthy donors taken by venipuncture 
carried out by a trained phlebotomist using syringes or BD vacutainer system® (BD, 
Oxford, UK) in the presence of the anticoagulants EDTA or lithium heparin. A 1 in 251 
fold dilution of the whole blood sample with Drabkin’s reagent was prepared (5 μl of 
whole blood per 1250 of Drabkin’s reagent) and left to stand for 10 mins to ensure 
conversion of haemoglobin to cyanmethemoglobin. The solutions were transferred into 
semi-micro cuvettes (Sarstedt AG & Co) and absorbance at 540 nM were recorded. The 
equation of the line on the standard curve was used to calculate the whole blood 
haemoglobin concentration. Normal adult whole blood haemoglobin concentration ranges 
from 135-175 g/L for males and 115 – 155 g/L for females [148].  
2.4.4 Determination of Hb contraction following LESA of DBS 
 
Adult DBS underwent direct surface sampling in accordance with the sampling routine 
described in section 2.2.1.The AUI was used to sample the DBS instead of the LESA 
settings. The 5 μl of extracted material sampled from the DBS was not directly infused 
into the mass spectrometer but was deposited into an empty well of the microtiter plate 
then transferred into a eppendorf to prevent sample evaporation. Each DBS spot was 
sampled three times at discrete locations and pooled to give a total extraction volume of 15 
μl. This solution was then added to 1250 μl of Drabkin’s reagent, left to react for 10 mins 
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and absorbance at 540 nm was recorded. The Hb concentration of the sample was 
determined as section 2.4.3.  
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Chapter 3: Development of a Method for the Direct Surface Sampling of Dried Blood 
Spots Couple with Mass Spectrometry for the Analysis of Haemoglobin 
 
3.1 Overview   
 
The aim of the work presented in this chapter was optimisation of direct surface sampling 
using liquid extraction surface analysis (LESA) of adult dried blood spots (DBS) for 
haemoglobin (Hb) analysis. The principal aim of the method optimisation was to maximise 
the abundance of the β globin chain in the resultant mass spectra. Abnormalities of the β 
globin chain are more prevalent and are highly clinically significant. They are responsible 
for sickle cell disease (SCD) as well as other important Hb disorders. This becomes 
challenging when analysing neonatal dried blood spots due to the presence of foetal 
haemoglobin (HbF) in the samples resulting in the reduction of HbA (normal adult Hb, i.e, 
two α- and two β globin chains) in the sample to about 25 %. Optimisation of surface 
sampling was completed by investigating the following parameters; electrospray solvent 
composition, sampling time delay, sample dispense tip height and sampling reproducibility 
of the DBS cards. 
The next stage of method development focused on the optimisation of the tandem mass 
spectrometry (MS/MS) experimental parameters. The aim was to maximise sequence 
coverage to aid in the identification of common Hb variants and diagnosis of unknown Hb 
variants from DBS samples. The parameters investigated were as follows; precursor ion 
charge state, collision induced dissociation (CID) energy and electron transfer dissociation 
(ETD) activation time.    
46 
 
3.2 Surface sampling optimisation 
3.2.1 Formic acid concentration of the electrospray solvent 
 
Four electrospray/ extraction solutions were prepared with equal parts methanol and water 
and varying formic acid composition (v/v) as follows: 49.5:49.5 methanol: water, with 1 % 
formic acid, 49:49 methanol: water with 2 % formic acid, 48.5:48.5 methanol: water with 
3 % formic acid and 47.5:47.5 methanol: water with 5 % formic acid. For each of the four 
ESI solutions, three DBS (containing 20 µL of whole blood) were each sampled at three 
discrete locations (n=9). The (deconvoluted) β-chain abundance was calculated for each 
spectrum using the Xtract program as described in section 2.3.1. The overall average β 
intensity across all the technical replicates for the same donor one calculated for each of 
the ESI solutions is shown in figure 3.1. The data suggest that changing the overall formic 
acid composition of the ESI solution from 1 to 3 % has little to no effect on extracted β 
chain intensities observed. An ESI solution of 5 %  appears to improve the observed 
extracted intensities, however spray stability was reduced. A one-way ANOVA statistical 
test was performed using the Microsoft office excel program. The null hypothesis is that 
there is no difference in average observed β- globin chain intensity with the differing % 
formic acid used in the ESI solution (the alpha value, for rejection of null hypothesis was 
set at 0.05). Following one-way ANOVA (table shown in Appendix 1) no significant 
difference [F(3,32) = 1.46, p = 0.24] in observed β- globin chain intensity when % formic 
acid in ESI solution increases. Empirical observations on neonatal samples, where β chain 
abundance is lower revealed that 3 % formic acid was optimum and this was used 
throughout the work published in this thesis.  
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3.2.2 methanol composition of electrospray solution 
 
Five ESI solutions were prepared with the following solvent compositions, each with 3 % 
formic acid (v/v); 10:87 methanol: water, 30:67 methanol: water, 48.5:48.5 methanol: 
water, 70: 27 methanol: water and 90: 7 methanol: water. The overall average β chain 
intensity across all the technical replicates from a single donor was calculated for each of 
the ESI solvents with increasing % of methanol compositions ranging from 10 to 70 %. 90 
% methanol solution was also trailed but LMJ repeatedly failed to form. Figure 3.2 shows 
the average β chain abundance for each of the solvent compositions. The data show an ESI 
solution with a methanol content ranging between 10 and 50 % results in similar β-chain 
abundances. There is a reduction in the average β chain abundance with a solution 
comprised of 70 % methanol. A one-way ANOVA statistical test was performed using the 
Microsoft office excel program. The null hypothesis is that there is no difference in 
average observed β- globin chain intensity with the differing % methanol used in the ESI 
solution (the alpha value, for rejection of null hypothesis was set at 0.05). The results one-
way ANOVA (results shown in Appendix 2) [F(3,32) = 1.14, p = 0.35] no significant 
difference in observed β- globin chain intensity when % methanol in ESI solution 
increases. The high methanol content of the solution caused the LMJ to collapse. This 
finding rules out the use of a solution of 90 % methanol for direct surface sampling of 
DBS using LESA. Based on the data shown in figure 3.2 the ESI solution used in all 
subsequent experiments is 48.5:48.5 methanol: water with 3% formic acid. A full scan 
mode mass spectrum of an adult DBS with these solvent conditions is shown in figure 3.3.  
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Figure 3.1 The average deconvoluted β- globin chain intensity (n=9) with ESI solution 
containing varying (1-5 % ) formic acid composition. The error bars represent the standard 
deviation of the data set.     
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Figure 3.2 The average deconvoluted β chain intensity with ESI solution containing 
varying (10-70 %) methanol composition (n=9). The error bars represent the standard 
deviation of the data set.     
  
 
Figure 3.3 Full scan mass spectrum obtained following direct surface sampling of a 
normal adult DBS using an extraction/ ESI solution made up of 48.5:48.5 methanol: water 
with 3% formic acid. Peaks corresponding to Hb (α = red, β= blue) are observed. 
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3.2.2 Sampling time delay  
One of the variable parameters in the liquid extraction surface analysis sampling method is 
termed ‘post dispense time delay’. It is the time between the ESI/ extraction solvent being 
dispensed and re-aspirated. Essentially, it is the amount of time the liquid microjunction 
remains intact between sample surface and tip. The purpose of a delay is to allow for the 
analyte of interest to mix with the ESI-extraction solvent prior to mass spectrometry 
analysis. Delay times measured in this investigation were 0, 2.5, 5, 7.5 and 10 seconds 
respectively. MS parameters are the same as described previously with each spectrum 
comprising of 30 co-added microscans. Data shown comprise five scans. Dispense height 
(the distance between the sample surface and the tip) remained at 1.6 mm across all 
experiments. The data shown in figure 3.4 suggest that a time delay of zero seconds is 
insufficient for appropriate sampling mixing to occur due to the relatively low amount β 
globin chain observed in the spectra. A one-way ANOVA statistical test was performed 
using the Microsoft office excel program. The null hypothesis in this case being that there 
is no difference in average observed β- globin chain intensity with relation to the sampling 
time delay (the amount of time the LMJ is maintained for) (the alpha value, for rejection of 
null hypothesis was set at 0.05). The results one-way ANOVA (results shown in 
Appendix 3) [F(4,40) = 53.03, p = 1.82 x 10
-15
]   means the null hypothesis is rejected. 
The data is shown to be statistically significant difference, the amount of time the 
ESI/sampling solution is able to mix with the DBS sample effects the average β- globin 
chain intensity observed. A post hoc analysis was perfomed using the Tukey HSD 
(Honestly Significant Difference) test to determine which specific time delay period/s was 
responsible for producing a significant difference in obserbed β- globin chain intensity. 
Results of the Tukey test revealed that mean score for the 0 sec [M = 2.07 x10
5
, SD = 
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1.86]  and for the 2.5 sec [M = 18.61 x10
5
, SD = 9.5] results is significantly different to all 
the other time delay intervels (5, 7.5, 10 sec) including each other.  The mean score for 
time dealy of 5, 7.5 and 10 sec are not significantly from each other. The conclusion drawn 
from experiment is that a delay of 5 seconds is optimum. This delay has a small standard 
deviation [SD = 3.6] and yields high extracted β- globin chain intensity with minimum 
time delay as lengthing the amount of time the LMJ is maintiend to 7.5 and 10 does not 
significantly improve the intensity of the obserbed β- globin chain ions.   
3.2.3 Dispense tip height  
 
The height at which the ESI/ extraction solvent is dispensed onto the surface of the DBS 
card, which equates to the distance between the sample surface and the tip in which the 
liquid microjunction is formed, was also studied with regards to its effect on β globin chain 
intensity/ mass spectrometer response. For each of the tip height intervals chosen, three 
DBS (containing 20 µL of whole blood) from a single donors were each sampled . The 
surface sampling parameters (5 second LMJ delay, ESI solvent dispense volume of 6 μl 
and a reaspiration volume of 5μl ) remained the same throughout and the tip height was 
varied between 1 mm, 1.2 mm, 1.6 mm, 2 mm, 2.4 mm, 2.8 mm and 3 mm respectively. 
The MS parameters are the same as described above.  Figure 3.5 shows the average β -
globin chain intensity across the multiple technical replicates varying  tip height. A one-
way ANOVA statistical test was performed using the Microsoft office excel program. The 
null hypothesis in this case being that there is no difference in average observed β- globin 
chain intensity with relation to tip height (the amount of time the LMJ is maintained for) 
(the alpha value, for rejection of null hypothesis was set at 0.05). The results one-way 
ANOVA (results shown in Appendix 4) [F(5,12) = 1.16, p = 0.38] shows there is 
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statistically no significant difference, between tip height and the average β- globin chain 
intensity observed. Overall there is no significant difference in β- globin chain intensity by 
varying the tip height between 1 mm to 2.8 mm however a tip height of 3 mm (figure 3.6) 
for the surface of the DBS appeared to be too large and the liquid microjuction’s  
collapsed. A tip height of 1.6 mm (figure 3.6) was chosen and used through all LESA 
experiments.     
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Figure 3.4 The average β chain intensity with various LMJ time delays (0-10 secs). The 
error bars represent the standard deviation of the data set.     
 
 
Figure 3.5 The average β chain intensity in response to varying tip height (1- 2.8 mm) 
(n=9). The error bars represent the standard deviation of the data set.     
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Figure 3.6. LMJ formation 1.6 mm (a) vs 3 mm (b)  
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3.3 Sampling Reproducibility  
 
The reproducibility of the surface sampling process was investigated using 20 μl of whole 
blood (collected in the absence of an anticoagulant) from three separate adult donors. The 
whole blood was spotted onto dried blood spot cards multiple times (producing nine 
technical replicates for each donor) and left to dry for 24hrs. Whole blood from the same 
three donors (taken at the same time) was also collected in the presence of an anticoagulant 
(lithium heparin or EDTA). The whole blood samples collected in the presence of an 
anticoagulant were used to determine donor total whole blood Hb concentration by 
diluting the whole blood with Drabkin’s reagent (Sigma) and measuring the absorbance at 
540 nm of the solution by use of a Campspec M501 spectrophotometer.    
The whole blood Hb concentration for each of the three donors was determined by 
spectrophotometry as described in section 2.4.3. A standard curve was created using a set 
of standards with known Hb concentrations of 0, 50, 100, 150 and 200 g/l (Stanbio). A plot 
of absorbance at 540 nm against Hb concentration (g/l) is shown in figure 3.7 (R
2
 = 
0.99948). Using the equation determined in excel (y = 0.00275 + 0.00460), donor whole 
blood Hb concentration could be calculated:  The whole blood samples were diluted by 
251 using Drabkin’s reagent (four replicates for each donor) and the absorbance at 540 nM 
was measured. The whole blood Hb concentration was calculated using the average 
absorbance value for each donor and was determined to be 155, 137 and 165 g/L (all 
within expected Hb concentration range for a normal adult) for donors one, two, and three 
respectively. See Table 3.1. Figure 3.8, 3.9 and 3.10 show example full mass spectra from 
donors 1,2 and 3 respectively.   
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In order to investigate the reproducibility of the surface sampling method whole blood 
collected without anticoagulant was taken from the same three separate donors. For each 
donor 3x 20 μl of the whole blood was pipetted onto a DBS card (yielding 3 separate spots 
for each donor).  Each of these spots was sampled at three discrete locations. 5 μl of 
sampled material was electrosprayed in to the mass spectrometer. The deconvoluted globin 
chain mass spectral intensity was recorded and an average intensity for each of the three 
spots (nine separate measurements) was calculated. Figure 3.11 shows the average α- 
globin intensity and figure 3.12 shows the average β- globin chain intensity for each 
donor. This tentatively fits the pattern seen in the data shown in table 3.1 whereby donor 
three has the highest average intensity and donor two the lowest. The investigations 
described above show that sampling reproducibility is poor, demonstrated by the error bars 
representing standard deviation on figures 3.11 and 3.12.  
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Figure 3.7. Standard curve: Absorbance at 540 nM versus Hb concentration (0-200g/L).  
 
 Abs at 540 nM   
 Abs 1 Abs 2 Abs 3 Abs 4 Ave Calc Conc 
g/l 
Donor 1 0.423 0.422 0.423 0.422 0.4225 155.31 
Donor 2 0.371 0.371 0.373 0.371 0.3715 136.78 
Donor 3 0.449 0.449 0.449 0.449 0.449 164.96 
 
Table 3.1 Absorbance at 540 nm of Hb solutions derived from whole blood samples.  
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Figure 3.8. Donor 1 full mass spectrum.  
 
Figure 3.9. Donor 2 full mass spectrum  
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Figure 3.10. Donor 3 full mass spectrum  
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Figure 3.11. Average alpha globin chain intensity across multiple technical replicates for 
donors 1 to 3. Error bars show the standard deviation calculated in excel where n=9. 
 
Figure 3.12. Average beta globin chain intensity across multiple technical replicates for 
donors 1 to 3. Error bars show the standard deviation calculated using excel where n=9. 
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The relationship between whole blood Hb concentration and the Hb concentration 
following LESA extraction of the DBS was investigated. For each donor, 20 μl 
(anticoagulant free) whole blood was pipetted onto DBS cards to give a total of three DBS 
per donor. Each spot was sampled in three discrete locations. The sampled solution (5 μl) 
was collected into eppendorf tubes for spectrophotometry analysis rather than being 
electrosprayed into the mass spectrometer. The sampled solutions were diluted with 
Drabkin’s reagent (251x) and the absorbance at 540 nm was measured. Data are shown in 
Table 3.2. Note the very low absorbance measurements, with some even not registering a 
response, suggesting that the Hb concentration is low and on the edge of the limits of 
detection of the spectroscopy technique, and questioning the reliability of the data 
collected. Nevertheless, the Hb concentration was calculated using the standard curve 
shown in figure 3.7. The concentration of Hb in LESA samples (and hence typically 
electrosprayed into the mass spectrometer) was determined to be between 1.7 to 2.6 g/L. 
The sample recovery rate was also calculated, see Table 3.1. Sample recovery rate was 
determined as the percentage of LESA sampled Hb concentration to the Hb concentration 
in whole blood for each donor. The average sample recovery rate across all donors and 
spots was 1.31 %. Despite the low sample recovery rate, high quality mass spectra data of 
Hb are able to be obtained. This is because the 1.7 to 2.6 g/L that is electrosprayed into the 
mass spectrometer equates to an Hb concentration of 26 μM to 40 μM, when only 1 μM - 
2μM is required for good quality spectra. In order to overcome the detection limit issue, 
LESA samples were combined/ pooled. Three repeats (5 μl each) from each DBS were 
pooled (forming a 15 μl sample volume for each DBS), diluted by 84x in Drabkin’s 
reagent and the absorbance at 540 nm measured, see Table 3.3. The Hb concentration in 
the pooled sample was calculated by use of the standard curve. Using this approach, the 
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concentration of LESA sampled was determined to be between 1.6 and 2.8 g/L,  25 μM to 
43 μM Hb concentration which is very similar to the results obtained without sample 
pooling. The average sample recovery rate across all donors and spots was 2.24 %. The 
conclusion drawn from this work is that sampling reproducibility appears non-consistent 
and there is little relationship between mass spectral response and Hb concentration 
suggesting direct quantitation in this manner is not possible.  
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    ABS Repeats   Hb Conc 
Donor  DBS a b c Average g/L %Recovery 
1 1 0.002 0 0.002 0.001 2.2 1.39 
2 0 0.001 0.001 0.001 1.9 1.22 
3 0 0.002 0 0.001 1.9 1.22 
2 1 0 0 0 0.000 1.7 1.24 
2 0 0 0.001 0.000 1.8 1.32 
3 0 0 0 0.000 1.7 1.24 
3 1 0.002 0.002 0.002 0.002 2.4 1.45 
2 0.004 0.002 0.002 0.003 2.6 1.58 
3 0.001 0 0.001 0.001 1.9 1.15 
 
Table 3.2 Absorbance at 540 nm of Hb solutions collected by direct surface sampling. 
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Donor  DBS 
Pooled 
3x 
Abs g/L %Recovery 
1 1 0.002 2.4 1.55 
  2 0.003 2.8 1.80 
  3 0.006 3.9 2.51 
2 1 0.003 2.8 2.05 
  2 0.003 2.8 2.05 
  3 0.003 2.8 2.05 
3 1 0.007 4.2 2.55 
  2 0.008 4.6 2.79 
  3 0.008 4.6 2.79 
 
Table 3.3 shows the absorbance at 540 nm of Hb solutions collected by direct surface 
sampling that have been pooled together. 
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3.4 Tandem mass spectrometry  
3.4.1 Collision induced dissociation  
 
The unambiguous diagnosis of Hb variants is dependent on a high % sequence coverage of 
the globin chains.  In order to maximise the sequence coverage obtained from collision 
induced dissociation (CID) of the intact β globin chain, the [M + 15H]15+ ions were 
isolated with a width of 10 Th and subjected to collision with helium gas at a normalised 
collision energy between 20 and 40 % at intervals of 5 %. See section 2.2.2. MS 
parameters are the same as described previously with spectra comprising of 30 co-added 
microscans. Each spectrum was acquired for 5 scans. Assignment of the product ions was 
performed manually. The experimentally measured fragment m/z values were compared 
with theoretical m/z values calculated using Protein Prospector 
(http://prospector.ucsf.edu/prospector/mshome.htm). The experiment was repeated three 
times for each energy interval with the average sequence coverage shown in figure 3.13. 
The data appear to be highly reproducible with small standard deviations represented by 
the error bars. A normalized CID energy of 30 % resulted in the the highest sequence 
coverage of 68 % and this was used throughout unless otherwise stated. An example of the 
sequence coverage from an individual experiment for each of the CID energies in shown in 
figure 3.14.  
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Figure 3.13 Average β -globin chain sequence coverage of the [M + 15H]15+ ions obtained 
by varying CID normalised collision energy.  Error bars represent the standard deviation.  
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Figure 3.14 Fragment ion maps showing the sequence coverage obtained using a CID 
collision energy of (a) 20 %, (b) 25 % , (c) 30 % and (d) 35 % .   
 
 
 
d 
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 3.4.2 Charge state optimisation 
 
 The work of Bakhtiar et al. [149] describes differences in fragment ions produced and 
sequence coverage when different charge states of α globin are isolated and fragmented. 
The effect the charge state of the precursor ions would have on the β globin chain 
sequence coverage obtained following CID was investigated. Isolation width of all the 
precursor ions was 10 Th. Fragmentation spectra from each charge state were acquired in 
triplicate. Charge states [M +14H]
14 
to [M+19H]19 were investigated.  Fragment ion assignment 
was performed manually. Figure 3.15 shows the average sequence coverage obtained with 
different precursor ion charge states at a normalised collision energy of 30 % and figure 3.16 
shows representative fragment ion maps of each charge state showing the sequence coverage.  The 
results show that a precursor ion charge state of [M+15H]15  yields greatest sequence coverage and 
is used throughout this work.   
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Figure 3.15. Average β globin chain sequence coverage for charge states [M + 14H]14+ to 
[M + 19H]
19+
. 
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Figure 3.16. Example of sequence coverage achieved from charge state (a) [M + 14H]
14+
, 
(b) [M + 15H]
15+
,
 
(c) [M + 16H]
16+
, (d)
 
[M + 17H]
17+
, (e)
  
[M + 18H]
18+ 
and (f)
 
[M + 
19H]
19+
. 
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3.4.2 Electron transfer dissociation  
 
With the aim of improving overall sequence coverage, electron transfer dissociation (ETD  
without supplemental activation was optimised for use as a complementary fragmentation 
technique. Firstly sequence coverage was optimised by fragmenting the [M + 15H]
15+
,
 
 β 
globin chain ions with different ETD activation times from 15 to 25 ms. Results are shown 
in figure 3.17. These reveal that an activation time of 20 ms is optimal in order to 
maximise sequence coverage. The sequence coverage (43 %) is displayed in figure 3.18. 
When combining the sequence coverage obtained at a CID normalised collision energy of 
30 %  (see figure 3.11) with the sequence coverage generated from ETD with an activation 
time of 20 ms, the overall sequence coverage achieved (CID + ETD) was 81 %.  
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Figure 3.17 β globin chain sequence coverage obtained using different ETD activation 
times.  
 
Figure 3.18 β -globin chain sequence coverage obtained using ETD activation times of 20 
ms * = fragments unique to ETD fragmentation when combine with fragments produced 
by CID at a normalised collision energy of 30 % total sequence coverage = 81 %. 
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3.4 Conclusion 
  
The data described in this chapter suggest that the optimum parameters for the LESA of 
DBS for identification of known and unknown Hb variants include an ESI/ extraction 
solvent of 48.5:48.5 (v/v) methanol: water with 3 % (v/v) formic acid, a sampling time 
delay of 5 seconds and a tip height at 1.6 mm. Investigation into the potential of directly 
quantifying Hb concentration with mass spectrometer response suggest quantitation is not 
possible due to the non- reproducible sampling process and poor sample recovery.  For 
MS/MS experiments, a CID normalised collision energy of 30 % and an ETD activation 
energy of 20 ms yield highest β globin chain coverage. Results from the two fragmentation 
techniques can be combined to further increase the sequence coverage. These parameters 
were used to obtain data in the following chapters unless otherwise stated.  
Having optimised the parameters for Hb analysis by direct surface sampling mass 
spectrometry of adult DBS, the approach was applied to neonatal DBS to investigate the 
suitability of the method for newborn screening. 
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Chapter 4: Direct Surface Sampling of Dried Blood Spots Coupled with Mass 
Spectrometry Analysis of Common Haemoglobin Variants in Neonates 
 
4.1 Overview   
 
This chapter describes the application of liquid extraction surface analysis (LESA) of 
neonatal dried blood spots coupled to a high-resolution orbitrap mass spectrometer for the 
analysis of common Hb variants routinely screened for in newborn screening programmes. 
Neonatal samples afford more of challenge than normal adult DBS for the diagnosis of Hb 
variants, particularly β- globin variants due to the presence of foetal haemoglobin in the 
samples and the subsequent reduction in the amount of β-globin present. In a practical 
sense the collection of neonatal blood samples is more difficult than adult samples as only 
a small amount of blood can be taken, hence the preference of using DBS opposed to 
whole blood. A successful Hb variant diagnosis method must use a minimal amount of 
blood. The common variants presented in this chapter are HbS, HbC, HbD and HbE. Using 
an orbitrap mass spectrometer it was possible, in selected ion monitoring (SIM) mode, to  
identify both homozygous (HbSS) and heterozygous (HbAS) sickle cell disease (Δm -
29.9745 Da). The variants HbC (both homo- and heterozygous), HbD (heterozygous), HbE 
(heterozygous) (Δm < 1 Da) and the compound heterozygotes disorders HbSC and HbSD 
were unambiguously identified and distinguished from HbAS using collision-induced 
dissociation tandem mass spectrometry (CID MS/MS). That is significant because whereas 
FAS is generally benign, the clinical severity of FSC is similar to that of homozygous 
sickle. The suitability of this method to diagnose thaslassemic disorders was also 
investigated using five neonatal DBS β thalassemia samples.  The results shown that 
Data shown in this chapter was published in Edwards RL, Creese AJ, Baumert M, Griffiths P, Bunch J, Cooper 
HJ: Hemoglobin Variant Analysis via Direct Surface Sampling of Dried Blood Spots Coupled with High-
Resolution Mass Spectrometry. Analytical Chemistry 83(6), 2265-2270 (2011). 
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LESA offers a fast, direct, and unambiguous determination of Hb variants with no sample 
preparation. It allows for repeated analysis of the dried blood spots. 
 
This thesis resulted in a publication in which I am first author, and which included work 
carried out by other collaborators and which was written in collaboration with other 
authors and with my supervisor 
4.2 Results   
4.2.1 Normal adult haemoglobin  
 
As shown in figure 4.1 in the spectrum for normal adult haemoglobin the β globin chains 
are less intense than the α globin chain. The β chain contains fewer basic amino acid 
residues than the α -globin chain and consequently ionizes less readily. Selected ion 
monitoring mode is used to increase the S/N of the β- globin peaks (especially important in 
neonatal samples) and there is no need see all of the charge states (as in full MS) for 
screening. Figure 4.1b shows a mass spectrum acquired in SIM mode over the m/z range 
1056-1084. Peaks corresponding to the 14+ charge state of α globin chain (MWmeas 15 
117.8883, MWcalc 15 117.8924, Δ -0.27 ppm) and the 15+ charge state of the β chain 
(MWmeas 15 858.2835, MWcalc 15 858.2570, Δ 1.67 ppm) are observed. The [M + 14H]
14+
 
of the α chain and [M + 15H]15+ of the β chain were isolated (separately) with a width of 
10 Th and subjected to a collision with helium gas at a normalised collision energy of 35 
%, producing fragment (product ion) laden MS/MS spectra figure 4.2. The spectra were 
analysed manually to determine sequence coverage for both globin chains. The percentage 
coverage for the α chain and β chain was 67 % and 68 % respectively, figure 4.3. All the 
assigned fragments for the α and β chain are shown in appendices 5 and 6.   
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Figure 4.1 (a) Full scan and (b) selected ion monitoring (SIM) mode mass spectra of adult 
hemoglobin HbA. Peaks labelled in red correspond to the α chains and blue to the β chain 
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Figure 4.2 Top down CID spectrum of adult [M + 15H]
15 β chain ions.  
 
 
Figure 4.3. The CID sequence coverage of adult α chain (top) (67 %) and the β chain 
(bottom) (68 %).   
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4.2.1 Normal foetal haemoglobin  
 
Peaks corresponding to ions of three major species are observed in the full scan mass 
spectrum obtained following LESA of a dried blood spot from a normal neonate: α chain, 
fetal γ chain, and very low abundance β chain (Figure 4.4a). Given that the most severe 
Hb variants occur in the β chain, the low abundance of these ions could be a problem. 
However, with acquisition of data in the SIM mode, the signal-to-noise is improved 
significantly, see Figure 4.4b. The measured masses of the globin chains were as follows; 
α MWmeas 15 117.8842 Da, β MWmeas 15 858.2687 Da γG MWmeas 15 986.2683 Da 
(MWcalc 15 986.2626 Da Δ 0.36 ppm) and γA  MWmeas 16 000. 2592 Da (MWcalc 16 
000.2782 Da, Δ -1.19 ppm).  These chains were isolated and fragmented by CID the 
sequence coverage for each of the α (64 %), β (64 %), γG (43 %) and γA (32 %) globin 
chains is shown in figure 4.5. For the respective fragment ion lists see appendices 7-10.     
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Figure 4.4 (a) Full scan and (b) selected ion monitoring (SIM) mode mass spectra of 
neonatal hemoglobin HbA. Peaks labeled in red correspond to the α chains, blue to the β 
chains and green to the γ chains. Peaks labeled Gγ and Aγ denote γ chains containing 
glycine or alanine at position 136, respectively. 
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Figure 4.5 The CID sequence coverage of neonatal (a) α chain and (b) the β chain (c) Gγ 
chain and (d) Aγ chain. 
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4.2.2. HbS Variant 
 
With confirmation that the method was suitable for the analysis of neonatal samples, it was 
applied to samples homozygous and heterozygous for HbS. It was not possible to 
determine the presence of HbS from the full scan mass spectra; however, with the data 
acquired in SIM mode, the variant could be identified unambiguously (MWmeas 15 
828.2408 Da; MWcalc 15 828.2828 Da, Δ 2.7 ppm) Figure 4.6. The sickle trait sample 
(heterozygous) can clearly be identified as such by the presence of both the β-chain and 
the sickle chain, whereas the SIM mode mass spectrum of homozygous sample shows no 
peak corresponding to the β-chain. The [M + 15H]15+ ions of the β and sickle chains from 
the heterozygous (FAS) sample were each selected for CID and the fragments detected in 
the orbitrap. Seven heterozygous and five homozygous sickle samples were analysed. 
Results presented are representative examples. For the sickle chain ions, sequence 
coverage was 32% in the heterozygous sample shown in Figure 4.7a and sequence 
coverage in the homozygous sickle sample was 45 %, Figure 4.7b, fragment ion list 
appendix 11. 
 
The sickle variant is the result of the HbS variant substitution at position 6 
on the β chain, Glu→ Val (+ 29.9745). Following CID of the β chain ions, the singly 
charged b6 fragment was observed at m/z meas 677.3628 (m/zcalc 677.3617) Figure 4.8. No 
peak was observed at that m/z following CID of the sickle ions; however, a peak was 
observed at 647.3854, corresponding to a mass shift of -29.9745 Da (m/zcalc 647.3875). 
Expanded m/z regions showing representative fragments b22
3+
 and b47
4+
 are shown in 
Figure 4.9. 
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Figure 4.6 Selected ion monitoring (SIM) mode mass spectra of neonatal (a) heterozygous 
sickle FAS and (b) homozygous sickle hemoglobin FS. Red = α- globin chain, green = γ- 
globin chains, blue = β- globin chain and yellow = sickle chain.   
 
 
 
 
 
 
 
 
 
Figure 4.7 The CID sequence coverage of (a) heterozygous FAS and (b) homozygous 
sickle FS chains.  
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Figure 4.8  Expanded m/z regions showing the b6 fragments observed following CID of 
the β chain ions (top)  and HbS variant ions. 
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Figure 4.9 Expanded regions of CID MS/MS spectra showing peaks corresponding to (a) 
b22
3+
 fragment ions and (b) b47
4+
 fragment ions of the β chain and sickle variant. Measured 
monoisotopic m/z values are given. 
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4.2.3 HbC Variant 
 
The HbC variant is the result of a Glu (129.0426 Da) → Lys (128.0950 Da)  substitution at 
position 6 on the β chain with an associated mass shift of 0.9476 Da. Figure 4.10 shows 
the mass spectra obtained in SIM mode from normal, heterozygous HbC and homozygous 
HbC samples. Comparison of these SIM mode spectra does not reveal the presence of the 
HbC variant in either the heterozygous or homozygous form (Figure 4.10). Five 
heterozygous HbC variant samples were analysed and two homozygous HbC variant 
samples were analysed and the results presented here are representive examples. The 
spectra were deconvoluted by use of the Xtract software (Thermo Fisher Scientific) to 
determine the monoisotopic masses of the ions. The measured MW of the β chain from the 
normal neonate sample was 15 858.2680 Da. For the homozygous variant C sample, the 
measured MW was 15 857.4033 Da (MWcalc 15 857.3094, Δ 5.9 ppm), suggesting the 
presence of a variant with a mass shift of -1 Da. However, the molecular weight obtained 
following deconvolution of the heterozygous sample was 15857.2442 Da suggesting the 
presence of the variant but failing to reveal the presence of the β chain. To confirm the 
presence or otherwise of the HbC variant, in each sample the ions centered at m/z 1058 
were selected and subjected to CID. Assigned fragment ions are shown in appendix 8. 
Figure 4.11 shows an expanded m/z region containing the b22
3+
 fragment ion of the β 
chain (monoisotopic m/zmeas 802.0898, m/zcalc 802.0884). That fragment was also observed 
for the heterozygous sample (Figure 4.11 (middle)) and is accompanied by the b22
3+
 
fragment of the HbC variant (monoisotopic m/zmeas 801.7727, m/zcalc 801.7725). In the 
MS/MS spectrum obtained from the homozygous sample (Figure 4.11 (bottom)), only the 
b22
3+
 fragment of the HbC variant is observed. Another example, b14
2+
 is given in Figure 
4.12.   
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Figure 4.10 SIM mode mass spectra from normal FA (top), heterozygous HbC (middle), 
and homozygous HbC (bottom). Red = α- globin chain, green = γ- globin chains and blue = 
β- globin chain.   
 
 
Figure 4.11. Expanded m/z regions showing the b22
3+
 fragments observed following CID 
of the β chain ions (m/zcalc 802.0884) (black) and HbC variant ions (m/zcalc 801.7725) 
(red). 
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Figure 4.12. Expanded m/z regions showing the b14
2+
 fragments observed following CID 
of the β chain ions (m/zcalc 738.9065) (black) and HbC variant ions (m/zcalc 738.4327) 
(red). 
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4.2.4 HbD Variant 
 
The HbD (Punjab/Los Angeles) variant is the result of a Glu (129.0426 Da) → Gln 
(128.0586 Da) substitution at position 121 of the β chain resulting in a mass shift of-
0.9840 Da. Although the mass shift is greater than for HbC, the HbD variant is more 
challenging to identify because of the problem of overlapping isotope peaks. The 
difference in mass between the 13C isotope of HbD and the 12C isotope of the β chain is 
0.0194 Da. Four heterozygous HbD samples were analysed. Figure 4.13 shows the SIM 
mode mass spectra obtained from normal and heterozygous HbD. As for HbC, we are 
unable to confirm the presence of the variant directly from the SIM spectrum. The 
[M+15H]
15+
 ions of HbD/β were isolated and subjected to CID. The resulting mass 
spectrum was compared with that obtained following CID of [M+15H]
15+
 ions of the β 
chain. Expanded m/z regions showing the y32
4+
 fragments are shown in Figure 4.14. Note 
that for the peaks at m/z 872.7 and m/z 872.95 in the lower spectrum (heterozygous D), the 
peak shapes suggest the presence of the two species. A further example y47
5+
 is shown in 
Figure 4.15. The HbD variant ion sequence coverage of the heterozygous HbD sample is 
50 % for the variant D ions only (fragments corresponding to the normal β –globin chain 
were excluded), as shown in Figure 4.16. Appendix 13 shows the assigned variant HbD 
ions only.    
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Figure 4.13 SIM mode mass spectra from normal FA (top) and heterozygous HbD 
(bottom). Red = α- globin chain, green = γ- globin chains and blue = β/D- globin chain.   
 
 
Figure 4.14 Expanded m/z region showing peaks corresponding to y32
4+
 fragments 
observed following CID of β chain ions (m/zmeas 872.4622, m/zcalc 872.4600), and variant 
HbD (m/zmeas 872.2138, m/zcalc 872.2140). 
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Figure 4.15 Expanded m/z region showing peaks corresponding to y47
5+
 fragments 
observed following CID of β chain ions and variant HbD. 
 
 
 
 
Figure 4.16 The CID sequence coverage of heterozygous FAD. 
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4.2.5 HbE Variant 
 
The HbE variant occurs at position 26 on the β- globin chain where a glutamic acid is 
substituted for a lysine, resulting in a mass shift of Δm 0. 9476 Da [113]. Figure 4.17 
shows a comparison of SIM-mode mass spectra from a normal (FA) and FAE neonatal 
sample. In total, six heterozygous HbE samples were analysed. The spectra shows peaks 
corresponding to [M + 14H]
14+
 ions of the α- chain (MWcalc 15117.8924),  [M + 15H]
15+
 
ions of the β- chain (MWcalc 15117.8924) and [M + 15H]
15+
 ions  of the γ- chains (γA 
MWcalc 15986.2626 and γG MWcalc 16000.2782). It is not possible to unambiguously 
determine the presence of the HbE variant because the small shift (Δm -0.9476 Da) of the 
variant means that peaks from the intact globin overlap with those from the β-globin. 
Precursor ions corresponding to both the β-globin and the HbE variant were isolated and 
subjected to CID. The resulting fragmentation allowed unambiguous diagnosis of the 
phenotype can be made. CID resulted in a sequence coverage of 43% (Figure 4.18). The 
assigned fragment ion list is shown in appendix 14. The variant is located at position 26 on 
the globin chain, no fragments were observed at this position. The normal b24
3+
 fragment 
ion was observed (m/z 852.1195) verifying that the Hb variant is not present before 
position 25 on the globin chain. A peak at m/z 842.9724  corresponds to the b32
4+ 
with a 
mass shift of -0.9476 Da shown in Figure
 
4.19. A mass shift of -0.9476 is the result of a 
substitution of a glutamic acid for a lysine. The only glutamic acid between position 24 
and 32 on the β -globin chain is located at position 26 therefore the amino acid substitution 
must have occurred there, diagnosing the neonate with an HbE variant. The CID 
fragmentation results are also able to determine if the variant is present in the carrier or 
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homozygous state. This is shown in Figure 4.20. The spectrum shows the b35
4+
 fragment 
ion is present in both variant (MWmeas 933.2719) and normal (MWmeas 933.5097) form. 
The neonate is a carrier of HbE. In England, FAE carrier rate has been reported as 1 in 639 
neonates [150].  
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Figure 4.17 SIM mode mass spectra from normal FA (top) and  heterozygous HbE 
(bottom). Red = α- globin chain, green = γ- globin chains and blue = β/E- globin chain.   
 
 
 
 
 
Figure 4.18 The CID sequence coverage of heterozygous FAE. 
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Figure 4.19 Expanded m/z region showing peaks corresponding to the isotopic 
distributions of b32
4+
 fragments observed following CID of β chain ions (m/zcalc 843.2096) 
and (red) variant HbE (m/zcalc 842.9727).  
 
 
 
Figure 4.20 Expanded m/z region showing peaks corresponding to the isotopic 
distributions of  b35
4+ 
fragments following CID of
 β chain ions(m/zcalc 933.5096) and HbE 
variant ions (m/zcalc 933.2727).  
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4.2.6 Hb SC 
 
 Figure 4.21 shows SIM mode mass spectra of heterozygous sickle (FAS) and compound 
heterozygous FSC samples. HbSC is a compound heterozygote composed of two normal α 
chains and two variant β chains. One abnormal chain is caused by a substitution of a Glu→ 
Lys at position 6 (HbC) on the β chain resulting in a mass shift of -0.9476 Da and the other 
abnormal chain is caused by the HbS variant, a substitution also at position 6 on the β 
chain, Glu→ Val (- 29.9745 Da). As described above it is possible to determine the 
presence of the sickle variant and its nature (homo- or heterozygous) in this mode. 
Nevertheless, there exists the possibility of misdiagnosis of compound heterozygotes- the 
mass spectra in figure 4.21 top (FAS) and bottom (FSC) appear identical. FSC has a 
prevalence rate of 1 in 7174 in England [150]. Two FSC samples were analysed in this 
study and the data presented are representative of both samples. For both the FAS and FSC 
sample, ions centred at m/z 1056 were isolated and subjected to CID.  The protein 
sequence coverage observed for the Hb C variant ions was 26% (Figure 4.22). The 
fragment ion list is shown in appendix 15. Figure 4.23 shows the expanded m/z region 
containing the b47
4+
 fragments of the FAS and FSC variants. The peaks at m/z 1300.4444 
and 1307.6914 in figure 4.23, bottom, confirm the presence of both HbS and HbC, i.e., 
that the sample is a compound heterozygote FSC. Figure 4.24 is another example that 
confirms that the HbC variant is present.  
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Figure 4.21 Selected ion monitoring mass spectra of normal neonate haemoglobin 
heterozygous and homozygous FAS (top) and FSC (bottom). 
 
 
Figure 4.22 The CID sequence coverage (26 %) of the variant HbC ions in a heterozygous 
FSC sample.  
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Figure 4.23 Expanded m/z region showing the b47
4+
 fragments observed following CID
 
of 
the sickle ions (m/zcalc 1300.4330), β chain ions (m/zcalc 1307.9266) and HbC variant
  
ions 
(m/zcalc 1307.6897) (red). 
 
 
 
 
Figure 4.24 Expanded m/z region showing b22
3+ fragments for the β chain ions (m/zcalc 
802.0884) and HbC variant
 
ions (m/zcalc 801.7726) (red). 
4.2.7 Hb SD 
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HbSD is another compound heterozygote where two variant chains are inherited instead of 
normal β chains: one HbS chain (substitution also position 6 on the β chain, Glu→ Val (+ 
29.974)) and one HbD chain (Glu→Gln substitution at position 121 of the β chain, Δ -
0.9840 Da). Only one Hb SD sample was available for analysis. The SIM-mode mass 
spectra of FAS and FSD samples shown in figure 4.25 look identical. This is because the 
normal β globin chain differs in mass from the variant D Punjab/ Los Angeles chain by 
only 0.9840 Da. The presence of the sickle variant in both samples is clear in SIM mode. 
CID fragmentation is required to differentiate between clinically benign FAS and the 
severe medical disorder FSD. Figure 4.26 shows the HbD  variant ions assigned yielding 
protein sequence coverage of 14 %, appendix 16. Despite the low sequence coverage FSD 
is diagnosed. The y23
4+ 
(m/zmeas 608.8415) is obserbed at the expected m/z for normal β- 
globin chain the next fragment observed y32
4+
 is present at m/zmeas 872.4143 corresponding 
to a variant with a mass shift of -0.9840 Da Glu→Gln (Figure 4.27). The only glutamic 
acid in the region between y23 and y32 is at position 121 diagnosing HbD Punjab/ Los 
Angeles (β121 Glu→Gln Δm -0.9840 Da).     
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Figure 4.25 Selected ion monitoring mass spectra of normal neonate haemoglobin 
heterozygous and homozygous FAS (top) and FSD (bottom). 
 
 
 
 
Figure 4.26 The CID sequence coverage of heterozygous FSD, variant HbD ions only. 
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Figure 4.27 Expanded m/z region showing the y32
4+
 fragments observed following CID
 
of 
the β chain ions (m/zcalc 1307.9266) in the FAS sample and HbD variant
  
ions (m/zcalc 
872.2140) (red) in the FSD sample. 
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4.2.8 Beta thalassemia   
 
The diagnosis of thalassemic variants poses a different challenge than the diagnosis the 
structural variants described above. Thalassemic variants result in the reduction in the 
synthesis of the globin chain and are not caused by amino acid substitutions that result in 
measureable mass shifts. Five different β thalassemia DBS samples were investigated in 
this study. The variant DBS underwent standard hospital screening (ceHPLC) and the 
samples were diagnosed as being β thalassemic. All the samples were then analysed by use 
of the LESA protocol. In full MS mode no peaks corresponding to β -globin chains were 
observed in any of the five β thalassemia samples. Figure 4.28 shows a full MS spectrum 
for a β thalassemia variant. The spectrum was deconvoluted by use of the Xtract software 
to determine the monoisotopic masses of the measured ions. The measured MW of the α 
chain from the spectrum shown in figure 4.28 was 15 117.8346 Da (Δ -3.8 ppm), γG chain 
15 986.1963 Da (Δ -4.2 ppm) and for the γA is 16 000.2017 (Δ -4.8 ppm). The β- globin 
chain was absent. The SIM mode mass spectrum (m/z range 1055-1090) also shows the 
absence of any peaks corresponding to the β- globin chain, Figure 4.29. All samples were 
analysed from full term neonates so the absence of β -globin cannot be explained by 
neonatal prematurity (production of β chain not yet switched on). The absence of the β 
chain in the samples must therefore be explained by the presence of the β thalassemia 
variant. The method offers the potential for diagnosis of β thalassemia.    
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Figure 4.28. Full MS spectra of β thalassamina sample.   
 
Figure 4.29 SIM mode mass spectrum of β thalassemia sample 
 
β  absent 
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4.3 Conclusion  
 
The results presented in this chapter show that LESA method used in this investigation is 
able to diagnose clinically significant structural variants including HbS as well as variants 
with mass shifts of less than 1 Da (HbC, HbE etc) from neonatal DBS without the need for 
any sample digestion or preparation. The diagnosis of four (HbS, HbC, HbD and HbE) out 
of the five structural variants that must be detected during neonatal screening is presented 
above. The HbO-Arab variant is rare [120], no samples were available for analysis during 
this study.  The O-Arab variant occurs at position 121 on the β -globin chain like the HbD 
variant and caused by a substitution of a glutamic acid for a lysine causing a mass shift of -
0.9476 Da the same as variants HbC and HbE variants. As all these variants have been 
diagnosed using this direct surface sampling MS/MS diagnosis of HbO-Arab should also 
be possible.  
 The method also allowed for the successful diagnosis of the compound heterozygotes 
samples FSC and FSD. Further sickle compound heterozygote variant samples were not 
available to sample during this study due to their rarity. Variants FSE, FSO-Arab and other 
sickle compound heterozygotes including FSD have a combined prevalence of rate of 1 in 
24, 871 [150].   The ability to determine other common structural variants suggests the 
diagnosis  other sickle compound heterozygotes would be possible.   
The method also has potential to be used in the diagnosis of β thalassimic disorders 
however further investigation (larger sample number, adult samples) is required.  
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Chapter 5:  The Diagnosis of Unknown Variants in Neonatal Samples 
5.1 Overview   
 
The previous chapter revealed liquid extraction surface analysis (LESA) of newborn dried 
blood spots (DBS) coupled with high resolution mass spectrometry for the screening of 
common Hb variants [151]. The work presented in this chapter aims to demonstrate the 
robustness and versatility of the surface sampling method by applying the technique for the 
diagnosis of unknown variants. The method was applied to six unknown neonate samples 
(FAV1-6). The samples had been identified as variants using ceHPLC and IEF by the 
Birmingham Children’s Hospital haemoglobinopathy department; however, the nature of 
the variant had not been diagnosed.  In this analysis five of the six were diagnosed 
unambiguously. The sixth was either mis-assigned as a variant by the standard screening 
methods, or was an isomeric substitution (Ile→Leu or vice versa). All data were analyzed 
manually, with the attendant time costs, constituting a bottle-neck in the workflow and 
highlighting the need for data analysis software specifically for the diagnosis of Hb 
variants from top-down MS/MS data. Therefore, the freely available web based top-down 
protein characterization software Prosight PTM [91] (described in section 2.3.3) was 
investigated as an alternative to manual data analysis. 
5.2. Results 
5.2.1  FAV 1 
 
Figure 5.1 shows the SIM-mode mass spectrum obtained from sample FAV1. Initially the 
mass spectrum appears identical to that expected for a normal neonatal sample[151]. Peaks 
corresponding to [M + 14H]
14+
 ions of the α-chain and [M + 15H]15+ ions of the γ-chains 
  Data shown in this chapter was published in Edwards RL, Griffiths P, Bunch J, Cooper HJ: Top-Down 
Proteomics and Direct Surface Sampling of Neonatal Dried Blood Spots: Diagnosis of Unknown 
Hemoglobin Variants. Journal of The American Society for Mass Spectrometry 23(11), 1921-1930 (2012). 
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(γA and γG) are present. However, the peak at m/z 1058 corresponds to a measured mass 
MWmeas 15856.3072 Da, suggesting the presence of a variant with a -1 Da mass shift. 
(The calculated mass of the β-chain is 15857.2497 Da). The ions centred at m/z 1058 were 
selected and subjected to CID. The resulting fragments were compared with those 
observed for CID of [M + 15H]
15+
 ions of the β-chain. The fragment peaks observed in the 
CID mass spectrum of FAV1 and their assignments are shown in Appendix 17. The 
sample was identified as heterozygous Hb D-Iran. Hb D-Iran is caused by an amino acid 
substitution at position 22 on the β chain, glutamic acid to glutamine, causing a mass shift 
Δm 0.9840Da [152]. Figure 5.2 shows an expanded m/z region containing the b21
3+
 
fragment ions of the β-chain (monoisotopic m/zcalc 759.0742) (top) and the equivalent 
region for the variant (bottom). Figure 5.3 shows the expanded m/z region containing the 
b22
3+ fragment ions of the β-chain (monoisotopic m/zcalc 802.0884) (top) and the equivalent 
region for the variant (bottom). Whereas the regions containing the b21 fragments are 
identical, the regions containing the b22 fragments are not. Two sets of peaks are observed 
for the variant sample: One set corresponds to the isotope distribution of the b22
3+
 fragment 
of the β-chain (monoisotopic m/zmeas 802.0865), confirming the heterozygous nature of the 
variant. The second set corresponds to the b22
3+
 fragment of Hb D-Iran (m/zmeas 801.7623, 
m/zcalc 801.7604, Δ 2.4 ppm). Similar observations are made for the b23
3+
 fragment ions 
shown in Figure 5.4. The protein sequence coverage obtained was 54 %, see Figure 5.5. It 
should be noted, however, that as this sample is heterozygous and the mass shift is <1 Da, 
both the normal β-chain and the variant ions were selected for CID. This is an unavoidable 
consequence of instrumental resolution limitations and overlapping isotopic distributions. 
Fifteen of the observed fragments were unique to Hb D-Iran, whereas the remaining 62 are 
common to both. 
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Figure 5.1. Selected ion monitoring mode mass spectrum of unknown variant FAV1. Red 
= α- globin chain, green = γ- globin chains and black = β/ variant chain.  
 
 
 
 
 
 
Figure 5.2 Expanded m/z region showing peaks corresponding to the isotopic distributions 
of (b) b21
3+
 fragments (m/z calc 759.0742) observed following CID of [M + 15H]
15+
 ions 
of β- chain (top) and variant Hb D-Iran (bottom). 
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Figure 5.3 Expanded m/z region showing peaks corresponding to the isotopic distributions 
of  b22
3+
 fragments observed following CID of [M + 15H]
15+
 ions of β chain (m/zcalc 
802.0884) (top) (black) and variant Hb D-Iran (m/zcalc 801.7604) (bottom) (red). 
 
 
Figure 5.4 Expanded m/z region showing peaks corresponding to the isotopic distributions 
of b23
3+
 fragments following CID of [M + 15H]
15+
 ions β chain ions (m/zcalc 835.1112) 
(top) (black) and Hb D-Iran variant ions (m/zcalc 834.7832) (bottom) (red). 
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Figure 5.5 Manually assigned protein sequence coverage obtained following CID of the 
Hb D-Iran variant (54 %). 
 
 
Figure 5.6 Data-base assigned protein sequence coverage obtained following CID of the 
Hb D-Iran variant (43 %). Fragment ion map generated by ProSight PTM. 
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 Clearly, manual analysis of top-down mass spectrometry data for the diagnosis of 
hemoglobin variants is time consuming and is a potential barrier to adoption in the clinical 
laboratory. Ideally, data collection would be followed by automated searching against a 
hemoglobin variant database. To test that approach, CID MS/MS data for FAV1 was 
searched against the Hb D-Iran sequence using ProSightPTM 1.0 (the data-base analysis is 
described in detail in section 2.33). The aim was to mimic a search against a dedicated Hb 
variant database. The protein sequence coverage for the Hb D-Iran variant chain generated 
using ProSightPTM was 43 % (see Figure 5.6). The source of the discrepancy in sequence 
coverage was investigated further. For example, fragment ions b32
4+
 and b33
4+
 were 
assigned manually but were not identified by ProSightPTM (see Figure 5.7 and 5.8). For 
these fragments, the Xtract program had failed to distinguish the presence of two 
overlapping isotope distributions, one from the β-chain and one from the Hb D-Iran 
variant. Despite the difference in sequence coverage, the site of the substitution was 
identified and the variant could be unequivocally diagnosed. 
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Figure 5.7 Expanded m/z region showing peaks corresponding to the isotopic distributions 
of b32
4+
 fragments following CID of [M + 15H]
15+
 ions β chain ions (m/zcalc 843.2096) 
(black) and Hb D-Iran variant ions (m/zcalc 842.9636) (red) . 
 
 
Figure 5.8 Expanded m/z region showing peaks corresponding to the isotopic distributions 
of b33
4+
 fragments following CID of [M + 15H]
15+
 ions β chain ions (m/zcalc 867.9767) 
(black) and Hb D-Iran variant ions (m/zcalc 867.7307) (red). 
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5.2.2. FAV2 
 
A second unknown variant, FAV2, was also identified as heterozygous Hb D-Iran. Again, 
because of the small mass difference, both the variant and the β-chain were selected for 
CID. The fragment peaks observed in the CID mass spectrum of FAV2 and their 
assignments are shown in Appendix 18. Figure 5.9 shows two sets of peaks are observed 
for the variant sample: One set corresponds to the isotope distribution of the b22
3+
 fragment 
of the β-chain (monoisotopic m/zmeas 802.0884), confirming the heterozygous nature of the 
variant. The second set corresponds to the b22
3+
 fragment of Hb D-Iran (m/zmeas 801.7624, 
m/zcalc 801.7604, Δ 2.5 ppm). As a further example, the b23
3+ 
fragment ions are shown in 
Figure 5.10. The protein sequence coverage obtained manually was 57 % (Figure 5.11). 
Again, the data were searched against the Hb D-Iran sequence using ProSightPTM and 
gave a coverage of 56 % (Figure 5.12), and unequivocal diagnosis. A study reviewing 
screening results over a 10 year period in the North Thames health region showed that Hb 
D variants are the third most common variants with a carrier incidence rate of 1 in 631. Hb 
D-Iran is the second most prevalent of the Hb D variants after Hb D Punjab (Los Angeles) 
[12]. Heterozygous Hb D-Iran is clinically benign. 
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Figure 5.9 Expanded m/z region showing peaks corresponding to the isotopic distributions 
of  b22
3+
 fragments observed following CID of 15+ ions of FAV2 β chain (m/zcalc 
802.0884) (top) (black) and variant Hb D-Iran (m/zcalc 801.7604) (bottom) (red). 
 
 
Figure 5.10 Expanded m/z region showing peaks corresponding to the isotopic 
distributions of b23
3+
 fragments following CID of  FAV2 15+ ions β chain ions (m/zcalc 
835.1112) (top) (black) and Hb D-Iran variant ions (m/zcalc 834.7832) (bottom) (red). 
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Figure 5.11 Manually assigned protein sequence coverage obtained following CID of the 
Hb D-Iran variant (57 %). 
 
 
Figure 5.12 Data-base assigned protein sequence coverage obtained following CID of the 
Hb D-Iran variant (56 %). 
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5.2.3 FAV3  
 
Figure 5.13 shows the SIM-mode mass spectrum obtained for variant FAV3. In addition 
to the peaks corresponding to the α, β, and γ chains, a peak is observed at m/z 1063 
(MWmeas 15926.24 Da) which corresponds to a β-chain mass shift Δm + 69.06 Da (i.e., 
substitution of a serine for an arginine residue). The presence of both the β-chain and the 
variant confirm the sample as heterozygous. The variant ions were isolated and fragmented 
by CID and ETD. The fragment peaks observed in the CID mass spectrum and their 
assignments are shown in Appendix 15. The β-chain contains five serine residues: Ser9, 
Ser44, Ser49, Ser72, Ser89. Two Ser→Arg variants are known: Hb Headington 
(Ser72→Arg) and Hb Vanderbilt (Ser89→Arg). The protein sequence coverage observed 
following CID was 46 % and is summarised in Figure 5.14. (Note, unlike Hb D Iran, there 
is no interference from β-chain fragments as the larger mass shift makes it possible to fully 
isolate the variant precursor ions). Potential substitution of Ser9, Ser44 and Ser49 are ruled 
out by the presence of the b11 through b49 fragments at the expected masses. The nature of 
the variant (Hb Vanderbilt or Hb Headington) could not be confirmed by the CID data due 
to the lack of fragments in the central region of the protein. The protein sequence coverage 
observed following ETD was 34 %, see Figure 5.15. The assigned fragment ions are 
shown in Appendix 20. Hb Vanderbilt is ruled out by the presence of fragments z61-63, z67-
70 and z74 at the expected masses. The variant is confirmed as Hb Headington [153] by the 
presence of the c + H72
6+
 fragment (m/zmeas 1309.0297, m/zcalc 1309.0339, Δ 3.2 ppm) and 
the z77
7+
 fragment (m/zmeas 1208.7861, m/zcalc 1208.7754, Δ 8.9 ppm), see Figure 5.16 
and 5.17. The combined protein sequence coverage (CID + ETD) was 63 %. The 
diagnostically informative ETD spectrum was searched against the Hb Headington 
sequence using ProSightPTM, which returned a coverage of 20 % (Figure 5.18). The 
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variant was assigned on the basis of the c77
6+
 fragment ion. That fragment was not assigned 
in the manual analysis due to the very low signal-to-noise of the monoisotopic peak. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
116 
 
 
 
Figure 5.13 Selected ion monitoring mode mass spectrum of an unknown variant FAV3.  
 
 
Figure 5.14 Protein sequence coverage observed following CID (46 %) of V3.  
 
Figure 5.15 Protein sequence coverage observed following ETD (34 %) of V3. Site of 
substitution (Ser72→Arg) is shown in both but can only be confirmed by ETD. * Indicates 
fragments unique to ETD. 
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Figure 5.17 Expanded m/z region showing peaks corresponding to c + H72
6+
 
(m/zcalc1309.0339) fragment ions following ETD of 15+ ions of V3 (bottom) and the 
equivalent regions (above) from the ETD of 15+ ions of β chain. 
 
 
 
 
Figure 5.18 Expanded m/z region showing peaks corresponding to z77
7+
 (m/zcalc 
1208.7754) fragment ions following ETD of 15+ ions of V3 (bottom) and the equivalent 
regions (above) from the ETD of 15+ ions of β chain. 
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Figure 5.19 Data-base assigned protein sequence coverage obtained following ETD of the 
Hb Headington  (20 %). 
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5.2.4 FAV4 
 
Figure 5.20 shows the SIM-mode mass spectrum obtained for unknown variant FAV4. An 
additional peak is observed at m/z 1062, corresponding to a β-chain variant with mass shift 
Δm +58.01 Da (MWmeas 15915.27). A mass shift of +58.01 Da could either result from a 
Gly→Asp substitution or an Ala→Glu substitution. The β-chain contains thirteen glycine 
residues and fifteen alanine residues, offering numerous possibilities for variation. The 
ions at m/z 1062 were isolated and subjected to CID. The fragment peaks observed in the 
CID mass spectrum and their assignments are shown in Appendix 21.  The protein 
sequence coverage, see Figure 5.21 was 28 %, the lowest of all the variants studied. 
Nevertheless, the fragmentation observed narrows down the region of substitution to 
between Gly16 and Glu22: The b15
2+
 fragment is observed at the expected mass m/zmeas 
831.9470 (m/zcalc 831.9461, Δ 1.1 ppm) while the b22
3+
 fragment is observed with the 
+58.01 mass shift, m/zmeas 821.4248 (m/zcalc 821.4236 Δ –1.7 ppm), see Figure 5.22 and 
5.23. The only glycine or alanine residue in this region is Gly16. Thus the variant 
corresponds to a Gly16→Asp substitution (i.e., Hb J-Baltimore) [154]. The ProsightPTM 
search of the data against the Hb J-Baltimore sequence gave a sequence coverage of 19 % 
(Figure 5.24). Again the reduced coverage appears to be the result of incomplete 
deconvolution by the Xtract program. Nevertheless, the variant could be diagnosed 
unambiguously.  
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Figure 5.20 Selected ion monitoring mode mass spectra spectrum of an unknown variant 
FAV4. Red = α- globin chain, green = γ- globin chains and blue = β- globin chain. 
 
 
Figure 5.21.  Manually assigned protein sequence coverage observed following CID of V4 
(Hb J-Baltimore), 28 %. 
 
Figure 5.22 Expanded m/z region showing peaks corresponding to isotopic distributions of 
the  b15
4+
 fragments (m/zcalc 831.9461) observed following CID of 15+ ions of β-chain 
(top) and variant Hb J Baltimore (bottom). 
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Figure 5.23 Expanded m/z region showing peaks corresponding to isotopic distributions of 
b22
3+
 fragments following CID of [M + 15H]
15+
 ions of variant Hb J-Baltimore (m/zcalc 
821.4248), (bottom) and the equivalent m/z region from the CID mass spectrum of [M + 
15H]
15+
 ions of β-chain (top). 
 
 
Figure 5.24 Data-base assigned protein sequence coverage obtained following CID of the 
Hb J-Baltimore (19 %) 
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5.2.5 FAV5  
 
The SIM-mode mass spectrum obtained for the variant FAV5 is shown in Figure 5.25. 
Peaks corresponding to 15+ ions of β and γ chains and 14+ ions of α-chains are observed, 
confirming the variant is heterozygous. In addition, a peak corresponding to 14+ ions was 
observed at m/z 1090 suggesting the presence of an α-chain variant. β variants are more 
common than α variants: ~60 % are β variants [155]. In addition, β variants are more 
abundant because only two β globin chains are inherited (one per chromosome) by an 
individual compared with four α globin chains, therefore inheritance of an β variant makes 
up 50 % of the Hb content whereas an α variant would be 25 % [156]. The measured mass 
of the α-chain was MWmeas 15116.95 Da (MWcalc 15116.89 Da) and the measured mass of 
the variant was 15229.88 Da, a mass shift Δm of +113 Da. That mass shift does not 
correspond to any possible amino acid substitution, however it does correspond to 
insertion of an isoleucine or leucine residue within the sequence. The α-chain and the 
variant were each selected for CID. The fragments observed for the α-chain are shown in 
Appendix 18. The α-chain sequence coverage was 54 %. The CID fragments observed for 
the variant are shown Appendix 23. The variant was identified as Hb Phnom Penh which 
arises through insertion of an isoleucine between position 117 and 118 on the α-chain 
coded by the α -1 gene [157]. The protein sequence coverage was 46 % and is summarised 
in Figure 5.26. Fragments y3 through y24 were observed at the expected masses. Figure 
5.27 shows an expanded m/z region containing the y25
3+
 of the Hb Phnom Penh variant 
(m/zmeas 902.1746, m/zcalc 902.1726 Δ 2.2 ppm) (i.e., the fragment adjacent to the insertion, 
and the corresponding region from the CID of the α- chain). Another example, the y48
4+
 
fragment (m/zmeas 1305.4803, m/zcalc 1305.4768 Δ 2.7 ppm), is shown in Figure 5.28. The 
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ProsightPTM search of the data against the Hb Phnom Penh sequence gave a sequence 
coverage of 44 % (Figure 5.29) and unequivocal diagnosis.  
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Figure 5.25 Selected ion monitoring mode mass spectrum of an unknown variant FAV5.  
 
 
Figure 5.26 Manually assigned protein sequence coverage observed following CID of V5 
(Hb Phnom Penh), 46%. 
 
 
Figure 5.27 Expanded m/z regions showing peaks corresponding to isotopic distributions 
of (c) y25
3+
 fragments (m/zcalc 902.1726)  observed following CID of 14+ ions of variant 
V5 (Hb Phnom Penh) (bottom) and the equivalent m/z regions from the CID mass 
spectrum of 14+ ions of α-chain (top) 
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Figure 5.28 Expanded m/z regions showing peaks corresponding to isotopic distributions 
of y48
4+
 fragments (m/zcalc 1305.4768) observed following CID of [M + 14H]
14+
 ions of 
variant V5 (Hb Phnom Penh) (bottom) and the equivalent m/z regions from the CID mass 
spectrum of [M + 14H]
14+
 ions of α-chain (top). 
 
 
 
Figure 5.29 Data-base assigned protein sequence coverage obtained following CID of the 
Hb Phnom Penh (44%). 
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5.2.6 FAV6 
 
The SIM-mode mass spectrum for the final unknown variant FAV6 is shown in Figure 
5.30. The mass spectrum does not reveal the presence of any additional peaks. The 
measured masses of the α, β, Gγ and Aγ chains were MWmeas 15117.8211 (MWcalc 
15117.8924 Δ -4.7 ppm), MWmeas 15858.3217 (MWcalc 15858.2570 Δ 4.1 ppm), MWmeas 
15986.3329 (MWcalc 15986.2626 Δ 4.4 ppm), MWmeas 16000.2849 (MWcalc 16000.2782 Δ 
0.4 ppm), respectively. Therefore CID of the peaks centered at m/z 1059 (β-chains), m/z 
1068 (γ-chains) and m/z 1081 (α- chains). The CID protein sequence coverages were 46 % 
(β- chain), 45 % (α-chain), 43 % (Gγ-chain) and 32 % (Aγ-chain). The ETD protein 
sequence coverages were 17 % (β-chain), 44 % (α-chain), 28 % (Gγ-chain) and 15 % (Aγ-
chain). The CID and ETD fragments observed are detailed in Appendix 24-30. No 
erroneous fragment peaks were observed for any of the globin chains suggesting that either 
the sample had been incorrectly identified as a variant in the screening process or contains 
an isomeric substitution (i.e., Leu→Ile or vice versa). (It is worth noting that no such 
substitution is currently described in the HbVar database [3].) It was not possible to 
reconfirm the screening results because the sample was anonymized prior to mass 
spectrometry analysis. The estimated false positive rate in screening is ~1 % [158] and 
documented sources of error include administration errors or unfocused/merged bands in 
IEF [159]. 
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Figure 5.30 Selected ion monitoring mode mass spectrum of an unknown variant FAV6. 
Red = α- globin chain, green =  γ- globin chains and blue = β- globin.  
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5.3. Conclusion  
 
The results presented in this chapter demonstrate the robustness of the direct surface 
sampling top-down proteomics approach and confirm that the approach is applicable both 
for screening and diagnosis. Results show direct surface sampling of newborn dried blood 
spots coupled with top down mass spectrometry may be used for the diagnosis of unknown 
haemoglobin variants. Six samples which had been identified as variants by ceHPLC and 
IEF, but which could not be diagnosed by those methods, were analyzed. Two of the 
samples were determined to be heterozygous Hb D-Iran following CID of the overlapping 
β-chain and variant peaks. Mass analysis of the third sample revealed the presence of a 
Ser→Arg β-chain variant. CID of the variant narrowed the possibilities to Hb Headington 
or Hb Vanderbilt. ETD confirmed the variant as Hb Headington. Mass analysis of the 
fourth variant suggested either a Gly→Asp or Ala→Gln β-chain substitution. CID 
confirmed the variant as Hb J Baltimore. The fifth sample was confirmed as a rare α- 
variant with a mass shift of +113 Da. CID revealed it to be the insertion variant Hb Phnom 
Penh. The mass analysis, CID and ETD of the sixth sample do not indicate the presence of 
a variant. Either the sample had been incorrectly identified as a variant by the ceHPLC and 
IEF (the false positive rate in screening is estimated as ~1 % [158]) or contained an 
isomeric substitution (Ile→Leu or vice versa). 
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Chapter 6: Native Mass Spectrometry of Haemoglobin 
6.1 Overview   
 
The previous two chapters have demonstrated the effectiveness of direct surface sampling 
of DBS coupled with electrospray ionisation mass spectrometry of intact (heme free) apo -
α and apo-β -globin chains [151, 160]. Several studies have demonstrated the potential of 
ESI mass spectrometry as a tool for the analysis of intact Hb non-covalent protein-protein 
and protein-ligand complexes [161, 162], often termed native mass spectrometry [163], in 
purified Hb aqueous solution phase samples. Native mass spectrometry allows for the 
study of structural aspects of proteins and protein complexes [164] by combining soft 
ionisation techniques with volatile buffers (ammonium acetate based). These volatile 
buffers allow for the preservation of non- covalent interactions, whereas traditional ESI 
solutions containing an acidified organic solvent (e.g. methanol) serve to denature 
quaternary and tertiary protein structure [165].  
 
The work presented in this chapter investigates the viability of LESA coupled with native 
MS for the study of Hb non-covalent interactions. The rationale for the study was to assess 
the potential application of the technique for the study of thalassemic variants. 
Thalassemia is responsible for the formation of abnormal Hb tetramers. For example β- 
thalassemia is caused by a reduction in the synthesis of β- globin chains resulting in a 
surplus of α- globin chains which can lead to the formation of all α – chain tetramers, Hb 
Barts [166]. Preserving the quaternary structure of Hb by native MS could allow for 
observation of these abnormal tetramers, and therefore the identification of thalassemic 
disorders.  
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6.2. Results 
6.2.1 Direct infusion of haemoglobin solution  
 
Figure 6.1 shows a full mass spectrum (m/z range 600- 4000) obtained following direct 
infusion ESI of a 10 μΜ solution of Hb. The ESI solution consisted of 
water/methanol/formic acid (48.5:48.5:3,v/v). The capillary temperature was 250 ºC. The 
free heme (m/zmeas 616.1765, m/zcalc 616.1773, Δ -1.30 ppm) is the dominant species in the 
mass spectrum. The mass spectrum also contains multiply-charged peaks corresponding to 
apo-α (MW 15117.8924) and apo-β chains (MW 15858.2570). No multiply-charged 
species are observed above m/z ~1800.  
 
Figure 6.2 shows a full ‘native’ mass spectrum obtained following direct infusion ESI of a  
10 μΜ solution of Hb in 10 mM ammonium acetate at a reduced capillary temperature of 
200 ºC. The high m/z range of 600-4000 was chosen to maximise the chance of observing 
tetramer ions and because no peaks corresponding to Hb were observed below m/z 600 in 
any data presented here. The sheath gas pressure was 0.7 psi and a voltage of 0.75 kV was 
applied to the analyte containing tip. The change in ESI solution dramatically affects the 
species observed in the spectrum. The free heme is no longer the dominant species. 
Multiply charged (heme attached) holo α- and holo β- chain ions are now observed. The 
non-covalent interactions between the heme group and the globin chains has been 
maintained. Two types of dimers are also observed:α- plus β- globin with either one or two 
heme groups attached. Species can be confidently assigned up to m/z ~3000. There is a low 
abundance multiply charged peak at m/z 3800. It was not possible to deconvolute the 
suspected tetramer using the Xcalibur xtract programme so its presence could not be 
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confirmed. This proved the case for all suspected tetramers in data obtained throughout 
this chapter. A major problem encountered when using ammonium acetate as the 
electrospray solution was poor spray stability. To overcome this, small amounts of 
methanol were added to the electrospray solution with the aim of improving electrospray 
stability while maintaining Hb non-covalent interactions. An electrospray solution of 10 
mM ammonium acetate with 5 % methanol (containing 10 μΜ Hb) proved optimal in 
maximising spray stability and yielding reproducible results without denaturing non- 
covalent interactions, Figure 6.3. The mass spectra obtained both with and without the 
addition of methanol appear identical. Figure 6.4 shows a mass spectrum obtained when 
ammonium acetate concentration was increased from 10 mM to 100 mM in the ESI 
solution. The resultant mass spectrum shows an increase in the relative abundance of the 
αhβh12+ and αhβh11+ dimers and an increase in relative abundance of the suspected tetramer 
peaks. Nevertheless, it was still not possible to confirm these species as tetramers, 
probably due to their low abundance. Charge states observed in this spectrum range from 
[M + 20H]20+ to [M + 7H]7+.  
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Figure 6.1 Full MS spectrum obtained following direct infusion electrospray of 10 μM 
Hb. ESI solution consisted of water/methanol/formic acid (48.5:48.5:3,v/v).    
 
 
 
Figure 6.2 Full MS spectrum obtained following direct infusion electrospray of 10 μΜ 
Hb. ESI solution consisting of 10 mM ammonium acetate, h = heme attached. 
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Figure 6.3 Full MS spectrum obtained following direct infusion electrospray of 10 μΜ 
Hb. ESI solution consisting of 10 mM ammonium acetate in 5% methanol, h = heme 
attached.  
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Figure 6.4 Full MS spectrum obtained following direct infusion electrospray of 10 μΜ 
Hb. ESI solution consisting of 100 mM ammonium acetate in 5% methanol, h = heme 
attached. 
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The super charging agent m-nitrobenzyl alcohol (0.5 % m-NBA) [167, 168] was added to 
the ESI solution comprising of 10 Mm ammonium acetate in 5 % methanol, with aim of 
increasing the number of charged species visible in the spectrum, figure 6.5. The aim was 
to supercharge the tetramer to provide confident identification of the presence of the non-
covalently bond tetramer molecule in sample.  It did increase the charge states of the apo- 
and holo- globin chains from [M + 20H]20+ to [M + 22H]22+ however the addition of 0.5 % 
m-NBA and 0.75 % m-NBA (figure 6.6) served to denature the protein complex. Hb 
tetramers and globin chain dimers were no longer observed in the spectra. This observation  
can be explained by work presented by Sterling and Williams [169] which concludes that 
supercharging of a protein upon the addition of m-NBA is due to increased ESI droplet 
heating caused by m-NBA’s increased boiling point leading to the dissociation of non- 
covalent complexes.  
The above results show that use of an ESI solution comprising ammonium acetate with a 
5% methanol is able to preserve (to some degree) Hb non- covalent interactions, figure 6.4.  
The same conditions were subsequently employed to investigate Hb non-covalent 
interactions following LESA of DBS.   
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Figure 6.5 Full MS spectrum obtained following direct infusion electrospray of 10 μΜ 
Hb. ESI solution consisting of 100 mM ammonium acetate in 5% methanol, with 0.5 % m-
NBA, h = heme attached. 
 
 
Figure 6.6  Full MS spectrum obtained following direct infusion electrospray of 10 μΜ 
Hb. ESI solution consisting of 100 mM ammonium acetate in 5% methanol, with 0.75 % 
m-NBA, h = heme attached. 
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6.2.2. Adult DBS  
 
Figure 6.7 shows a full ‘native’ mass spectrum following liquid extraction surface analysis 
(LESA) of a normal adult DBS using an extraction/ESI solution of 100 mM ammonium 
acetate in 5% methanol and capillary temperature of 200 ºC (m/z range 600-4000). The 
surface sampling routine is identical to the method described in the previous section. The 
only difference is the extraction/ESI solution used. It appears Hb was not extracted from 
the DBS under these conditions. The concentration of ammonium acetate in the ESI 
solution was reduced to 50 mM, but again Hb was not extracted as shown in figure 6.8.  It 
was possible, by use of an ESI solution comprising 10 mM ammonium acetate with 5 % 
methanol, to extract Hb from the DBS by LESA as shown in figure 6.9. The mass 
spectrum produced is similar to the spectrum obtained when 10 μM Hb (in the same  ESI 
solution) was directly infused into the mass spectrometer, figure 6.3. In figure 6.9  the 
presence of multiply charged holo α- and holo β- chains as well as multiple dimers is also 
observed. This shows that ‘native’ Hb MS spectra can be produced directly from DBS 
without the need for any sample preparation.  
 
 
 
 
138 
 
 
 
Figure 6.7 Full MS spectrum obtained following LESA of an adult DBS. ESI solution 
consisting of 100 mM ammonium acetate in 5% methanol. 
 
 
 
 
Figure 6.8 Full MS spectrum obtained following LESA of an adult DBS with an ESI 
solution consisting of 50 mM ammonium acetate in 5% methano 
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Figure 6.9  Full MS spectrum obtained following LESA of a DBS. ESI solution consisting 
of 10 mM ammonium acetate in 5% methanol, h = heme attached. 
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6.2.3 Neonatal DBS 
 
The ESI solution consisting of 10 mM ammonium acetate in 5% methanol was used and  
applied to neonatal DBS. The resultant mass spectrum is shown in figure 6.10. Numerous 
(> 20) neonatal DBS were sampled, however no informative mass spectra were obtained. 
The only two peaks able to be successfully assigned were holo α- globin chains, that is α- 
globin+heme. This result demonstrates that although mass spectra were poor quality; some 
non- covalent interactions were preserved. One possible reason for the difference in 
spectra quality obtained between adult and neonatal samples could be sample age. Spectra 
acquired from adult DBS in this chapter were all obtained within a few days of the sample 
being initially taken (1-7 days) whereas neonatal samples were several months old. This 
may have an effect on the efficiency of Hb extraction process and the increased age of the 
newborn DBS may have allowed for increased haemoglobin denaturation, breaking some 
of the non-covalent interactions. This is backed up by observations reported by others the 
ability to distinguish between haemoglobin disorders by electrophoresis decreases the 
older the sample is before analysis [170]. 
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Figure 6.10 Full MS spectrum of LESA of a neonatal DBS using an ESI solution 
composed of of 10 mM ammonium acetate in 5% methanol. 
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6.3 Conclusion  
 
When whole blood is dried onto blood spot cards the red blood cells lyse. The cells 
contents are then released into solution upon resolubilisation of the DBS [171]. LESA  
resolubilises the dried blood spot during the liquid microjunction formation in the 
sampling process. Results obtained from native MS of liquid extraction surface analysis of 
adult DBS look promising: Hb non-covalent interactions were able to be maintained 
during the ionisation and analysis process in the presence of an ammonium acetate buffer. 
Non-covalent interactions between the heme group and the globin chains (holo α- and holo 
β- globin) as well as dimers of the globin chains were observed. No unexpected non-
covalent interactions such as two alpha globin chains or one globin chain plus two heme 
groups were observed. These interactions do usually not occur naturally. This suggests that 
native non-covalent interactions are preserved from sampling rather than formed during 
the ESI process. The presence of tetramers could not be confirmed in any of the spectra 
obtained during this investigation. This could be due to a combination of poor molecule 
charging and the need for a higher mass-to-charge range (greater than m/z 4000). An Hb 
tetramer has a large mass ~ 65 kDa, and for it to be observed within the mass range of the 
instrument, it would need to be highly multiply charged. An alternative instrument with a 
higher mass range may offer the opportunity to observe these species.  
 
Neonatal DBS were sampled in an identical fashion to adult DBS, however only poor 
quality spectra were obtained. Nevertheless, some non-covalent interactions were 
maintained.  
Results obtained from this work show that native mass spectrometry can be coupled to 
LESA to study a proteins non-covalent interactions from a complex sample without any 
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sample preparation. However the initial aim of being able to screen for abnormal Hb 
tetramers or dimers with the aim of detecting thalassimc disorders in newborn samples was 
not able to be completed in this study due to the difficultly of applying the native MS 
method to the neonatal samples.   
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Chapter 7: Discussion and future work 
 
The work presented in this thesis demonstrates the effectiveness of liquid extraction 
surface analysis (LESA) as a direct surface sampling technique to probe haemoglobin and 
haemoglobin variants in dried blood spot (DBS) samples by mass spectrometry. It offers a 
rapid, sample preparation free alternative screening technique to current protocols without 
the need for further confirmatory analysis. This would reduce the work flow Hb variant 
analysis in the clinical setting.  
7.1 Development of a method for the direct surface sampling of dried blood spots coupled 
with mass spectrometry for the analysis of haemoglobin 
 
Following investigations presented in chapter three, an optimal surface sampling method 
was determined to allow for the sampling of DBS for the extraction, detection and MS/MS 
of haemoglobin. Optimal surface sampling conditions to assure liquid microjunction 
formation and Hb extraction from the surface of a DBS and the detection of Hb by mass 
spectrometry were as follows; an ESI/ extraction solvent of 48.5:48.5 (v/v) methanol: 
water with 3 % (v/v) formic acid, a sampling time delay of 5 seconds and a tip height at 
1.6 mm from surface of the DBS. Further work to optimise the surface sampling routine to 
improve the detection of Hb by mass spectrometry could include investigating the use of 
other solvents such as acetonitrile and investigating the role the age of the DBS sample 
may play in spectra quality. 
Data presented in chapter three reveals that between 12 and 40 μΜ of Hb is electrosprayed 
into the mass spectrometer following LESA. Results also show that a directly quantitative 
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technique to diagnose quantitative globin chain variants showed that surface sampling 
technique is not reproducible under the conditions described in the chapter. An alternative 
approach for the diagnosis of quantitative Hb variants such as β thalassemia would need to 
be investigated.   
The optimisation of CID (normalised collision energy of 30 %) and ETD (activation 
energy of 20) fragmentation parameters to yield maximum sequence coverage (of up to 81 
%) increases the chance of Hb variant diagnosis while the semi- automated (and 
potentially automated) nature of the sampling technique allows for the sequential analysis 
of multiple samples. Future work to improve the % sequence coverage would be to 
investigate alternative fragmentation techniques such as higher energy collision induced 
dissociation (HCD) [172]. An alternative approach could be to combine the top-down 
approach described in this thesis with a bottom-up approach by performing automated 
[173] or on-spot tryptic digests to ensure maximum sequence coverage of Hb variants.  
7.2 Diagnosis of common haemoglobin variants in neonatal samples 
 
Liquid extraction surface analysis (LESA) was employed for the diagnosis of structural 
variants including HbS (which can be identified in SIM mode and confirmed by top-down 
CID analysis). The technique also diagnosed common Hb variants with mass shifts of less 
than 1 Da (HbC, HbD, and HbE). The technique can also successfully diagnose the 
clinically significant compound heterozygotes FSC and FSD. The ability to diagnose 
common structural variants without any sample preparation and minimal sampling 
handling offers considerable advantages in the clinical setting. However, high resolution 
mass spectrometers such as the Orbitrap are not routinely used in clinical laboratories. 
Quadrupoles are often used in clinical based screening programmes such as for the 
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diagnosis of phenylketonuria (PKU) [174], further work to assess the application of the 
direct surface sampling method to diagnose Hb variants using other mass spectrometers, 
particularly those instruments commonly used in a clinical setting would be useful. Other 
interesting further experiments would be to investigate what other proteins and small 
molecules can be extracted from DBS and observed by mass spectrometry using this 
surface sampling technique.     
Investigation of this technique to diagnosis of β thalassemia disorders revealed that in all 
samples analysed β- globin chains were not detected. This result indicates the potential of 
the technique to diagnose quantitative Hb variants. However, the failure to obserb β- 
globin chain cannot be used to definitively conclude the absence of β- globin in the 
sample. The absence of β- globin chain in the mass spectra could be due to ion 
suppression, particularly due to presence of foetal Hb in relatively large quantities in 
neonatal samples. A comparison of data obtained when sampling DBS of adult β 
thalassemia patients to see if only α- globin chains where observed would be worthwhile. 
If reliable diagnosis of β thalassemia proved possible using this technique could be 
considered a viable alternative to the current screening methods employed.   
 
7.3 Diagnosis of unknown haemoglobin variants in neonatal samples 
 
The robustness of the technique is demonstrated by the ability to use LESA of DBS 
coupled with top-down proteomics to diagnose unknown variants. Six samples which had 
been identified as variants by ceHPLC and IEF, but from which the nature of the variant 
was not determined, were analysed. Two of the samples were determined to be 
heterozygous Hb D-Iran following CID of the overlapping β-chain and variant peaks. ETD 
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confirmed a third variant as Hb Headington. Mass analysis of the fourth variant suggested 
either a Gly→Asp or Ala→Gln β-chain substitution. CID confirmed the variant as Hb J 
Baltimore. The fifth sample was confirmed as a rare α- variant with a mass shift of +113 
Da. CID revealed it to be the insertion variant Hb Phnom Penh. The mass analysis, CID 
and ETD of the sixth sample did not indicate the presence of a variant. This sample was 
likely to have been mis-diagnosed as a variant during ceHPLC and IEF analysis. 
 A comparison of manual and automated data analysis of the same resultant unknown Hb 
variants studied. Following spectrum deconvolution, the ProSightPTM software was used 
to search against (the manually assigned) Hb variant sequences to illustrate such an 
approach. In all cases, the automated search identified unique fragment ions, allowing 
variant diagnosis, albeit with reduced overall protein sequence coverage. Efficient 
application of  automated data analysis would require improvements to Xtract programme 
and the use or/development of software capable of searching top-down MS/MS data (CID, 
ETD) against a dedicated haemoglobin variant database. These results demonstrates the 
both the potential of using top-down proteomics (with is associated complex data analysis) 
in clinical diagnostics with automated data analysis procedure.  
 
7.4 Analysis of haemoglobins non-covalent reactions by mass spectrometry 
 
Data presented in chapter six show that Hb non-covalent interactions can be probed by 
liquid extraction surface analysis of DBS. Hb non-covalent interactions were able to be 
maintained during the ionisation and analysis process in the presence of an ammonium 
acetate buffer. Non-covalent interactions between the heme group and the globin chains 
(holo α- and holo β- globin) as well as interactions between the globin chains (dimers) 
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were observed however, spectra obtained under these conditions were often not 
reproducible due to problems with spray stability.  
Sampling of neonatal DBS with an ammonium acetate buffer containing 5 % methanol 
produced poor quality mass spectra. Results obtained from this work show that native 
mass spectrometry can be coupled to LESA to yield some structural information from a 
complex sample without any sample preparation. However the initial aim of being able to 
screen for abnormal Hb tetramers or dimers with the aim of detecting thalassemias was not 
able to be met due to the difficultly of applying the native MS method to the neonatal 
samples. Further interesting work to study Hb covalent and non-covalent structure could 
include coupling the surface sampling with ion mobility mass spectrometry. Ion mobility 
mass spectrometry could also be used to separate Hb variants where changes to the 
molecules’ structure has occurred (i.e. it could potentially be used to separate HbA from 
HbS).   
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Appendices 
 
Appendix 1. Results of one-way ANOVA. Does formic acid % in ESI solution effect the 
intenstity of obserbed β- globin chains. 
SUMMARY 
      Groups Count Sum Average Variance 
  1% 9 362.3965 40.26628 372.8786 
  2% 9 390.3501 43.37223 201.5902 
  3% 9 376.717 41.85744 312.5474 
  5% 9 502.4478 55.82753 358.6493 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 1365.578 3 455.1926 1.461685 0.243459 2.90112 
Within Groups 9965.324 32 311.4164 
   
       Total 11330.9 35         
 
 
 
 
 
 
 
 
 
 
 
159 
 
 
 
 
Appendix 2. Results of one-way ANOVA. Does MeOH % in ESI solution effect the 
intenstity of obserbed β- globin chains. 
 
SUMMARY 
     Groups Count Sum Average Variance 
  0.1 9 258.8943 28.76604 502.8608 
  0.3 9 242.9414 26.99349 152.0132 
  0.5 9 376.717 41.85744 312.5474 
  0.7 9 431.3282 47.92536 2283.784 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 2784.389 3 928.1298 1.14189 0.347059 2.90112 
Within Groups 26009.64 32 812.8014 
   
       Total 28794.03 35         
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Appendix 3. Results of one-way ANOVA. Does sampling time delay effect the intenstity 
of obserbed β- globin chains. 
SUMMARY 
     Groups Count Sum Average Variance 
  0 9 18.59248 2.065831 3.473802 
  2.5 9 167.5195 18.61328 91.40132 
  5 9 327.7643 36.41825 12.90067 
  7.5 9 333.3878 37.04309 52.94357 
  10 9 268.9366 29.88184 22.97202 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 7792.379 4 1948.095 53.0263 
1.82E-
15 2.605975 
Within Groups 1469.531 40 36.73828 
   
       Total 9261.91 44         
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Appendix 4. Results of one-way ANOVA. Does sampling time delay effect the intenstity 
of obserbed β- globin chains. 
 
SUMMARY 
     Groups Count Sum Average Variance 
  1 mm 3 99.49147 33.16382 46.85932 
  1.2 mm 3 124.6958 41.56525 63.54393 
  1.6 mm 3 106.4071 35.46904 8.924575 
  2 mm 3 87.86103 29.28701 55.29712 
  2.4 mm 3 105.1101 35.03671 38.27925 
  2.8 mm 3 103.2488 34.41626 33.28988 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 238.4594 5 47.69188 1.1623 0.381919 3.105875 
Within Groups 492.3882 12 41.03235 
   
       Total 730.8475 17         
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Appendix 5. CID (normalized collision energy 30 %) fragment ions of normal adult α- 
globin chain 
Meas m/z Calc m/z  Δ ppm  Fragment 
338.1822 338.1823 -0.30 y2 
433.7592 433.7584 1.84 y7
2+
 
466.2777 466.2772 1.07 y3 
484.2827 484.2822 1.03 y8
2+
 
527.7986 527.7982 0.76 y9
2+
 
553.3096 553.3093 0.54 y4 
583.3089 583.3086 0.51 b6 
612.8513 612.8510 0.49 b12
2+
 
620.8487 620.8484 0.48 y11
2+
 
648.3699 648.3695 0.62 b13
2+
 
654.3574 654.3570 0.61 y5 
656.3681 656.3670 1.68 y12
2+
 
672.3757 672.3772 -2.23 y18
3+
 
677.7099 677.7093 0.89 b20
3+
 
696.0566 696.0563 0.43 y19
3+
 
701.3889 701.3884 0.71 b21
3+
 
711.4044 711.4036 1.12 b7 
712.9094 712.9090 0.56 y13
2+
 
720.3962 720.3955 0.97 b22
3+
 
741.4101 741.4092 1.21 b14
2+
 
759.6610 759.6605 0.66 y28
4+
 
763.4101 763.4097 0.52 b23
3+
 
767.4417 767.4410 0.91 y6 
774.7658 774.7654 0.52 y21
3+
 
786.4438 786.4432 0.76 y14
2+
 
787.9321 787.9315 0.76 y29
4+
 
795.1673 795.1665 1.01 b31
4+
 
798.4407 798.4444 -4.63 y22
3+
 
817.7649 817.7642 0.86 b24
3+
 
822.1969 822.1962 0.85 y30
4+
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827.9268 827.9266 0.24 b32
4+
 
830.7961 830.7953 0.96 y23
3+
 
833.9681 833.9674 0.84 b16
2+
 
839.9567 839.9555 1.39 y31
4+
 
842.2601 842.2605 -0.47 y39
5+
 
850.4915 850.4907 0.94 y15
2+
 
860.4508 860.4503 0.58 b26
3+
 
864.4788 864.4779 1.04 y24
3+
 
864.6945 864.6937 0.93 b33
4+
 
866.5103 866.5094 1.04 y7 
867.0523 867.0514 1.04 b41
5+
 
883.0631 883.0656 -2.83 y56
7+
 
883.5036 883.5016 2.26 b17
2+
 
892.9660 892.9647 1.46 b34
4+
 
903.4656 903.4645 1.22 b27
3+
 
904.9014 904.9006 0.88 y42
5+
 
908.0052 908.0042 1.10 y16
2+
 
911.2480 911.2477 0.33 y34
4+
 
912.0126 912.0123 0.33 b18
2+
 
913.2971 913.2964 0.77 b50
6+
 
913.5017 913.5007 1.09 y25
3+
 
914.7238 914.7227 1.20 b35
4+
 
918.6145 918.6136 0.98 b60
7+
 
922.8014 922.8000 1.52 b51
6+
 
926.4951 926.4942 0.97 b9 
927.1444 927.1436 0.86 b28
3+
 
936.0169 936.0148 2.24 y35
4+
 
936.9110 936.9128 -1.92 b61
7+
 
947.5319 947.5309 1.06 b19
2+
 
950.6678 950.6674 0.42 y61
7+
 
952.7433 952.7429 0.42 b72
8+
 
956.5161 956.5149 1.25 y26
3+
 
964.2871 964.2858 1.35 y36
4+
 
964.5475 964.5462 1.35 y17
2+
 
964.8387 964.8383 0.41 b29
3+
 
965.1266 965.1264 0.21 b73
8+
 
966.8235 966.8222 1.34 y62
7+
 
967.5581 967.5571 1.03 y8 
975.7542 975.7530 1.23 b37
4+
 
975.9030 975.9001 2.97 b45
5+
 
977.6475 977.6461 1.43 b64
7+
 
980.1950 980.1939 1.12 y27
3+
 
992.5591 992.5568 2.32 y37
4+
 
993.8811 993.8832 -2.11 b75
8+
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1001.0169 1001.0149 2.00 b38
4+
 
1005.3194 1005.3138 5.57 b46
5+
 
1007.8582 1007.8525 5.66 b30
3+
 
1008.0637 1008.0622 1.49 y18
2+
 
1012.5461 1012.5449 1.19 y28
3+
 
1016.0617 1016.0603 1.38 b20
2+
 
1017.8595 1017.8521 7.27 b57
6+
 
1018.3102 1018.3091 1.08 y38
4+
 
1021.9671 1021.9661 0.98 y47
5+
 
1025.5636 1025.5626 0.98 b10 
1026.2774 1026.2768 0.58 b39
4+
 
1028.3208 1028.3192 1.56 b47
5+
 
1030.0769 1030.0754 1.46 y56
6+
 
1043.5821 1043.5808 1.25 y19
2+
 
1044.8239 1044.8245 -0.57 b69
7+
 
1050.2406 1050.2396 0.95 y29
3+
 
1051.5789 1051.5789 0.00 b21
2+
 
1052.5714 1052.5739 -2.38 y39
4+
 
1054.5905 1054.5891 1.33 y9 
1089.1168 1089.1153 1.38 b1121
1+
 
1094.4401 1094.4387 1.28 y60
6+
 
1099.3977 1099.3957 1.82 b113
11+
 
1108.9458 1108.9441 1.53 y61
6+
 
1112.1123 1112.1102 1.89 y20
2+
 
1127.3811 1127.3844 -2.93 b105
10+
 
1130.8770 1130.8739 2.74 y42
4+
 
1132.5057 1132.5028 2.56 y105
10+
 
1140.8393 1140.8304 7.80 y138
13+
 
1147.5302 1147.5252 4.36 y139
13+
 
1153.6593 1153.6575 1.56 y10 
1153.6593 1153.6575 1.56 b11 
1154.4457 1154.4426 2.69 b76
7+
 
1161.6458 1161.6444 1.21 y21
2+
 
1170.0069 1170.0128 -5.04 b109
10+
 
1174.8155 1174.8135 1.70 y65
6+
 
1177.1134 1177.1165 -2.63 b110
10+
 
1190.2855 1190.2838 1.43 b34
3+
 
1194.7492 1194.7473 1.59 b79
7+
 
1206.4017 1206.4011 0.50 y91
8+
 
1209.2393 1209.2345 3.97 b113
10+
 
1210.7496 1210.7530 -2.81 y101
9+
 
1214.6612 1214.6612 0.00 y34
3+
 
1219.7977 1219.7940 3.03 b69
6+
 
1234.9976 1234.9959 1.38 y68
6+
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1240.6909 1240.6896 1.05 y11 
1245.6907 1245.6894 1.04 y23
2+
 
1247.1453 1247.1449 0.32 b71
6+
 
1254.6584 1254.6533 4.06 b25
2+
 
1268.3184 1268.3173 0.87 b36
3+
 
1274.3440 1274.3505 -5.10 y70
6+
 
1277.2068 1277.2058 0.78 y47
4+
 
1296.2146 1296.2132 1.08 y24
2+
 
1311.7280 1311.7267 0.99 y12 
1324.8417 1324.8418 -0.08 b75
6+
 
1330.5340 1330.5314 1.95 y61
5+
 
1346.6811 1346.6819 -0.59 b76
6+
 
1354.6960 1354.6932 2.07 b27
2+
 
1357.4090 1357.4098 -0.59 y38
3+
 
1368.0320 1368.0333 -0.95 b39
3+
 
1369.7490 1369.7474 1.17 y25
2+
 
1393.6997 1393.7040 -3.09 b79
6+
 
1403.0982 1403.0961 1.50 y39
3+
 
1409.5746 1409.5748 -0.14 y65
5+
 
1410.7316 1410.7317 -0.07 b40
3+
 
1424.8119 1424.8108 0.77 y13 
1469.7883 1469.7873 0.68 y27
2+
 
1518.3149 1518.3137 0.79 y28
2+
 
1571.8806 1571.8792 0.89 y14 
1574.8571 1574.8557 0.89 y29
2+
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Appendix 6. CID (normalized collision energy 30 %) fragment ions of normal adult β- 
globin chain 
Meas m/z Calc m/z Δ ppm Fragment 
350.2179 350.2187 -2.28 b3 
447.2348 447.2350 -0.45 y3 
451.2660 451.2663 -0.66 b4 
511.2690 511.2693 -0.59 b9
2+
 
512.7693 512.7698 -0.98 y9
2+
 
526.6342 526.6352 -1.90 y15
3+
 
546.7873 546.7878 -0.91 b10
2+
 
562.3029 562.3040 -1.96 y10
2+
 
584.2933 584.2940 -1.20 y4 
590.8140 590.8147 -1.18 y11
2+
 
596.3214 596.3220 -1.01 b11
2+
 
608.8346 608.8354 -1.31 y23
4+
 
623.6753 623.6758 -0.80 y17
3+
 
626.3327 626.3333 -0.96 y12
2+
 
646.8451 646.8459 -1.24 b12
2+
 
647.3535 647.3549 -2.16 y18
3+
 
649.6942 649.6948 -0.92 b18
3+
 
655.3304 655.3311 -1.07 y5 
671.0330 671.0339 -1.34 y19
3+
 
675.8668 675.8675 -1.04 y13
2+
 
677.3611 677.3617 -0.89 b6 
682.3637 682.3644 -1.03 b13
2+
 
687.7083 687.7091 -1.16 b19
3+
 
694.5838 694.5828 1.44 b33
5+
 
713.7194 713.7201 -0.98 y20
3+
 
720.7312 720.7319 -0.97 b20
3+
 
725.4011 725.4017 -0.83 y14
2+
 
738.9058 738.9065 -0.95 b14
2+
 
747.0090 747.0092 -0.27 b35
5+
 
759.0736 759.0742 -0.79 b21
3+
 
761.2002 761.2018 -2.10 y35
5+
 
768.4145 768.4151 -0.78 y6 
779.0931 779.0938 -0.90 y22
3+
 
781.0148 781.0155 -0.90 y36
5+
 
786.6664 786.6676 -1.53 b30
4+
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789.4485 789.4492 -0.89 y15
2+
 
802.0878 802.0884 -0.75 b22
3+
 
803.6342 803.6356 -1.74 b37
5+
 
806.4037 806.4043 -0.74 b7 
811.4441 811.4448 -0.86 y23
3+
 
814.9379 814.9386 -0.86 b31
4+
 
820.4351 820.4360 -1.10 y30
4+
 
823.8485 823.8451 4.13 b38
5+
 
831.9455 831.9461 -0.72 b15
2+
 
835.1106 835.1112 -0.72 b23
3+
 
839.4515 839.4522 -0.83 y7 
843.2090 843.2096 -0.71 b32
4+
 
845.1268 845.1273 -0.59 y24
3+
 
853.4779 853.4785 -0.70 y16
2+
 
854.1175 854.1184 -1.05 b24
3+
 
854.7001 854.7007 -0.70 y31
4+
 
859.7956 859.7962 -0.70 y47
6+
 
867.9761 867.9767 -0.69 b33
4+
 
872.4601 872.4600 0.11 y32
4+
 
880.6765 880.6770 -0.57 b40
5+
 
888.6131 888.6139 -0.90 y56
7+
 
892.7431 892.7438 -0.78 b34
4+
 
894.1492 894.1501 -1.01 y25
3+
 
900.7302 900.7310 -0.89 y33
4+
 
916.1391 916.1397 -0.65 b26
3+
 
918.3206 918.3220 -1.52 y50
6+
 
919.4805 919.4817 -1.31 y58
7+
 
924.5037 924.5043 -0.65 b17
2+
 
925.4985 925.4981 0.43 y34
4+
 
933.5090 933.5096 -0.64 b35
4+
 
934.4994 934.4993 0.11 b8 
937.1637 937.1643 -0.64 y26
3+
 
939.8182 939.8188 -0.64 b27
3+
 
949.1375 949.1397 -2.32 y97
11+
 
951.2499 951.2504 -0.53 y35
4+
 
953.4945 953.4952 -0.73 y8 
958.5162 958.5185 -2.40 y52
6+
 
968.5166 968.5097 7.12 y70
8+
 
970.5281 970.5287 -0.62 y18
2+
 
974.0381 974.0386 -0.51 b18
2+
 
976.0172 976.0175 -0.31 y36
4+
 
977.5119 977.5135 -1.64 b28
3+
 
977.6892 977.6899 -0.72 y53
6+
 
982.7166 982.7193 -2.75 b44
5+
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986.3351 986.3350 0.10 y45
5+
 
994.8571 994.8578 -0.70 y54
6+
 
996.5208 996.5206 0.20 b29
3+
 
998.6509 998.6525 -1.60 y73
8+
 
998.8693 998.8698 -0.50 y28
3+
 
1003.8111 1003.8112 -0.10 y64
7+
 
1004.2871 1004.2885 -1.39 y37
4+
 
1006.0470 1006.0472 -0.20 y19
2+
 
1011.6075 1011.6106 -3.06 y111
12+
 
1017.7001 1017.7010 -0.88 y55
6+
 
1024.5315 1024.5323 -0.78 y9 
1025.1945 1025.1992 -4.58 y112
12+
 
1031.5523 1031.5540 -1.65 y47
5+
 
1033.8461 1033.8482 -2.03 y96
10+
 
1048.5539 1048.5543 -0.38 b30
3+
 
1052.6534 1052.6561 -2.56 y98
10+
 
1069.1601 1069.1595 0.56 b48
5+
 
1070.0765 1070.0765 0.00 y20
2+
 
1071.4683 1071.4589 8.77 b99
10+
 
1072.5598 1072.5607 -0.84 y58
6+
 
1075.4656 1075.4672 -1.49 y100
10+
 
1080.5940 1080.5942 -0.19 b20
2+
 
1081.1679 1081.1641 3.51 b100
10+
 
1081.1679 1081.1694 -1.39 y101
10+
 
1085.3623 1085.3569 4.98 y140
14+
 
1086.2491 1086.2490 0.09 b31
3+
 
1091.5880 1091.5832 4.40 y91
9+
 
1093.5769 1093.5789 -1.83 y30
3+
 
1100.5956 1100.5945 1.00 b40
4+
 
1103.4821 1103.4837 -1.45 y111
11+
 
1107.2619 1107.2728 -9.84 y132
13+
 
1113.9167 1113.9188 -1.89 y123
12+
 
1115.9714 1115.9715 -0.09 y133
13+
 
1116.7974 1116.8017 -3.85 y144
14+
 
1118.3025 1118.3076 -4.56 y112
11+
 
1123.9434 1123.9437 -0.27 b32
3+
 
1137.3597 1137.3616 -1.67 b41
4+
 
1141.1725 1141.1732 -0.61 y73
7+
 
1148.6069 1148.6083 -1.22 y96
9+
 
1151.3864 1151.3808 4.86 b96
9+
 
1156.9662 1156.9665 -0.26 b33
3+
 
1159.8330 1159.8358 -2.41 y97
9+
 
1166.6020 1166.6096 -6.51 b97
9+
 
1168.1368 1168.1371 -0.26 y22
2+
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1169.5041 1169.5060 -1.62 y98
9+
 
1174.1284 1174.1287 -0.26 b4
24+
 
1177.4504 1177.4497 0.59 b65
6+
 
1180.6227 1180.6222 0.42 y11 
1182.0697 1182.0709 -1.02 y99
9+
 
1185.4191 1185.4181 0.84 y109
10+
 
1185.4191 1185.4197 -0.51 b109
10+
 
1189.9888 1189.9893 -0.42 b34
3+
 
1190.3980 1190.3979 0.08 b99
9+
 
1191.6402 1191.6368 2.85 b11 
1194.8529 1194.8517 1.00 y100
9+
 
1201.1846 1201.1816 2.50 b100
9+
 
1201.1846 1201.1874 -2.33 y101
9+
 
1202.6283 1202.6290 -0.58 b22
2+
 
1206.3890 1206.3893 -0.25 b43
4+
 
1209.3424 1209.3427 -0.25 y78
7+
 
1213.7287 1213.7313 -2.14 y111
10+
 
1216.6628 1216.6635 -0.58 y23
2+
 
1221.5420 1221.5470 -4.09 b123
11+
 
1225.4916 1225.4975 -4.81 y79
7+
 
1228.1459 1228.1473 -1.14 b44
4+
 
1230.0349 1230.0376 -2.20 y112
10+
 
1239.6480 1239.6502 -1.77 y80
7+
 
1244.3430 1244.3437 -0.56 b35
3+
 
1251.6594 1251.6593 0.08 y12 
1252.1637 1252.1632 0.40 b23
2+
 
1257.9404 1257.9494 -7.15 y81
7+
 
1264.9140 1264.9145 -0.40 b45
4+
 
1267.1863 1267.1873 -0.79 y24
2+
 
1268.1649 1268.1673 -1.89 y69
6+
 
1279.1689 1279.1698 -0.70 b46
4+
 
1289.1906 1289.1907 -0.08 y47
4+
 
1291.0107 1291.0105 0.15 y70
6+
 
1292.0563 1292.0584 -1.63 y96
8+
 
1302.8489 1302.8500 -0.84 y71
6+
 
1307.9255 1307.9266 -0.84 b47
4+
 
1313.6912 1313.6886 1.98 b73
6+
 
1315.5643 1315.5683 -3.04 y98
8+
 
1336.1961 1336.1976 -1.12 b48
4+
 
1340.7220 1340.7215 0.37 y25
2+
 
1350.7271 1350.7277 -0.44 y13 
1357.9555 1357.9556 -0.07 b49
4+
 
1373.7039 1373.7060 -1.53 b26
2+
 
1383.2152 1383.2175 -1.66 b50
4+
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1405.2417 1405.2428 -0.78 y26
2+
 
1409.2229 1409.2245 -1.14 b27
2+
 
1410.7269 1410.7319 -3.54 y78
6+
 
1412.7318 1412.7382 -4.53 b65
5+
 
1449.7947 1449.7961 -0.97 y14 
1476.8045 1476.8057 -0.81 b14 
1497.7973 1497.8011 -2.54 y28
2+
 
1498.3018 1498.2925 6.21 y83
6+
 
1571.3352 1571.3353 -0.06 y29
2+
 
1577.8898 1577.8911 -0.82 y15 
1662.8840 1662.8850 -0.60 b15 
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Appendix 7. CID (normalized collision energy 30 %) fragment ions of normal neonatal α- 
globin chain 
Meas m/z Calc m/z Δ ppm Fragment  
466.2792 466.2772 4.29 y3 
527.7999 527.7982 3.22 y9
2+
 
553.3110 553.3093 3.07 y4 
577.3344 577.3324 3.46 b11
2+
 
583.3104 583.3086 3.09 b6 
612.8532 612.8510 3.59 b12
2+
 
620.8498 620.8484 2.25 y11
2+
 
648.3713 648.3695 2.78 b13
2+
 
654.3588 654.3570 2.75 y5 
677.7101 677.7093 1.18 b20
3+
 
701.3899 701.3884 2.14 b21
3+
 
712.9108 712.9090 2.52 y13
2+
 
720.3958 720.3955 0.42 b22
3+
 
741.4120 741.4092 3.78 b14
2+
 
741.7438 741.7426 1.62 y20
3+
 
759.6620 759.6605 1.97 y28
4+
 
763.4113 763.4097 2.10 b23
3+
 
767.4429 767.4410 2.48 y6 
774.7663 774.7654 1.16 y21
3+
 
786.4451 786.4432 2.42 y14
2+
 
787.9330 787.9315 1.90 y29
4+
 
795.1677 795.1665 1.51 b31
4+
 
817.7661 817.7642 2.32 b24
3+
 
822.1977 822.1962 1.82 y30
4+
 
827.9272 827.9266 0.72 b32
4+
 
830.7971 830.7953 2.17 y23
3+
 
833.9696 833.9674 2.64 b16
2+
 
850.4928 850.4907 2.47 y15
2+
 
172 
 
860.4530 860.4503 3.14 b26
3+
 
864.4796 864.4779 1.97 y24
3+
 
866.5118 866.5094 2.77 y7 
883.5046 883.5016 3.40 b17
2+
 
892.9669 892.9647 2.46 b34
4+
 
903.4673 903.4645 3.10 b27
3+
 
908.0065 908.0042 2.53 y16
2+
 
911.2501 911.2477 2.63 y34
4+
 
912.0140 912.0123 1.86 b18
2+
 
913.5032 913.5007 2.74 y25
3+
 
914.7230 914.7227 0.33 b35
4+
 
926.4966 926.4942 2.59 b9 
927.1463 927.1436 2.91 b28
3+
 
936.0170 936.0148 2.35 y35
4+
 
947.5336 947.5309 2.85 b19
2+
 
956.5174 956.5149 2.61 y26
3+
 
964.5490 964.5462 2.90 y17
2+
 
967.5599 967.5571 2.89 y8 
980.1966 980.1939 2.75 y27
3+
 
992.5604 992.5568 3.63 y37
4+
 
993.8851 993.8832 1.91 b75
8+
 
1008.0652 1008.0622 2.98 y18
2+
 
1012.5478 1012.5449 2.86 y28
3+
 
1016.0634 1016.0603 3.05 b20
2+
 
1018.3096 1018.3091 0.49 y38
4+
 
1021.9686 1021.9661 2.45 y47
5+
 
1025.5657 1025.5626 3.02 b10 
1028.3208 1028.3192 1.56 b47
5+
 
1030.0766 1030.0754 1.16 y56
6+
 
1043.5839 1043.5808 2.97 y19
2+
 
1044.8273 1044.8245 2.68 b69
7+
 
1050.2425 1050.2396 2.76 y29
3+
 
1052.5716 1052.5739 -2.19 y39
4+
 
1054.5923 1054.5891 3.03 y9 
1089.1205 1089.1153 4.77 b1121
1+
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1091.5765 1091.5722 3.94 y121
12+
 
1094.4403 1094.4387 1.46 y60
6+
 
1095.9289 1095.9259 2.74 y30
3+
 
1099.3966 1099.3957 0.82 b113
11+
 
1100.6752 1100.6754 -0.18 y111
11+
 
1102.5806 1102.5880 -6.71 y102
10+
 
1108.9465 1108.9441 2.16 y6
16+
 
1112.1138 1112.1102 3.24 y20
2+
 
1113.4631 1113.4618 1.17 b94
9+
 
1119.6090 1119.6049 3.66 y31
3+
 
1127.7885 1127.7914 -2.57 y62
6+
 
1130.8758 1130.8739 1.68 y42
4+
 
1132.4917 1132.5028 -9.80 y105
10+
 
1135.7258 1135.7226 2.82 b75
7+
 
1140.8752 1140.8760 -0.70 y115
11+
 
1142.0975 1142.0974 0.09 b128
12+
 
1147.5282 1147.5252 2.61 y139
13+
 
1153.6607 1153.6575 2.77 b10 
1153.6607 1153.6575 2.77 y10 
1154.4429 1154.4426 0.26 b76
7+
 
1161.6465 1161.6444 1.81 y21
2+
 
1174.8153 1174.8135 1.53 y65
6+
 
1177.1162 1177.1165 -0.25 b110
10+
 
1184.2223 1184.2202 1.77 b111
10+
 
1194.7493 1194.7473 1.67 b79
7+
 
1209.2370 1209.2345 2.07 b113
10+
 
1218.7960 1218.7940 1.64 b69
6+
 
1219.2968 1219.2945 1.89 b35
3+
 
1234.9987 1234.9959 2.27 y68
6+
 
1240.6929 1240.6896 2.66 y11 
1245.6926 1245.6894 2.57 y23
2+
 
1247.1451 1247.1449 0.16 b71
6+
 
1268.3195 1268.3173 1.73 b36
3+
 
1277.2075 1277.2085 -0.78 y47
4+
 
1296.2165 1296.2132 2.55 y24
2+
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1307.8007 1307.7953 4.13 b110
9+
 
1311.7302 1311.7267 2.67 y12 
1346.6827 1346.6819 0.59 b76
6+
 
1369.7510 1369.7474 2.63 y25
2+
 
1424.8144 1424.8108 2.53 y13 
1434.2723 1434.2687 2.51 y26
2+
 
1518.3176 1518.3137 2.57 y28
2+
 
1571.8832 1571.8793 2.48 y14 
1574.8603 1574.8557 2.92 y29
2+
 
1699.9788 1699.9741 2.76 y15 
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Appendix 8. CID (normalized collision energy 30 %) fragment ions of normal neonatal β- 
globin chain 
Meas m/z Calc m/z Δ ppm Fragment 
350.2192 350.2187 1.43 b3 
451.2678 451.2663 3.32 b4 
512.7711 512.7698 2.54 y9
2+
 
546.7895 546.7878 3.11 b10
2+
 
584.2957 584.2940 2.91 y4 
590.8164 590.8147 2.88 y11
2+
 
596.3237 596.3220 2.85 b11
2+
 
608.8370 608.8354 2.63 y23
4+
 
623.6776 623.6758 2.89 y17
3+
 
626.3352 626.3333 3.03 y12
2+
 
646.8478 646.8459 2.94 b12
2+
 
649.6961 649.6948 2.00 b18
3+
 
655.3331 655.3311 3.05 y5 
671.0362 671.0339 3.43 y19
3+
 
675.8694 675.8675 2.81 y13
2+
 
677.3637 677.3617 2.95 b6 
682.3665 682.3644 3.08 b13
2+
 
687.7108 687.7091 2.47 b19
3+
 
694.5849 694.5828 3.02 b33
5+
 
713.7220 713.7201 2.66 y20
3+
 
714.3916 714.3965 -6.86 b34
5+
 
720.7341 720.7319 3.05 b20
3+
 
725.4039 725.4017 3.03 y14
2+
 
738.9088 738.9065 3.11 b14
2+
 
747.0115 747.0092 3.08 b35
5+
 
759.0768 759.0742 3.43 b21
3+
 
761.2044 761.2018 3.42 y35
5+
 
768.4176 768.4151 3.25 y6 
779.0963 779.0938 3.21 y22
3+
 
781.0175 781.0155 2.56 y36
5+
 
786.1738 786.1713 3.18 y29
4+
 
786.6694 786.6676 2.29 b30
4+
 
789.4516 789.4492 3.04 y15
2+
 
802.0909 802.0884 3.12 b22
3+
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806.4070 806.4043 3.35 b7 
811.4473 811.4448 3.08 y23
3+
 
814.9412 814.9386 3.19 b31
4+
 
820.4386 820.4360 3.17 y30
4+
 
831.9488 831.9461 3.25 b15
2+
 
835.1139 835.1112 3.23 b23
3+
 
839.4547 839.4522 2.98 y7 
843.2123 843.2096 3.20 b32
4+
 
845.1302 845.1273 3.43 y24
3+
 
853.4816 853.4785 3.63 y16
2+
 
854.1214 854.1184 3.51 b24
3+
 
854.7033 854.7007 3.04 y31
4+
 
859.7991 859.7962 3.37 y47
6+
 
867.9795 867.9767 3.23 b33
4+
 
872.4633 872.4600 3.78 y32
4+
 
873.1281 873.1255 2.98 b25
3+
 
888.6148 888.6139 1.01 y56
7+
 
891.1355 891.1341 1.57 b48
6+
 
892.7467 892.7438 3.25 b34
4+
 
894.1534 894.1501 3.69 y25
3+
 
900.7335 900.7310 2.78 y33
4+
 
905.6342 905.6395 -5.85 b49
6+
 
916.1429 916.1397 3.49 b26
3+
 
918.3231 918.3220 1.20 y50
6+
 
919.4830 919.4817 1.41 y58
7+
 
924.5074 924.5043 3.35 b17
2+
 
933.5128 933.5096 3.43 b35
4+
 
934.5029 934.4993 3.85 b8 
935.0133 935.0101 3.42 y17
2+
 
937.1674 937.1693 -2.03 y51
6+
 
939.8221 939.8188 3.51 b27
3+
 
939.9557 939.9535 2.34 y96
11+
 
949.1309 949.1397 -9.27 y97
11+
 
951.2536 951.2504 3.36 y35
4+
 
953.4984 953.4952 3.36 y8 
958.5201 958.5185 1.67 y52
6+
 
968.5034 968.5097 -6.50 y70
8+
 
970.5321 970.5287 3.50 y18
2+
 
974.0419 974.0386 3.39 b18
2+
 
976.0209 976.0175 3.48 y36
4+
 
977.5158 977.5135 2.35 b28
3+
 
977.6926 977.6896 3.07 y53
6+
 
982.7199 982.7193 0.61 b44
5+
 
986.3388 986.3350 3.85 y45
5+
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994.8593 994.8578 1.51 y54
6+
 
996.5268 996.5206 6.22 b29
3+
 
998.6554 998.6525 2.90 y73
8+
 
998.8734 998.8698 3.60 y28
3+
 
1003.8108 1003.8112 -0.40 y64
7+
 
1004.2922 1004.2926 -0.40 b37
4+
 
1006.0511 1006.0472 3.88 y19
2+
 
1011.6053 1011.6106 -5.24 y111
12+
 
1017.7053 1017.7010 4.23 y55
6+
 
1024.5350 1024.5323 2.64 y9 
1025.1979 1025.1992 -1.27 y112
12+
 
1031.5566 1031.5540 2.52 y47
5+
 
1033.8506 1033.8482 2.32 y96
10+
 
1043.9543 1043.9529 1.34 y97
10+
 
1069.1641 1069.1595 4.30 b48
5+
 
1070.0805 1070.0765 3.74 y20
2+
 
1071.4658 1071.4589 6.44 b99
10+
 
1072.5659 1072.5607 4.85 y58
6+
 
1075.4730 1075.4672 5.39 y100
10+
 
1080.5982 1080.5942 3.70 b20
2+
 
1085.3582 1085.3569 1.20 y140
14+
 
1086.2533 1086.2490 3.96 b31
3+
 
1093.5805 1093.5789 1.46 y30
3+
 
1103.4877 1103.4837 3.62 y111
11+
 
1107.2639 1107.2728 -8.04 y132
13+
 
1108.7224 1108.7243 -1.71 y143
14+
 
1118.3069 1118.3076 -0.63 y112
11+
 
1123.9475 1123.9437 3.38 b32
3+
 
1137.3623 1137.3616 0.62 b41
4+
 
1141.1753 1141.1732 1.84 y73
7+
 
1148.6115 1148.6083 2.79 y96
9+
 
1151.3910 1151.3808 8.86 b96
9+
 
1156.9705 1156.9665 3.46 b33
3+
 
1159.8386 1159.8358 2.41 y97
9+
 
1166.6173 1166.6096 6.60 b97
9+
 
1168.1411 1168.1371 3.42 y22
2+
 
1169.5085 1169.5060 2.14 y98
9+
 
1174.1331 1174.1287 3.75 b42
4+
 
1177.4500 1177.4497 0.25 b65
6+
 
1180.6265 1180.6222 3.64 y11 
1182.0738 1182.0709 2.45 y99
9+
 
1185.4211 1185.4181 2.53 y109
10+
 
1185.4211 1185.4197 1.18 b109
10+
 
1189.9934 1189.9893 3.45 b34
3+
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1190.3950 1190.3979 -2.44 b99
9+
 
1194.8565 1194.8517 4.02 y100
9+
 
1200.6338 1200.6389 -4.25 y33
3+
 
1201.1901 1201.1874 2.25 y101
9+
 
1202.6327 1202.6290 3.08 b22
2+
 
1206.3938 1206.3893 3.73 b43
4+
 
1209.3351 1209.3427 -6.28 y78
7+
 
1213.7349 1213.7313 2.97 y111
10+
 
1216.6676 1216.6635 3.37 y23
2+
 
1225.4956 1225.4975 -1.55 y79
7+
 
1228.1510 1228.1473 3.01 b44
4+
 
1230.0354 1230.0376 -1.79 y112
10+
 
1239.6546 1239.6502 3.55 y80
7+
 
1244.3478 1244.3437 3.29 b35
3+
 
1251.6649 1251.6593 4.47 y12 
1252.1681 1252.1632 3.91 b23
2+
 
1257.9451 1257.9494 -3.42 y81
7+
 
1264.9187 1264.9145 3.32 b45
5+
 
1267.1913 1267.1873 3.16 y24
2+
 
1268.1718 1268.1673 3.55 y69
6+
 
1276.6854 1276.6947 -7.28 b36
3+
 
1289.1965 1289.1907 4.50 y47
4+
 
1291.0206 1291.0105 7.82 y70
6+
 
1292.0629 1292.0584 3.48 y96
8+
 
1292.6890 1292.6845 3.48 b12 
1295.1798 1295.1775 1.78 b96
8+
 
1307.9307 1307.9266 3.13 b47
4+
 
1313.6970 1313.6886 6.39 b73
6+
 
1321.6986 1321.6973 0.98 y72
6+
 
1336.2015 1336.1976 2.92 b48
4+
 
1340.7268 1340.7215 3.95 y25
2+
 
1350.7327 1350.7277 3.70 y13 
1357.9603 1357.9556 3.46 b49
4+
 
1363.7256 1363.7216 2.93 b13 
1373.7130 1373.7060 5.10 b26
2+
 
1383.2215 1383.2175 2.89 b50
4+
 
1405.2484 1405.2428 3.99 y26
2+
 
1476.8103 1476.8057 3.11 b14 
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Appendix 9. CID (normalized collision energy 30 %) fragment ions of normal neonatal γG- 
globin chain 
Meas m/z Calc m/z  Δ ppm  Fragment 
558.7490 558.7515 -4.47 b10
2+ 
562.2728 562.2732 -0.71 y4 
615.2935 615.2935 0.00 b11
2+ 
649.3039 649.3052 -2.00 y5 
665.8170 665.8173 -0.45 b12
2+ 
701.2885 701.2889 -0.57 b6 
705.6872 705.6884 -1.70 b19
3+ 
709.3310 709.3333 -3.24 b13
2+ 
738.7109 738.7112 -0.41 b20
3+ 
739.8735 739.8747 -1.62 y14
2+ 
762.3874 762.3893 -2.49 y6 
765.8739 765.8754 -1.96 b14
2+ 
769.3939 769.3952 -1.69 y21
3+ 
781.7250 781.7254 -0.51 b21
3+ 
800.6454 800.6468 -1.75 b30
4+ 
811.1575 811.1579 -0.49 y29
4+ 
816.3138 816.3159 -2.57 b7 
820.0672 820.0677 -0.61 b22
3+ 
828.9171 828.9178 -0.84 b31
4+ 
833.4236 833.4264 -3.36 y7 
843.7447 843.7467 -2.37 b23
3+ 
845.4236 845.4227 1.06 y30
4+ 
857.1867 857.1889 -2.57 b32
4+ 
858.9129 858.9150 -2.44 b15
2+ 
862.7523 862.7539 -1.85 b24
3+ 
867.9491 867.9514 -2.65 y16
2+ 
873.6938 873.6957 -2.17 y31
4+ 
881.7587 881.7610 -2.61 b25
3+ 
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881.9552 881.9560 -0.91 b33
4+ 
887.4231 887.4258 -3.04 b16
2+ 
891.4529 891.4530 -0.11 y32
4+ 
897.9512 897.9537 -2.78 b48
6+ 
906.7247 906.7231 1.76 b34
4+ 
917.7362 917.7349 1.42 y66
8+ 
919.7203 919.7240 -4.02 y33
4+ 
920.4550 920.4585 -3.80 y8 
924.7724 924.7752 -3.03 b26
3+ 
927.4639 927.4657 -1.94 y25
3+ 
944.4115 944.4108 0.74 b8 
947.4857 947.4889 -3.38 b35
4+ 
951.4700 951.4732 -3.36 b17
2+ 
966.1857 966.1858 -0.10 y52
6+ 
969.7510 969.7530 -2.06 y35
4+ 
977.7602 977.7595 0.72 y70
8+ 
980.0727 980.0738 -1.12 y80
9+ 
991.4927 991.4956 -2.92 y9 
994.5189 994.5201 -1.21 y36
4+ 
995.5324 995.5358 -3.42 y45
5+ 
1001.0083 1001.0074 0.90 b18
2+ 
1004.5066 1004.5071 -0.50 y18
2+ 
1016.7852 1016.7866 -1.38 y73
8+ 
1017.6171 1017.6180 -0.88 y111
12+ 
1022.7897 1022.7911 -1.37 y37
4+ 
1032.1854 1032.1853 0.10 y28
3+ 
1032.1829 1032.1853 -2.33 y28
3+ 
1040.7528 1040.7549 -2.02 y47
5+ 
1048.6939 1048.6960 -2.00 y66
7+ 
1077.3399 1077.3430 -2.88 b48
5+ 
1079.6505 1079.6590 -7.87 b99
10+ 
1081.2082 1081.2081 0.09 y29
3+ 
1082.4399 1082.4365 3.14 b80
8+ 
1090.3284 1090.3243 3.76 y40
4+ 
1098.6499 1098.6565 -6.01 y131
13+ 
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1104.8870 1104.8880 -0.91 b31
3+ 
1110.0375 1110.0372 0.27 y111
11+ 
1122.4354 1122.4270 7.48 y123
12+ 
1142.5784 1142.5827 -3.76 b32
3+ 
1148.6843 1148.6859 -1.39 y126
12+ 
1159.2191 1159.2215 -2.07 y52 
5+ 
1169.5127 1169.5122 0.43 y97
9+ 
1175.6029 1175.6055 -2.21 b33
3+ 
1178.8884 1178.8901 -1.44 y43
4+ 
1179.1795 1179.1825 -2.54 y98
9+ 
1183.1138 1183.1143 -0.42 y86
8+ 
1188.1067 1188.1080 -1.09 b42
4+ 
1199.5149 1199.5092 4.75 b99
9+ 
1208.6262 1208.6283 -1.74 b34
3+ 
1216.8670 1216.8647 1.89 b43
4+ 
1220.9359 1220.9402 -3.52 y111
10+ 
1225.9633 1225.9629 0.33 y33
3+ 
1229.5991 1229.5979 0.98 b22
2+ 
1236.9345 1236.9264 6.55 b80
7+ 
1238.6199 1238.6227 -2.26 b44
4+ 
1242.4827 1242.4820 0.56 y67
6+ 
1262.9791 1262.9828 -2.93 b35
3+ 
1266.6329 1266.6368 -3.08 y23
2+ 
1275.3876 1275.3898 -1.72 b45
4+ 
1289.6423 1289.6452 -2.25 b46
4+ 
1292.6634 1292.6682 -3.71 y35
3+ 
1300.6893 1300.6918 -1.92 y47
4+ 
1303.3459 1303.3436 1.76 y70 
6+ 
1318.1513 1318.1559 -3.49 b47
4+ 
1325.6887 1325.6910 -1.73 y36
3+ 
1344.2948 1344.3008 -4.46 y60 
5+ 
1346.4239 1346.4269 -2.23 b48
4+ 
1354.2132 1354.2156 -1.77 y49
4+ 
1363.3841 1363.3857 -1.17 y37
3+ 
1434.4193 1434.4228 -2.44 y39
3+ 
182 
 
1490.7649 1490.7769 -8.05 y67
5+ 
1490.9491 1490.9563 -4.83 y81
6+ 
1521.7981 1521.8090 -7.16 y83
6+ 
1563.8093 1563.8109 -1.02 y70
5+ 
1571.5106 1571.5177 -4.52 y43
3+ 
1658.5542 1658.5548 -0.36 y45
3+ 
1697.8949 1697.8835 6.71 y61 
4+ 
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Appendix 10. CID (normalized collision energy 30 %) fragment ions of normal neonatal 
γA- globin chain 
Meas m/z Calc m/z  Δ ppm  Fragment 
558.7532 558.7515 3.04 b10
2+ 
562.2701 562.2732 -5.51 y4 
615.2919 615.2935 -2.60 b11
2+ 
649.3059 649.3052 1.08 y5 
665.8153 665.8173 -3.00 b12
2+ 
701.2872 701.2889 -2.42 b6 
705.6860 705.6884 -3.40 b19
3+ 
709.3339 709.3333 0.85 b13
2+ 
738.7124 738.7112 1.62 b20
3+ 
762.3875 762.3893 -2.36 y6 
765.8741 765.8754 -1.70 b14
2+ 
781.7243 781.7254 -1.41 b21
3+ 
800.6448 800.6468 -2.50 b30
4+ 
816.3134 816.3159 -3.06 b7 
820.0663 820.0677 -1.71 b22
3+ 
828.9159 828.9178 -2.29 b31
4+ 
833.4239 833.4264 -3.00 y7 
843.7445 843.7467 -2.61 b23
3+ 
849.4314 849.4322 -0.94 y23
3+ 
857.1874 857.1889 -1.75 b32
4+ 
858.9129 858.9150 -2.44 b15
2+ 
862.7533 862.7539 -0.70 b24
3+ 
881.7592 881.7610 -2.04 b25
3+ 
881.9538 881.9560 -2.49 b33
4+ 
887.4235 887.4258 -2.59 b16
2+ 
897.9531 897.9537 -0.67 b48
6+ 
906.7204 906.7231 -2.98 b34
4+ 
920.4577 920.4585 -0.87 y8 
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923.2261 923.2279 -1.95 y33
4+ 
924.7728 924.7752 -2.60 b26
3+ 
932.1367 932.1376 -0.97 y25
3+ 
944.4094 944.4108 -1.48 b8 
947.4859 947.4889 -3.17 b35
4+ 
951.4766 951.4732 3.57 b17
2+ 
973.2581 973.2569 1.23 y35
4+ 
979.5079 979.5115 -3.68 y70
8+ 
991.4928 991.4956 -2.82 y9 
998.0262 998.0240 2.20 y36
4+ 
1001.0094 1001.0074 2.00 b18
2+ 
1043.5554 1043.5580 -2.49 y47
5+ 
1050.6944 1050.6983 -3.71 y66
7+ 
1077.3398 1077.3430 -2.97 b48
5+ 
1079.6513 1079.6590 -7.13 b99
10+ 
1082.4373 1082.4365 0.74 b80
8+ 
1099.7327 1099.7346 -1.73 y131
13+ 
1104.8849 1104.8880 -2.81 b31
3+ 
1111.3099 1111.3113 -1.26 y111
11+ 
1114.0467 1114.0484 -1.53 y132
13+ 
1123.5933 1123.5950 -1.51 y123
12+ 
1142.5789 1142.5827 -3.33 b323+ 
1175.6013 1175.6055 -3.57 b33
3+ 
1188.1066 1188.1080 -1.18 b42
4+ 
1199.5143 1199.5092 4.25 b99
9+ 
1208.6295 1208.6283 0.99 b34
3+ 
1216.8627 1216.8647 -1.64 b43
4+ 
1229.5991 1229.5979 0.98 b22
2+ 
1236.9349 1236.9264 6.87 b80
7+ 
1238.6195 1238.6227 -2.58 b44
4+ 
1262.9789 1262.9828 -3.09 b35
3+ 
1275.3879 1275.3898 -1.49 b45
4+ 
1289.6403 1289.6452 -3.80 b46
4+ 
1318.1533 1318.1559 -1.97 b47
4+ 
1346.4239 1346.4269 -2.23 b48
4+ 
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Appendix 11. CID (normalized collision energy 30 %) fragment ions of the sickle globin 
chain in a neonatal sample. 
Meas m/z Calc m/z Δ ppm Fragment 
451.2661 451.2663 -0.44 b4 
581.3341 581.3350 -1.55 b11
2+
 
584.2932 584.2940 -1.37 y4 
608.8344 608.8354 -1.64 y23
4+
 
631.8590 631.8588 0.32 b12
2+
 
647.3854 647.3875 -3.24 b6 
655.3306 655.3311 -0.76 y5 
667.3767 667.3774 -1.05 b13
2+
 
675.8667 675.8675 -1.18 y13
2+
 
723.9188 723.9194 -0.83 b14
2+
 
725.4009 725.4017 -1.10 y14
2+
 
749.0819 749.0828 -1.20 b21
3+
 
768.4146 768.4151 -0.65 y6 
776.4296 776.4301 -0.64 b7 
779.0940 779.0938 0.26 y22
3+
 
779.1732 779.1740 -1.03 b30
4+
 
781.0157 781.0155 0.26 y36
5+
 
789.4487 789.4492 -0.63 y15
2+
 
792.0964 792.0970 -0.76 b22
3+
 
807.4430 807.4450 -2.48 b31
4+
 
811.4441 811.4448 -0.86 y23
3+
 
816.9584 816.9590 -0.73 b15
2+
 
820.4356 820.4360 -0.49 y30
4+
 
825.1187 825.1198 -1.33 b23
3+
 
835.7155 835.7160 -0.60 b32
4+
 
844.1260 844.1270 -1.18 b24
3+
 
845.1273 845.1273 0.00 y24
3+
 
845.4694 845.4698 -0.47 b16
2+
 
853.4784 853.4785 -0.12 y16
2+
 
854.7014 854.7007 0.82 y31
4+
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859.7960 859.7962 -0.23 y47
6+
 
860.4825 860.4831 -0.70 b33
4+
 
872.4592 872.4600 -0.92 y32
4+
 
885.2497 885.2502 -0.56 b34
4+
 
900.7307 900.7310 -0.33 y33
4+
 
904.5243 904.5251 -0.88 b8 
906.1465 906.1483 -1.99 b26
3+
 
909.5175 909.5173 0.22 b17
2+
 
918.3249 918.3220 3.16 y50
6+
 
925.4938 925.4981 -4.65 y34
4+
 
926.0156 926.0161 -0.54 b35
4+
 
929.8265 929.8274 -0.97 b27
3+
 
934.1133 934.1127 0.64 y43
5+
 
935.0094 935.0101 -0.75 y17
2+
 
937.1652 937.1643 0.96 y26
3+
 
939.9561 939.9535 2.77 y96
11+
 
950.2736 950.2793 -6.00 b36
4+
 
953.4946 953.4952 -0.63 y8 
959.0509 959.0515 -0.63 b18
2+
 
967.5210 967.5221 -1.14 b28
3+
 
970.5286 970.5287 -0.10 y18 
2+
 
976.0171 976.0175 -0.41 y36
4+
 
979.8645 979.8626 1.94 y27
3+
 
998.6500 998.6525 -2.50 y73
8+
 
998.8708 998.8698 1.00 y28
3+
 
1006.0480 1006.0472 0.80 y19
2+
 
1024.5332 1024.5323 0.88 y9 
1031.5542 1031.5540 0.19 y47
5+
 
1033.8462 1033.8482 -1.93 y96
10+
 
1076.2585 1076.2576 0.84 b31
3+
 
1093.5763 1093.5789 -2.38 y30
3+
 
1103.4810 1103.4837 -2.45 y111
11+
 
1113.9524 1113.9523 0.09 b32
3+
 
1146.9748 1146.9751 -0.26 b33
3+
 
1148.6074 1148.6083 -0.78 y96
9+
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1159.8341 1159.8358 -1.47 y97
9+
 
1166.6343 1166.6351 -0.69 b42
4+
 
1169.5027 1169.5060 -2.82 y98
9+
 
1179.9977 1179.9979 -0.17 b34
3+
 
1187.0606 1187.0675 -5.81 b99
9+
 
1198.8956 1198.8958 -0.17 b43
4+
 
1201.1939 1201.1874 5.41 y101
9+
 
1213.7291 1213.7313 -1.81 y111
10+
 
1216.6649 1216.6635 1.15 y23
2+
 
1220.6550 1220.6538 0.98 b44
4+
 
1234.3516 1234.3523 -0.57 b35
3+
 
1257.4185 1257.4209 -1.91 b45
4+
 
1268.0014 1267.9981 2.60 y35
3+
 
1271.6818 1271.6763 4.33 b46
4+
 
1300.4324 1300.4330 -0.46 b47
4+
 
1318.1903 1318.1965 -4.70 b74
6+
 
1328.7058 1328.7040 1.35 b48
4+
 
1375.7227 1375.7240 -0.94 b50
4+
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Appendix 12. CID (normalized collision energy 30 %) fragment ions of the HbC globin 
chain in a neonatal sample. 
Meas m/z Calc m/z Δ ppm Fragment 
451.2667 451.2663 0.89 b4 
584.2941 584.2940 0.17 y4 
608.8355 608.8354 0.16 y23
4+
 
655.3311 655.3311 0.00 y5 
671.0337 671.0339 -0.30 y19
3+
 
675.8678 675.8675 0.44 y13
2+
 
681.8906 681.8906 0.00 b13
2+
 
713.7207 713.7201 0.84 y20
3+
 
720.4157 720.4160 -0.42 b20
3+
 
725.4016 725.4017 -0.14 y14
2+
 
738.4330 738.4327 0.41 b14
2+
 
758.7587 758.7583 0.53 b21
3+
 
768.4150 768.4151 -0.13 y6 
779.0939 779.0938 0.13 y22
3+
 
786.1729 786.1713 2.04 y29
4+
 
786.4308 786.4306 0.25 b30
4+
 
789.4497 789.4492 0.63 y15
2+
 
801.7727 801.7725 0.25 b22
3+
 
811.4450 811.4448 0.25 y23
3+
 
820.4374 820.4360 1.71 y30
4+
 
834.7956 834.7953 0.36 b23
3+
 
842.9729 842.9727 0.24 b32
4+
 
845.1277 845.1273 0.47 y24
3+
 
853.4782 853.4785 -0.35 y16
2+
 
853.8031 853.8025 0.70 b24
3+
 
854.7007 854.7007 0.00 y31
4+
 
859.7964 859.7962 0.23 y47
6+
 
867.7404 867.7398 0.69 b33
4+
 
872.4612 872.4600 1.38 y32
4+
 
892.5073 892.5069 0.45 b34
4+
 
900.7321 900.7310 1.22 y33
4+
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933.2721 933.2727 -0.64 b35
4+
 
935.0111 935.0101 1.07 y17
2+
 
939.9543 939.9535 0.85 y96
11+
 
953.4956 953.4952 0.42 y8 
970.5296 970.5287 0.93 y18
2+
 
976.0187 976.0175 1.23 y36
4+
 
998.6521 998.6525 -0.40 y73
8+
 
998.8716 998.8698 1.80 y28
3+
 
1006.0484 1006.0472 1.19 y19
2+
 
1024.5322 1024.5323 -0.10 y9 
1031.5549 1031.5540 0.87 y47
5+
 
1033.8483 1033.8482 0.10 y96
10+
 
1103.4820 1103.4837 -1.54 y111
11+
 
1148.6090 1148.6083 0.61 y96
9+
 
1156.6505 1156.6506 -0.09 b33
3+
 
1159.8394 1159.8358 3.10 y97
9+
 
1169.5072 1169.5060 1.03 y98
9+
 
1173.8883 1173.8918 -2.98 b42
4+
 
1189.6753 1189.6734 1.60 b34
3+
 
1202.1539 1202.1552 -1.08 b22
2+
 
1206.1546 1206.1524 1.82 b43
4+
 
1213.7287 1213.7313 -2.14 y111
10+
 
1216.6638 1216.6635 0.25 y23
2+
 
1227.9149 1227.9104 3.66 b44
4+
 
1244.0288 1244.0279 0.72 b35
3+
 
1251.6605 1251.6593 0.96 y12 
1264.9286 1264.9275 0.87 y46
4+
 
1307.6917 1307.6896 1.61 b47
4+
 
1382.9813 1382.9806 0.51 b50
4+
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Appendix 13. CID (normalized collision energy 30 %) fragment ions of HbD globin chain 
in a neonatal sample. 
Meas m/z Calc m/z Δ ppm Fragment 
350.2181 350.2187 -1.71 b3 
451.2664 451.2663 0.22 b4 
512.7696 512.7698 -0.39 y9
2+
 
546.7876 546.7878 -0.37 b10
2+
 
584.2937 584.2940 -0.51 y4 
590.8144 590.8147 -0.51 y11
2+
 
596.3217 596.3220 -0.50 b11
2+
 
608.8350 608.8354 -0.66 y23
4+
 
626.3331 626.3333 -0.32 y12
2+
 
646.8456 646.8459 -0.46 b12
2+
 
649.6942 649.6948 -0.92 b18
3+
 
655.3309 655.3311 -0.31 y5 
671.0337 671.0339 -0.30 y19
3+
 
675.8672 675.8675 -0.44 y13
2+
 
677.3615 677.3617 -0.30 b6 
682.3641 682.3644 -0.44 b13
2+
 
687.7088 687.7091 -0.44 b19
3+
 
713.7199 713.7201 -0.28 y20
3+
 
720.7318 720.7319 -0.14 b20
3+
 
725.4015 725.4017 -0.28 y14
2+
 
738.9063 738.9065 -0.27 b14
2+
 
759.0741 759.0742 -0.13 b21
3+
 
768.4150 768.4151 -0.13 y6 
779.0937 779.0938 -0.13 y22
3+
 
780.8183 780.8187 -0.51 y36
5+
 
786.6671 786.6676 -0.64 b30
4+
 
789.4490 789.4492 -0.25 y15
2+
 
802.0883 802.0884 -0.12 b22
3+
 
806.4042 806.4043 -0.12 b7 
811.4446 811.4448 -0.25 y23
3+
 
814.9384 814.9386 -0.25 b31
4+
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820.1899 820.1900 -0.12 y30
4+
 
831.9461 831.9461 0.00 b15
2+
 
835.1110 835.1112 -0.24 b23
3+
 
839.4519 839.4522 -0.36 y7 
843.2096 843.2096 0.00 b32
4+
 
845.1272 845.1273 -0.12 y24
3+
 
853.4783 853.4785 -0.23 y16
2+
 
854.1183 854.1184 -0.12 b24
3+
 
854.4531 854.4547 -1.87 y31
4+
 
859.6322 859.6322 0.00 y47
6+
 
867.9766 867.9767 -0.12 b33
4+
 
872.2138 872.2140 -0.23 y32
4+
 
873.1259 873.1255 0.46 b25
3+
 
892.7436 892.7438 -0.22 b34
4+
 
894.1502 894.1501 0.11 y25
3+
 
900.4850 900.4850 0.00 y33
4+
 
916.1393 916.1397 -0.44 b26
3+
 
924.5043 924.5043 0.00 b17
2+
 
925.2515 925.2521 -0.65 y34
4+
 
933.5097 933.5096 0.11 b35
4+
 
936.8368 936.8363 0.53 y26
3+
 
939.8188 939.8188 0.00 b27
3+
 
939.8610 939.8641 -3.30 y96
11+
 
949.0511 949.0502 0.95 y97
11+
 
951.0045 951.0044 0.11 y35
4+
 
953.4951 953.4952 -0.10 y8 
958.3555 958.3545 1.04 y52
6+
 
968.3866 968.3867 -0.10 y70
8+
 
970.5288 970.5287 0.10 y18
2+
 
974.0386 974.0386 0.00 b18
2+
 
975.7714 975.7715 -0.10 y36
4+
 
977.5131 977.5135 -0.41 b28
3+
 
977.5259 977.5256 0.31 y53
6+
 
998.5288 998.5295 -0.70 y73
8+
 
998.5420 998.5418 0.20 y28
3+
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1006.0478 1006.0472 0.60 y19
2+
 
1017.5365 1017.5370 -0.49 y55
6+
 
1021.9651 1021.9699 -4.70 y65
7+
 
1024.5311 1024.5323 -1.17 y9 
1031.3582 1031.3572 0.97 y47
5+
 
1033.7480 1033.7498 -1.74 y96
10+
 
1069.1602 1069.1595 0.65 b48
5+
 
1103.3934 1103.3942 -0.73 y111
11+
 
1123.9438 1123.9437 0.09 b32
3+
 
1137.3597 1137.3616 -1.67 b41
4+
 
1148.4970 1148.4989 -1.65 y96
9+
 
1156.9667 1156.9665 0.17 b33
3+
 
1159.7241 1159.7264 -1.98 y97
9+
 
1168.1372 1168.1371 0.09 y22
2+
 
1169.3943 1169.3967 -2.05 y98
9+
 
1174.1293 1174.1287 0.51 b42
4+
 
1180.6228 1180.6222 0.51 y11 
1189.9895 1189.9893 0.17 b34
3+
 
1190.3995 1190.3979 1.34 b99
9+
 
1202.6289 1202.6290 -0.08 b22
2+
 
1206.3895 1206.3893 0.17 b43
4+
 
1216.6635 1216.6635 0.00 y23
2+
 
1228.1469 1228.1473 -0.33 b44
4+
 
1244.3437 1244.3437 0.00 b35
3+
 
1251.6600 1251.6593 0.56 y12 
1252.1647 1252.1632 1.20 b23
2+
 
1264.9141 1264.9145 -0.32 b45
4+
 
1267.1870 1267.1873 -0.24 y24
2+
 
1279.1704 1279.1698 0.47 b46
4+
 
1288.9404 1288.9447 -3.34 y47
4+
 
1291.9325 1291.9354 -2.24 y96
8+
 
1307.9264 1307.9266 -0.15 b47
4+
 
1336.1971 1336.1976 -0.37 b48
4+
 
1340.7220 1340.7215 0.37 y25
2+
 
1350.7279 1350.7277 0.15 y13 
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1357.9552 1357.9556 -0.29 b49
4+
 
1363.7217 1363.7216 0.07 b13 
1383.2169 1383.2175 -0.43 b50
4+
 
1449.7961 1449.7961 0.00 y14 
1476.8056 1476.8057 -0.07 b14 
1662.8850 1662.8850 0.00 b15 
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Appendix 14. CID (normalized collision energy 30 %) fragment ions of HbE globin chain 
in a neonatal sample. 
Meas m/z Calc m/z  Δ ppm Fragment 
350.2185 350.2187 -0.57 b3 
451.2669 451.2663 1.33 b4 
546.7882 546.7878 0.73  b10
2+
 
584.2945 584.2940 0.86 y4 
596.3224 596.3220 0.67 b11
2+
 
608.8359 608.8354 0.82 y23
4+
 
626.3338 626.3333 0.80 y12
2+
 
646.8466 646.8459 1.08 b12
2+
 
655.3318 655.3311 1.07 y5 
675.8682 675.8675 1.04 y13
2+
 
677.3625 677.3617 1.18 b6 
682.3651 682.3644 1.03 b13
2+
 
713.7208 713.7201 0.98 y20
3+
 
720.7325 720.7319 0.83 b20
3+
 
725.4025 725.4017 1.10 y14
2+
 
738.9072 738.9065 0.95 b14
2+
 
759.0751 759.0742 1.19 b21
3+
 
768.4160 768.4151 1.17 y6 
779.0946 779.0938 1.03 y22
3+
 
781.0174 781.0155 2.43 y36
5+
 
786.1718 786.1713 0.64 y29
4+
 
789.4501 789.4492 1.14 y15
2+
 
802.0894 802.0884 1.25 b22
3+
 
806.4051 806.4043 0.99 b7 
811.4456 811.4448 0.99 y23
3+
 
820.4366 820.4360 0.73 y30
4+
 
831.9472 831.9461 1.32 b15
2+
 
835.1123 835.1112 1.32 b23
3+
 
839.4530 839.4522 0.95 y7 
842.9724 842.9727 -0.36 b32
4+
 
845.1285 845.1273 1.42 y24
3+
 
853.4796 853.4785 1.29 y16
2+
 
854.1195 854.1184 1.29 b24
3+
 
854.7018 854.7007 1.29 y31
4+
 
859.7974 859.7962 1.40 y47
6+
 
872.4616 872.4600 1.83 y32
4+
 
892.5066 892.5069 -0.34 b34
4+
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900.7321 900.7310 1.22 y33
4+
 
924.5055 924.5043 1.30 b17
2+
 
933.2719 933.2727 -0.86 b35
4+
 
935.0115 935.0101 1.50 y17
2+
 
937.1652 937.1693 -4.37 y51
6+
 
939.9464 939.9535 -7.55 y96
11+
 
951.2515 951.2504 1.16 y35
4+
 
953.4966 953.4952 1.47 y8 
958.5188 958.5185 0.31 y52
6+
 
965.1238 965.1234 0.41 b43
5+
 
968.5056 968.5097 -4.23 y70
8+
 
970.5301 970.5297 0.41 y18
2+
 
974.0398 974.0386 1.23 b18
2+
 
976.0189 976.0175 1.43 y36
4+
 
982.5315 982.5298 1.73 b44
5+
 
986.3367 986.3350 1.72 y45
5+
 
998.6529 998.6525 0.40 y73
8+
 
998.8708 998.8698 1.00 y28
3+
 
1003.8165 1003.8112 5.28 y64
7+
 
1006.0490 1006.0472 1.79 y19
2+
 
1011.6153 1011.6106 4.65 y111
12+
 
1017.7028 1017.7010 1.77 y55
6+
 
1023.3508 1023.3478 2.93 b46
5+
 
1025.1977 1025.1992 -1.46 y112
12+
 
1031.5546 1031.5540 0.58 y47
5+
 
1033.8484 1033.8482 0.19 y96
10+
 
1068.9674 1068.9700 -2.43 b48
5+
 
1075.4676 1075.4672 0.37 y100
10+
 
1092.8780 1092.8861 -7.41 y131
13+
 
1103.4838 1103.4837 0.09 y111
11+
 
1116.7441 1116.7340 9.04 y144
14+
 
1148.6091 1148.6083 0.70 y96
9+
 
1159.8331 1159.8358 -2.33 y97
9+
 
1168.1382 1168.1371 0.94 y22
2+
 
1169.5077 1169.5060 1.45 y98
9+
 
1170.9423 1170.9451 -2.39 y64
6+
 
1201.1908 1201.1874 2.83 y101
9+
 
1202.6301 1202.6290 0.91 b22
2+
 
1209.3361 1209.3427 -5.46 y78
7+
 
1213.7303 1213.7313 -0.82 y111
10+
 
1216.6651 1216.6635 1.32 y23
2+
 
1227.9034 1227.9104 -5.70 b44
4+
 
1230.0329 1230.0376 -3.82 y112
10+
 
1244.0267 1244.0279 -0.96 b35
3+
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1252.1646 1252.1632 1.12 b23
2+
 
1264.6703 1264.6775 -5.69 b45
4+
 
1278.9291 1278.9329 -2.97 b46
4+
 
1280.6755 1280.6739 1.25 b24
2+
 
1292.0485 1292.0584 -7.66 y96
8+
 
1307.6914 1307.6896 1.38 b47
4+
 
1313.5358 1313.5307 3.88 b73
6+
 
1350.7306 1350.7277 2.15 y13 
1363.7225 1363.7216 0.66 b13 
1382.9860 1382.9806 3.90 b50
4+
 
1476.8071 1476.8057 0.95 b14 
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Appendix 15. CID (normalized collision energy 30 %) fragment ions of HbC globin chain 
in a neonatal compound heterozygote FSC sample. 
Meas m/z Calc m/z Δ ppm Fragment 
350.2222 350.2187 9.99 b3 
451.2705 451.2663 9.31 b4 
584.2897 584.2940 -7.36 y4 
590.8201 590.8147 9.14 y11
2+
 
608.8415 608.8354 10.02 y23
4+
 
623.6723 623.6758 -5.61 y17
3+
 
626.3388 626.3333 8.78 y12
2+
 
725.4084 725.4017 9.24 y14
2+
 
738.4401 738.4327 10.02 b14
2+
 
758.7652 758.7583 9.09 b21
3+
 
768.4228 768.4151 10.02 y6 
779.1011 779.0938 9.37 y22
3+
 
786.4376 786.4306 8.90 b30
4+
 
801.7803 801.7725 9.73 b22
3+
 
820.4278 820.4360 -9.99 y30
4+
 
845.1240 845.1273 -3.90 y24
4+
 
859.9746 859.9830 -9.77 b16
2+
 
872.4682 872.4600 9.40 y32
4+
 
892.5157 892.5069 9.86 b34
4+
 
900.7400 900.7310 9.99 y33
4+
 
918.3309 918.3220 9.69 y50
6+
 
925.5069 925.4981 9.51 y34
4+
 
935.0192 935.0101 9.73 y17
2+
 
939.9591 939.9535 5.96 y96
11+
 
951.2598 951.2504 9.88 y35 
4+
 
953.5051 953.4952 10.38 y8  
958.5091 958.5185 -9.81 y52
6+
 
970.5191 970.5287 -9.89 y18
2+
 
973.5744 973.5647 9.96 b18
2+
 
976.0273 976.0175 10.04 y36
4+
 
998.6525 998.6525 0.00 y73
8+
 
1024.5428 1024.5329 9.66 y9 
1031.5449 1031.5540 -8.82 y47
5+
 
1033.8512 1033.8482 2.90 y96
10+
 
1103.4939 1103.4837 9.24 y111
11+
 
1148.6195 1148.6083 9.75 y96
9+
 
1156.6621 1156.6506 9.94 b33
3+
 
1168.1484 1168.1371 9.67 y22
2+
 
1189.6852 1189.6734 9.92 b34
3+
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1216.6755 1216.6635 9.86 y23
2+
 
1244.0398 1244.0279 9.57 b35
3+
 
1307.6914 1307.6896 1.38 b47
4+
 
Appendix 16. CID (normalized collision energy 30 %) fragment ions of HbD globin chain 
in a neonatal compound heterozygote FSD sample. 
Meas m/z Calc m/z Δ ppm Fragment 
738.9069 738.9065 0.54 b14
2+
 
802.0876 802.0884 -1.00 b22
3+
 
811.4454 811.4448 0.74 y23
3+
 
831.9465 831.9461 0.48 b15
2+
 
867.9769 867.9767 0.23 b33
4+
 
872.2143 872.2140 0.34 y32
4+
 
977.5241 977.5256 -1.53 y53
6+
 
1024.5328 1024.5323 0.49 y9 
1031.3566 1031.3572 -0.58 y47
5+
 
1033.7489 1033.7498 -0.87 y96
10+
 
1103.3966 1103.3942 2.18 y111
11+
 
1123.9450 1123.9437 1.16 b32
3+
 
1146.5972 1146.5970 0.17 b63
6+
 
1148.4982 1148.4989 -0.61 y96
9+
 
1156.9669 1156.9665 0.35 b33
3+
 
1168.1412 1168.1371 3.51 y22
2+
 
1169.3942 1169.3967 -2.14 y98
9+
 
1174.1325 1174.1287 3.24 b42
4+
 
1189.9908 1189.9893 1.26 b34
3+
 
1202.6303 1202.6290 1.08 b22
2+
 
1213.6274 1213.6329 -4.53 y111
10+
 
1216.6656 1216.6635 1.73 y23
2+
 
1220.6552 1220.6432 9.83 b91
8+
 
1228.1469 1228.1473 -0.33 b44
4+
 
1244.3448 1244.3437 0.88 b35
3+
 
1307.9273 1307.9266 0.54 b47
4+
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Appendix 17. CID (normalized collision energy 30 %) fragment ions of HbD -Iran globin 
chain in a previously undiagnosed (FAV1) neonatal sample. 
Meas m/z Calc m/z Δ ppm  Fragment  
350.2179 350.2187 -2.28 b3 
451.2663 451.2663 0.00 b4 
512.7696 512.7698 -0.39 y9
2+
 
546.7874 546.7878 -0.73 b10
2+
 
584.2934 584.2940 -1.03 y4 
590.8139 590.8147 -1.35 y11
2+
 
596.3215 596.3220 -0.84 b11
2+
 
608.8349 608.8354 -0.82 y23
4+
 
626.3323 626.3333 -1.60 y12
2+
 
646.8451 646.8459 -1.24 b12
2+
 
655.3305 655.3311 -0.92 y5 
675.8670 675.8675 -0.74 y13
2+
 
677.3611 677.3617 -0.89 b6 
682.3638 682.3644 -0.88 b13
2+
 
687.7080 687.7091 -1.60 b19
3+
 
713.7199 713.7201 -0.28 y20
3+
 
720.7312 720.7319 -0.97 b20
3+
 
725.4010 725.4017 -0.96 y14
2+
 
738.9058 738.9065 -0.95 b14
2+
 
759.0737 759.0742 -0.66 b21
3+
 
768.4145 768.4151 -0.78 y6 
779.0931 779.0938 -0.90 y22
3+
 
781.0142 781.0155 -1.66 y36
5+
 
786.1702 786.1713 -1.40 y29
4+
 
789.4485 789.4492 -0.89 y15
2+
 
801.7598 801.7604 -0.75 b22
3+
 
806.4037 806.4043 -0.74 b7 
811.4441 811.4448 -0.86 y23
3+
 
820.4352 820.4360 -0.98 y30
4+
 
831.9455 831.9461 -0.72 b15
2+
 
834.7824 834.7832 -0.96 b23
3+
 
839.4515 839.4522 -0.83 y7 
842.9634 842.9636 -0.24 b32
4+
 
845.1267 845.1273 -0.71 y24
3+
 
853.4780 853.4785 -0.59 y16
2+
 
853.7901 853.7904 -0.35 b24
3+
 
854.7001 854.7007 -0.70 y31
4+
 
859.7955 859.7962 -0.81 y47
6+
 
867.7299 867.7307 -0.92 b33
4+
 
872.4602 872.4600 0.23 y32
4+
 
880.4768 880.4802 -3.86 b40
5+
 
892.4969 892.4978 -1.01 b34
4+
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894.1495 894.1501 -0.67 y25
3+
 
900.7305 900.7310 -0.56 y33
4+
 
919.4805 919.4817 -1.31 y58
7+
 
924.5035 924.5043 -0.87 b17
2+
 
925.5067 925.4981 9.29 y34
4+
 
933.2629 933.2636 -0.75 b35
4+
 
934.4988 934.4993 -0.54 b8 
937.1633 937.1693 -6.40 y51
6+
 
939.9490 939.9535 -4.79 y96
11+
 
951.2497 951.2504 -0.74 y35
4+
 
953.4945 953.4952 -0.73 y8 
958.5189 958.5185 0.42 y52
6+
 
968.5116 968.5097 1.96 y70
8+
 
970.5281 970.5287 -0.62 y18
2+
 
974.0379 974.0386 -0.72 b18
2+
 
976.0173 976.0175 -0.20 y36
4+
 
977.6872 977.6896 -2.45 y53
6+
 
986.3337 986.3350 -1.32 y45
5+
 
998.6506 998.6525 -1.90 y73
8+
 
998.8696 998.8698 -0.20 y28
3+
 
1003.8139 1003.8112 2.69 y64
7+
 
1006.0469 1006.0472 -0.30 y19
2+
 
1011.6013 1011.6106 -9.19 y111
12+
 
1017.6995 1017.7010 -1.47 y55
6+
 
1024.5310 1024.5323 -1.27 y9 
1031.5519 1031.5540 -2.04 y47
5+
 
1033.8463 1033.8482 -1.84 y96
10+
 
1036.2487 1036.2450 3.57 b96
10+
 
1075.4673 1075.4672 0.09 y100
10+
 
1081.0700 1081.0657 3.98 b100
10+
 
1103.4818 1103.4837 -1.72 y111
11+
 
1104.5769 1104.5794 -2.26 y103
10+
 
1113.9170 1113.9188 -1.62 y123
12+
 
1116.8958 1116.8954 0.36 b133
13+
 
1118.3032 1118.3076 -3.93 y112
11+
 
1123.6147 1123.6157 -0.89 b32
3+
 
1137.1131 1137.1156 -2.20 b41
4+
 
1148.6068 1148.6083 -1.31 y96
9+
 
1149.9892 1149.9832 5.22 y85
8+
 
1156.6379 1156.6385 -0.52 b33
3+
 
1159.8328 1159.8358 -2.59 y97
9+
 
1169.5036 1169.5060 -2.05 y98
9+
 
1180.6214 1180.6222 -0.68 y11 
1185.3194 1185.3213 -1.60 b109
10+
 
1189.6604 1189.6613 -0.76 b34
3+
 
1190.2843 1190.2886 -3.61 b99
9+
 
1201.1868 1201.1874 -0.50 y101
9+
 
1202.1367 1202.1370 -0.25 b22
2+
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1206.1431 1206.1433 -0.17 b43
4+
 
1209.2321 1209.2238 6.86 b55
5+
 
1209.9141 1209.9088 4.38 y122
11+
 
1213.7274 1213.7313 -3.21 y111
10+
 
1215.0933 1215.0925 0.66 y123
11+
 
1216.6626 1216.6635 -0.74 y23
2+
 
1221.4617 1221.4576 3.36 b123
11+
 
1227.9013 1227.9013 0.00 b44
4+
 
1230.2870 1230.2805 5.28 b124
11+
 
1244.0149 1244.0157 -0.64 b35
3+
 
1249.3141 1249.3200 -4.72 y68
6+
 
1251.6594 1251.6593 0.08 y12 
1264.6687 1264.6684 0.24 b45
4+
  
1267.1867 1267.1873 -0.47 y24
2+
 
1307.6794 1307.6806 -0.92 b47
4+
 
1317.0231 1317.0193 2.89 y109
9+
 
1335.9526 1335.9516 0.75 b48
4+
 
1338.7100 1338.7156 -4.18 y37
3+
 
1340.7204 1340.7215 -0.82 y25
2+
 
1350.7260 1350.7277 -1.26 y13 
1363.7212 1363.7216 -0.29 b13 
1477.8077 1477.8057 1.35 b14 
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Appendix 18. CID (normalized collision energy 30 %) fragment ions of HbD -Iran globin 
chain in a previously undiagnosed (FAV2) neonatal sample. 
Meas m/z Calc m/z Δ ppm Fragment  
451.2688 451.2663 5.54 b4 
512.7716 512.7698 3.51 y9
2+
 
562.3058 562.3040 3.20 y10
2+
 
584.2959 584.2940 3.25 y4 
590.8167 590.8147 3.39 y11
2+
 
596.3241 596.3220 3.52 b11
2+
 
608.8373 608.8354 3.12 y23
4+
 
623.6776 623.6758 2.89 y17
3+
 
626.3355 626.3333 3.51 y12
2+
 
646.8481 646.8459 3.40 b12
2+
 
655.3332 655.3311 3.20 y5 
675.8698 675.8675 3.40 y13
2+
 
677.3641 677.3617 3.54 b6 
682.3666 682.3644 3.22 b13
2+
 
687.7108 687.7091 2.47 b19
3+
 
713.7222 713.7201 2.94 y20
3+
 
720.7344 720.7319 3.47 b20
3+
 
738.9086 738.9065 2.84 b14
2+
 
759.0764 759.0742 2.90 b21
3+
 
768.4177 768.4151 3.38 y6 
779.0963 779.0938 3.21 y22
3+
 
781.0176 781.0155 2.69 y36
5+
 
789.4513 789.4492 2.66 y15
2+
 
801.7624 801.7604 2.49 b22
3+
 
806.4068 806.4043 3.10 b7 
820.4375 820.4360 1.83 y30
4+
 
831.9485 831.9461 2.88 b15
2+
 
834.7852 834.7832 2.40 b23
3+
 
839.4548 839.4522 3.10 y7 
842.9663 842.9636 3.20 b32
4+
 
845.1296 845.1273 2.72 y24
3+
 
853.4810 853.4785 2.93 y16
2+
 
 853.7928 853.7904 2.81 b24
3+
 
854.7028 854.7007 2.46 y31
4+
 
859.7981 859.7962 2.21 y47
6+
 
860.4562 860.4569 -0.81 b16
2+
 
867.7331 867.7307 2.77 b33
4+
 
872.4639 872.4600 4.47 y32
4+
 
892.5001 892.4978 2.58 b34
4+
 
894.1528 894.1501 3.02 y25
3+
 
900.7343 900.7310 3.66 y33
4+
 
924.5070 924.5043 2.92 b17
2+
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935.0130 935.0101 3.10 y17
2+
 
939.9563 939.9535 2.98 y96
11+
 
951.2533 951.2504 3.05 y35
4+
 
953.4983 953.4952 3.25 y8 
958.5215 958.5185 3.13 y52
6+
 
970.5320 970.5287 3.40 y18
2+
 
974.0415 974.0386 2.98 b18
2+
 
976.0205 976.0175 3.07 y36
4+
 
977.6928 977.6896 3.27 y53
6+
  
979.8654 979.8626 2.86 y27
3+
 
982.5214 982.5256 -4.27 y91
10+
 
986.3379 986.3350 2.94 y45
5+
 
998.6549 998.6525 2.40 y73
8+
 
998.8728 998.8698 3.00 y28
3+
 
1006.0507 1006.0472 3.48 y19
2+
 
1011.6044 1011.6106 -6.13 y111
12+
 
1017.7028 1017.7010 1.77 y55
6+
 
1024.5352 1024.5323 2.83 y9 
1031.5559 1031.5540 1.84 y47
5+
 
1033.8493 1033.8482 1.06 y96
10+
 
1036.2529 1036.2450 7.62 b96
10+
 
1048.2304 1048.2263 3.91 b30
3+
 
1052.6589 1052.6561 2.66 y98
10+
 
1054.5602 1054.5594 0.76 y48
5+
 
1070.0806 1070.0765 3.83 y20
2+
 
1072.5649 1072.5607 3.92 y58
6+
 
1073.8994 1073.8897 9.03 b59
6+
 
1093.9657 1093.9700 -3.93 b101
10+
 
1103.4857 1103.4837 1.81 y111
11+
 
1106.1418 1106.1432 -1.27 y92
9+
 
1106.3092 1106.3075 1.54 b112
11+
 
1108.2493 1108.2494 -0.09 y60
6+
 
1113.9107 1113.9188 -7.27 y123
12+
 
1116.9023 1116.8954 6.18 b133
13+
 
1118.3066 1118.3076 -0.89 y112
11+
 
1137.8238 1137.8246 -0.70 y95
9+
 
1141.1001 1141.1036 -3.07 y84
8+
 
1144.6057 1144.6003 4.72 y62
6+
 
1146.6050 1146.6004 4.01 y115
11+
 
1148.6104 1148.6083 1.83 y96
9+
 
1151.2798 1151.2715 7.21 b96
9+
 
1156.6419 1156.6385 2.94 b33
3+
 
1159.8388 1159.8358 2.59 y97
9+
 
1166.5084 1166.5002 7.03 b97
9+
 
1168.1408 1168.1371 3.17 y22
2+
 
1169.5091 1169.5060 2.65 y98
9+
 
1177.2902 1177.2857 3.82 b65
6+
 
1180.6263 1180.6222 3.47 y11 
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1185.3173 1185.3113 5.06 b109
10+
 
1189.6653 1189.6613 3.36 b34
3+
 
1190.2938 1190.2886 4.37 b99
9+
 
1201.1928 1201.1874 4.50 y101
9+
 
1202.1415 1202.1370 3.74 b22
2+
 
1206.1477 1206.1433 3.65 b43
4+
 
1213.7336 1213.7313 1.89 y111
10+
 
1216.6673 1216.6635 3.12 y23
2+
 
1224.0689 1224.0615 6.05 b135
12+
 
1224.1025 1224.0988 3.02 y124
11+
 
1227.9056 1227.9013 3.50 b44
4+
 
1230.0354 1230.0376 -1.79 y112
10+
 
1244.0191 1244.0157 2.73 b35
3+
 
1246.1943 1246.1974 -2.49 y126
11+
 
1251.6632 1251.6712 -6.39 b23
2+
 
1264.6714 1264.6684 2.37 b45
4+
 
1264.9213 1264.9275 -4.90 y46
4+
 
1267.1903 1267.1873 2.37 y24
2+
 
1278.9309 1278.9238 5.55 b46
4+
 
1289.1953 1289.1907 3.57 y47
4+
 
1292.0571 1292.0584 -1.01 y96
8+
 
1307.6839 1307.6806 2.52 b47
4+
 
1313.5352 1313.5246 8.07 b73 
6+
 
1317.0250 1317.0193 4.33 y109
9+
 
1335.9541 1335.9516 1.87 b48
4+
 
1338.7058 1338.7156 -7.32 y37
3+
 
1340.7276 1340.7215 4.55 y25
2+
 
1350.7318 1350.7277 3.04 y13 
1357.7068 1357.7096 -2.06 b49
4+
 
1363.7258 1363.7216 3.08 b13 
1382.9755 1382.9715 2.89 b50
4+
 
1405.2453 1405.2428 1.78 y26
2+
 
1449.8004 1449.7961 2.97 y14 
1476.8096 1476.8057 2.64 b14 
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Appendix 19. CID (normalized collision energy 30 %) fragment ions of Hb Headington 
globin chain in a previously undiagnosed (FAV3) neonatal sample. 
Meas m/z Calc m/z Δ ppm Fragment 
350.2177 350.2187 -2.86 b3 
451.2658 451.2663 -1.11 b4 
584.2931 584.2940 -1.54 y4 
596.3208 596.3220 -2.01 b11 
2+ 
608.8343 608.8354 -1.81 y23 
4+ 
626.3323 626.3333 -1.60 y12 
2+ 
646.8442 646.8459 -2.63 b12 
2+ 
655.3299 655.3311 -1.83 y5 
675.8662 675.8675 -1.92 y13 
2+ 
677.3607 677.3617 -1.48 b6 
682.3631 682.3644 -1.91 b13 
2+ 
713.7182 713.7201 -2.66 y20 
3+ 
720.7304 720.7319 -2.08 b20 
3+ 
725.4006 725.4017 -1.52 y14 
2+ 
738.9051 738.9065 -1.89 b14 
2+ 
759.0729 759.0742 -1.71 b21 
3+ 
768.4137 768.4151 -1.82 y6 
779.0924 779.0938 -1.80 y22 
3+ 
781.0146 781.0155 -1.15 y36 
5+ 
786.1701 786.1713 -1.53 y29 
4+ 
789.4476 789.4492 -2.03 y15 
2+ 
802.0868 802.0884 -1.99 b22 
3+ 
806.4031 806.4043 -1.49 b7 
811.4434 811.4448 -1.73 y23 
3+ 
814.9379 814.9386 -0.86 b31 
4+ 
820.4345 820.4360 -1.83 y30 
4+ 
831.9447 831.9461 -1.68 b15 
2+ 
835.1099 835.1112 -1.56 b23 
3+ 
839.4507 839.4522 -1.79 y7 
843.2080 843.2096 -1.90 b32 
4+ 
845.1258 845.1273 -1.77 y24 
3+ 
853.4771 853.4785 -1.64 y16 
2+ 
854.1169 854.1184 -1.76 b24 
3+ 
854.6989 854.7007 -2.11 y31 
4+ 
859.7944 859.7962 -2.09 y47 
6+ 
867.9751 867.9767 -1.84 b33 
4+ 
872.4588 872.4600 -1.38 y32 
4+ 
888.6144 888.6139 0.56 y56 
7+ 
892.7423 892.7438 -1.68 b34 
4+ 
894.1483 894.1501 -2.01 y25 
3+ 
900.7293 900.7310 -1.89 y33 
4+ 
916.1373 916.1397 -2.62 b26 
3+ 
924.5028 924.5043 -1.62 b17 
2+ 
925.5049 925.4981 7.35 y34 
4+ 
933.5083 933.5096 -1.39 b35 
4+ 
934.4988 934.4993 -0.54 b8 
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935.0087 935.0101 -1.50 y17
 2+ 
937.1624 937.1643 -2.03 y26
 3+ 
939.8171 939.8188 -1.81 b27 
3+ 
939.9051 939.9044 0.74 y86 
10+ 
946.2234 946.2325 -9.62 y96 
11+ 
951.2486 951.2504 -1.89 y35 
4+ 
953.4937 953.4952 -1.57 y8 
958.5174 958.5185 -1.15 y56 6
+ 
970.5278 970.5287 -0.93 y18 
2+ 
974.0371 974.0386 -1.54 b18 
2+ 
976.0161 976.0175 -1.43 y36 
4+ 
977.6881 977.6896 -1.53 y53 
6+ 
998.8684 998.8698 -1.40 y28 
3+ 
1003.8107 1003.8112 -0.50 y64 
7+ 
1006.0459 1006.0472 -1.29 y19 
2+ 
1017.3679 1017.3664 1.47 y111 
12+ 
1031.5516 1031.5540 -2.33 y47 
5+ 
1040.7531 1040.7551 -1.92 y96 
10+ 
1069.1589 1069.1595 -0.56 b48 
5+ 
1086.2483 1086.2490 -0.64 b31 
3+ 
1123.9418 1123.9437 -1.69 b32 
3+ 
1137.3570 1137.3616 -4.04 b41 
4+ 
1146.4904 1146.4902 0.17 b95 
9+ 
1156.2811 1156.2826 -1.30 y96 
9+ 
1164.1489 1164.1551 -5.33 y139 
13+ 
1167.5091 1167.5101 -0.86 y97 
9+ 
1174.1267 1174.1287 -1.70 b42 
4+ 
1189.9874 1189.9893 -1.60 b34 
3+ 
1198.0752 1198.0723 2.42 b99 
9+ 
1202.6268 1202.6290 -1.83 b22 
2+ 
1206.3877 1206.3893 -1.33 b43 
4+ 
1213.5347 1213.5419 -5.93 b111 
10+ 
1216.6616 1216.6635 -1.56 y23 
2+ 
1220.6404 1220.6382 1.80 y111 
10+ 
1227.8349 1227.8260 7.25 b123 
11+ 
1228.1446 1228.1473 -2.20 b44 
4+ 
1244.3418 1244.3437 -1.53 b35 
3+ 
1251.6581 1251.6593 -0.96 y12 
1252.1617 1252.1632 -1.20 b23 
2+ 
1261.0784 1261.0841 -4.52 y139 
12+ 
1264.9121 1264.9145 -1.90 b45 
4+ 
1279.1679 1279.1698 -1.49 b46 
4+ 
1292.6849 1292.6845 0.31 b12 
1307.9242 1307.9266 -1.83 b47 
4+ 
1334.6968 1334.7037 -5.17 b74 
6+ 
1336.1952 1336.1976 -1.80 b48 
4+ 
1357.9525 1357.9556 -2.28 b49 
4+ 
1363.7189 1363.7216 -1.98 b13 
1375.6293 1375.6365 -5.23 y139 
11+ 
1383.2151 1383.2175 -1.74 b50 
4+ 
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Appendix 20. ETD (activation energy 20 ms) fragment ions of Hb Headington globin 
chain in a previously undiagnosed (FAV3) neonatal sample. 
Meas m/z Calc m/z Δ ppm  Fragment  
367.2435 367.2452 -4.63 c3 
565.3440 565.3457 -3.01 c5 
781.4366 781.4398 -4.10 z15
2+
 
789.4470 789.4492 -2.79 y15
2+
 
823.4286 823.4308 -2.67 c7 
839.7847 839.7877 -3.57 z24
3+
 
840.7888 840.7867 2.50 c23
3+
 
896.9743 896.9783 -4.46 z’33
4+
 
926.9979 927.0008 -3.13 z17
2+
 
931.8220 931.8247 -2.90 z26
3+
 
933.0149 933.0176 -2.89 c17
2+
 
951.5229 951.5258 -3.05 c8 
962.5165 962.5193 -2.91 z18
2+
 
970.5257 970.5287 -3.09 y18
2+
 
974.5202 974.5231 -2.98 z27
3+
 
982.5491 982.5518 -2.75 c18
2+
 
983.1293 983.1312 -1.93 z45
5+
 
993.5267 993.5302 -3.52 z28
3+
 
998.0350 998.0379 -2.91 z19
2+
 
998.8670 998.8698 -2.80 y28
3+
 
1042.5498 1042.5530 -3.07 z29
3+
 
1047.8896 1047.8936 -3.82 y29
3+
 
1051.5538 1051.5572 -3.23 z’48
5+
 
1053.5583 1053.5617 -3.23 z39
4+
 
1068.8431 1068.8452 -1.96 z’68
7+
 
1071.1648 1071.1694 -4.29 z49
5+
 
1088.2362 1088.2393 -2.85 z30
3+
 
1089.1037 1089.1075 -3.49 c20
2+
 
1093.5754 1093.5789 -3.20 y30
3+
 
1098.7773 1098.7827 -4.91 z’50
5+
 
1104.8477 1104.8511 -3.08 c40
4+
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1117.5833 1117.5871 -3.40 z’61
6+
 
1124.6078 1124.6110 -2.85 z’42
4+
 
1128.3739 1128.3638 8.95 y42
4+
 
1133.9262 1133.9256 0.53 z31
3+
 
1141.9420 1141.9305 10.07 z62
6+
 
1146.6172 1146.6210 -3.31 c21
2+
 
1146.8156 1146.8169 -1.13 z52
5+
 
1149.5966 1149.6019 -4.61 c+H63
6+
 
1159.1043 1159.1055 -1.04 c+H64
6+
 
1163.3791 1163.3844 -4.56 z43
4+
 
1170.0209 1170.0239 -2.56 z’53
5+
 
1195.6315 1195.6353 -3.18 z’33
3+
 
1200.1409 1200.1515 -8.83 z44
4+
 
1208.7861 1208.7754 8.85 z77
7+
 
1210.6379 1210.6460 -6.69 c43
4+
 
1227.6399 1227.6470 -5.78 z’67
6+
 
1228.9100 1228.9142 -3.42 z’45
4+
 
1259.1742 1259.1780 -3.02 z24
2+
 
1265.4978 1265.4975 0.24 z69
6+
 
1288.5052 1288.5086 -2.64 z’70
6+
 
1292.1225 1292.1172 4.10 z’83
7+
 
1309.0297 1309.0339 -3.21 c+H72
6+
 
1309.7093 1309.7110 -1.30 c12 
1312.0797 1312.0827 -2.29 c+H60
5+
 
1312.9538 1312.9428 8.38 z48
4+
 
1337.4957 1337.5010 -3.96 c61
5+
 
1338.9569 1338.9618 -3.66 z’49
4+
 
1340.4636 1340.4542 7.01 c48
4+
 
1347.6965 1347.7023 -4.30 z74
6+
 
1351.6994 1351.7084 -6.66 c62 
5+
 
1370.3158 1370.3167 -0.66 z’ 62 
5+
 
1379.1164 1379.1202 -2.76 c63 
5+
 
1390.3177 1390.3247 -5.03 z63 
5+
 
1410.0831 1410.0700 9.29 z77 
6+
 
1472.7654 1472.7734 -5.43 z67 
5+
 
1507.1296 1507.1342 -3.05 z83 
6+
 
1529.7792 1529.7840 -3.14 c· 56 
4+
 
1530.1337 1530.1454 -7.65 z’ 84 
6+
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1617.2371 1617.2428 -3.52 z’ 74 
5+
 
1632.3530 1632.3593 -3.86 z’ 30 
2+
 
1671.6155 1671.6244 -5.32 c61 
4+
 
1675.8771 1675.8770 0.06 z’ 61 
4+
 
1691.8865 1691.8826 2.31 z77 
5+
 
1712.6354 1712.6441 -5.08 z’ 62 
4+
 
1716.3929 1716.3968 -2.27 y62 
4+
 
1723.6444 1723.6484 -2.32 c63 
4+
 
1751.9170 1751.9239 -3.94 z’48 
3+
 
1808.5590 1808.5612 -1.22 z’83 
5+
 
1840.9592 1840.9668 -4.13 z’67 
4+
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Appendix 21. CID (normalised collision energy 30%) fragment ions of Hb J -Baltimore 
globin chain in a previously undiagnosed (FAV4) neonatal sample. 
Meas m/z Calc m/z Δ ppm Fragment 
451.2680 451.2663 3.77 b4 
584.2954 584.2940 2.40 y4 
596.3232 596.3220 2.01 b11
2+
 
608.8366 608.8354 1.97 y23
4+
 
655.3327 655.3311 2.44 y5 
677.3632 677.3617 2.21 b6 
682.3655 682.3644 1.61 b13
2+
 
725.4032 725.4017 2.07 y14
2+
 
738.9074 738.9065 1.22 b14
2+
 
768.4162 768.4151 1.43 y6 
789.4506 789.4492 1.77 y15
2+
 
801.1671 801.1689 -2.25 b30
4+
 
806.4051 806.4043 0.99 b7 
811.4455 811.4448 0.86 y23
3+
 
820.4365 820.4360 0.61 y30
4+
 
821.4222 821.4236 -1.70 b22
3+
 
831.9470 831.9461 1.08 b15
2+
 
845.1290 845.1273 2.01 y24
3+
 
854.4459 854.4464 -0.59 b23
3+
 
857.7121 857.7110 1.28 b32
4+
 
859.7967 859.7962 0.58 y47
6+
 
872.4610 872.4600 1.15 y32
4+
 
882.4785 882.4781 0.45 b33
4+
 
907.2457 907.2452 0.55 b34
4+
 
934.5014 934.4993 2.25 b8 
935.0118 935.0101 1.82 y17
2+
 
948.0132 948.0110 2.32 b35
4+
 
951.2525 951.2504 2.21 y35
4+
 
958.5190 958.5185 0.52 y52
6+
 
970.5309 970.5287 2.27 y18
2+
 
976.0194 976.0175 1.95 y36
4+
 
977.6915 977.6896 1.94 y53
6+
 
1017.7052 1017.7010 4.13 y55
6+
 
1025.1970 1025.1992 -2.15 y112
12+
 
1031.5550 1031.5540 0.97 y47
5+
 
1033.8500 1033.8482 1.74 y96
10+
 
1044.0531 1044.0559 -2.68 b38
4+
 
1062.3773 1062.3721 4.89 b58
6+
 
1080.2855 1080.2829 2.41 y139
14+
 
1103.4746 1103.4837 -8.25 y111
11+
 
1148.6092 1148.6083 0.78 y96
9+
 
1149.9727 1149.9832 -9.13 y85
8+
 
1159.8375 1159.8358 1.47 y97
9+
 
1169.5059 1169.5060 -0.09 y98
9+
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1176.3046 1176.3017 2.47 b33
3+
 
1201.1870 1201.1874 -0.33 y101
9+
 
1209.3270 1209.3245 2.07 b34 
3+
 
1213.7315 1213.7313 0.16 y111
10+
 
1216.6661 1216.6635 2.14 y23
2+
 
1220.8900 1220.8907 -0.57 b43
4+
 
1322.4299 1322.4279 1.51 b47
4+
 
1374.6416 1374.6307 7.93 y139
11+
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Appendix 22. CID (normalised collision energy 30%) fragment ions of the normal α -
globin chain in a previously undiagnosed (FAV5) neonatal sample. 
Meas m/z Calc m/z Δ ppm Fragment  
466.2792 466.2772 4.29 y3 
527.7999 527.7982 3.22 y9
2+ 
553.3110 553.3093 3.07 y4 
577.3344 577.3324 3.46 b11
2+ 
583.3104 583.3086 3.09 b6 
612.8532 612.8510 3.59 b12
2+ 
620.8498 620.8484 2.25 y11
2+ 
648.3713 648.3695 2.78 b13
2+ 
654.3588 654.3570 2.75 y5 
677.7101 677.7093 1.18 b20
3+ 
701.3899 701.3884 2.14 b21
3+ 
712.9108 712.9090 2.52 y13
2+ 
720.3958 720.3955 0.42 b22
3+ 
741.4120 741.4092 3.78 b14
2+ 
741.7438 741.7426 1.62 y20
3+ 
759.6620 759.6605 1.97 y28
4+ 
763.4113 763.4097 2.10 b23
3+ 
767.4429 767.4410 2.48 y6 
774.7663 774.7654 1.16 y21
3+ 
786.4451 786.4432 2.42 y14
2+ 
787.9330 787.9315 1.90 y29
4+ 
795.1677 795.1665 1.51 b31
4+ 
817.7661 817.7642 2.32 b24
3+ 
822.1977 822.1962 1.82 y30
4+ 
827.9272 827.9266 0.72 b32
4+ 
830.7971 830.7953 2.17 y23
3+ 
833.9696 833.9674 2.64 b16
2+ 
850.4928 850.4907 2.47 y15
2+ 
860.4530 860.4503 3.14 b26
3+ 
864.4796 864.4779 1.97 y24
3+ 
866.5118 866.5094 2.77 y7 
883.5046 883.5016 3.40 b17
2+ 
213 
 
892.9669 892.9647 2.46 b34
4+ 
903.4673 903.4645 3.10 b27
3+ 
908.0065 908.0042 2.53 y16
2+ 
911.2501 911.2477 2.63 y34
4+ 
912.0140 912.0123 1.86 b18
2+ 
913.5032 913.5007 2.74 y25
3+ 
914.7230 914.7227 0.33 b35
4+ 
926.4966 926.4942 2.59 b9 
927.1463 927.1436 2.91 b28
3+ 
936.0170 936.0148 2.35 y35
4+ 
947.5336 947.5309 2.85 b19
2+ 
956.5174 956.5149 2.61 y26
3+ 
964.5490 964.5462 2.90 y17
2+ 
967.5599 967.5571 2.89 y8 
980.1966 980.1939 2.75 y27
3+ 
992.5604 992.5568 3.63 y37
4+ 
993.8851 993.8832 1.91 b75
8+ 
1008.0652 1008.0622 2.98 y18
2+ 
1012.5478 1012.5449 2.86 y28
3+ 
1016.0634 1016.0603 3.05 b20
2+ 
1018.3096 1018.3091 0.49 y38
4+ 
1021.9686 1021.9661 2.45 y47
5+ 
1025.5657 1025.5626 3.02 b10 
1028.3208 1028.3192 1.56 b47
5+ 
1030.0766 1030.0754 1.16 y56
6+ 
1043.5839 1043.5808 2.97 y19
2+ 
1044.8273 1044.8245 2.68 b69
7+ 
1050.2425 1050.2396 2.76 y29
3+ 
1052.5716 1052.5739 -2.19 y39
4+ 
1054.5923 1054.5891 3.03 y9 
1089.1205 1089.1153 4.77 b1121
1+ 
1091.5765 1091.5722 3.94 y121
12+ 
1094.4403 1094.4387 1.46 y60
6+ 
1095.9289 1095.9259 2.74 y30
3+ 
1099.3966 1099.3957 0.82 b113
11+ 
214 
 
1100.6752 1100.6754 -0.18 y111
11+ 
1102.5806 1102.5880 -6.71 y102
10+ 
1108.9465 1108.9441 2.16 y6
16+ 
1112.1138 1112.1102 3.24 y20
2+ 
1113.4631 1113.4618 1.17 b94
9+ 
1119.6090 1119.6049 3.66 y31
3+ 
1127.7885 1127.7914 -2.57 y62
6+ 
1130.8758 1130.8739 1.68 y42
4+ 
1132.4917 1132.5028 -9.80 y105
10+ 
1135.7258 1135.7226 2.82 b75
7+ 
1140.8752 1140.8760 -0.70 y115
11+ 
1142.0975 1142.0974 0.09 b128
12+ 
1147.5282 1147.5252 2.61 y139
13+ 
1153.6607 1153.6575 2.77 b10 
1153.6607 1153.6575 2.77 y10 
1154.4429 1154.4426 0.26 b76
7+ 
1161.6465 1161.6444 1.81 y21
2+ 
1174.8153 1174.8135 1.53 y65
6+ 
1177.1162 1177.1165 -0.25 b110
10+ 
1184.2223 1184.2202 1.77 b111
10+ 
1194.7493 1194.7473 1.67 b79
7+ 
1209.2370 1209.2345 2.07 b113
10+ 
1218.7960 1218.7940 1.64 b69
6+ 
1219.2968 1219.2945 1.89 b35
3+ 
1234.9987 1234.9959 2.27 y68
6+ 
1240.6929 1240.6896 2.66 y11 
1245.6926 1245.6894 2.57 y23
2+ 
1247.1451 1247.1449 0.16 b71
6+ 
1268.3195 1268.3173 1.73 b36
3+ 
1277.2075 1277.2085 -0.78 y47
4+ 
1296.2165 1296.2132 2.55 y24
2+ 
1307.8007 1307.7953 4.13 b110
9+ 
1311.7302 1311.7267 2.67 y12 
1346.6827 1346.6819 0.59 b76
6+ 
1369.7510 1369.7474 2.63 y25
2+ 
215 
 
1424.8144 1424.8108 2.53 y13 
1434.2723 1434.2687 2.51 y26
2+ 
1518.3176 1518.3137 2.57 y28
2+ 
1571.8832 1571.8793 2.48 y14 
1574.8603 1574.8557 2.92 y29
2+ 
1699.9788 1699.9741 2.76 y15 
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Appendix 23. CID (normalised collision energy 30%) fragment ions of the Hb Phnom 
Penh variant chain in a previously undiagnosed (FAV5) neonatal sample. 
Meas m/z Calc m/z Δ ppm Fragment  
338.1832 338.1823 2.66 y2 
466.2796 466.2772 5.15 y3 
484.2848 484.2822 5.37 y8
2+ 
527.8005 527.7982 4.36 y9
2+ 
553.3115 553.3093 3.98 y4 
577.3349 577.3324 4.33 b11
2+ 
583.3110 583.3086 4.11 b6 
612.8533 612.8510 3.75 b12
2+ 
623.3499 623.3483 2.57 y23
4+ 
648.3719 648.3695 3.70 b13
2+ 
654.3594 654.3570 3.67 y5 
677.7114 677.7093 3.10 b20
3+ 
701.3908 701.3884 3.42 b21
3+ 
711.4071 711.4036 4.92 b7 
712.9121 712.9090 4.35 y13
2+ 
720.3981 720.3955 3.61 b22
3+ 
741.7448 741.7426 2.97 y20
3+ 
763.4118 763.4097 2.75 b23
3+ 
767.4436 767.4410 3.39 y6 
774.7670 774.7654 2.07 y21
3+ 
786.4459 786.4432 3.43 y14
2+ 
787.9338 787.9315 2.92 y29
4+ 
795.1687 795.1665 2.77 b31
4+ 
817.7665 817.7642 2.81 b24
3+ 
827.9294 827.9266 3.38 b32
4+ 
830.7979 830.7953 3.13 y23
3+ 
833.9703 833.9674 3.48 b16
2+ 
836.7739 836.7713 3.11 b25
3+ 
850.4937 850.4907 3.53 y15
2+ 
860.4529 860.4503 3.02 b26
3+ 
864.4810 864.4779 3.59 y24
3+ 
866.5127 866.5094 3.81 y7 
217 
 
868.2277 868.2265 1.38 y32
4+ 
883.5061 883.5016 5.09 b17
2+ 
892.9675 892.9647 3.14 b34
4+ 
902.1746 902.1726 2.22 y25
3+ 
903.4676 903.4645 3.43 b27
3+ 
908.0074 908.0042 3.52 y16
2+ 
912.0147 912.0123 2.63 b18
2+ 
926.4962 926.4942 2.16 b9 
927.1472 927.1436 3.88 b28
3+ 
947.5345 947.5309 3.80 b19
2+ 
951.1994 951.1954 4.21 y26
3+ 
964.2895 964.2858 3.84 y36
4+ 
967.5609 967.5571 3.93 y8 
975.9027 975.9001 2.66 b45
5+ 
977.6489 977.6461 2.86 b64
7+ 
992.5609 992.5568 4.13 y37
4+ 
993.7614 993.7651 -3.72 y83
9+ 
1002.2199 1002.2164 3.49 b94
10+ 
1008.0662 1008.0622 3.97 y18
2+ 
1025.5664 1025.5626 3.71 b10 
1028.3221 1028.3192 2.82 b47
5+ 
1030.0776 1030.0754 2.14 y56
6+ 
1031.1016 1031.0969 4.56 y105
11+ 
1043.5849 1043.5808 3.93 y19
2+ 
1050.2435 1050.2396 3.71 y29
3+ 
1054.5933 1054.5891 3.98 y9 
1099.3990 1099.3957 3.00 b113
11+ 
1102.8551 1102.8577 -2.36 b73
7+ 
1112.1146 1112.1102 3.96 y20
2+ 
1118.8098 1118.8169 -6.35 b85
8+ 
1152.5879 1152.5891 -1.04 b33
3+ 
1153.6619 1153.6575 3.81 b11 
1219.2964 1219.2945 1.56 b35
3+ 
1240.6938 1240.6896 3.39 y11 
1245.6937 1245.6894 3.45 y23
2+ 
218 
 
1247.1460 1247.1449 0.88 b71
6+ 
1268.3203 1268.3173 2.37 b36
3+ 
1296.2178 1296.2132 3.55 y24
2+ 
1298.9215 1298.9176 3.00 y59
5+ 
1305.4803 1305.4768 2.68 y48
4+ 
1311.7313 1311.7267 3.51 y12 
1349.5184 1349.5284 -7.41 y1381
1+ 
1352.7613 1352.7553 4.44 y25
2+ 
1410.7327 1410.7317 0.71 b40
3+ 
1424.8158 1424.8108 3.51 y13 
1426.2903 1426.2895 0.56 y26
2+ 
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Appendix 24. CID and ETD fragment ions of the β -globin chain in a previously 
undiagnosed (FAV6) neonatal sample. 
Meas m/z Calc m/z Δ ppm Fragment 
350.2193 350.2187 1.71 b3 
451.2688 451.2663 5.54 b4 
546.7895 546.7878 3.11 b10
2+ 
565.3450 565.3457 -1.24 c5 
584.2959 584.2940 3.25 y4 
590.8167 590.8147 3.39 y11
2+ 
608.8371 608.8354 2.79 y23
4+ 
626.3355 626.3333 3.51 y12
2+ 
646.8480 646.8459 3.25 b12
2+ 
655.3333 655.3311 3.36 y5 
671.0357 671.0339 2.68 y19
3+ 
675.8699 675.8675 3.55 y13
2+ 
677.3640 677.3617 3.40 b6 
682.3667 682.3644 3.37 b13
2+ 
687.7089 687.7091 -0.29 b19
2+ 
713.7219 713.7201 2.52 y20
3+ 
720.7342 720.7319 3.19 b20
3+ 
725.4039 725.4017 3.03 y14  
738.9088 738.9065 3.11 b14
2+ 
759.0769 759.0742 3.56 b21
3+ 
768.4177 768.4151 3.38 y6 
779.0959 779.0938 2.70 y22
3+ 
781.0182 781.0155 3.46 y36
5+ 
781.4392 781.4398 -0.77 z15 
2+ 
786.1730 786.1713 2.16 y29
4+ 
789.4482 789.4492 -1.27 y15 
2+ 
789.4517 789.4492 3.17 y15
2+ 
802.0907 802.0884 2.87 b22
3+ 
806.4069 806.4043 3.22 b7 
811.4467 811.4448 2.34 y23
3+ 
820.4378 820.4360 2.19 y30
4+ 
831.9486 831.9461 3.01 b15
2+ 
220 
 
835.1136 835.1112 2.87 b23
3+ 
843.2113 843.2096 2.02 b32
4+ 
845.1293 845.1273 2.37 y24
3+ 
859.7982 859.7963 2.21 y47
6+ 
867.9795 867.9767 3.23 b33
4+ 
872.4641 872.4600 4.70 y32
4+ 
892.7463 892.7438 2.80 b34
4+ 
900.7338 900.7310 3.11 y33
4+ 
916.1408 916.1397 1.20 b26
3+ 
924.5068 924.5043 2.70 b17
2+ 
925.5003 925.4981 2.38 y34
4+ 
931.8239 931.8247 -0.86 z26
3+ 
933.0165 933.0176 -1.18 c17
2+ 
933.5120 933.5096 2.57 b35
4+ 
935.0130 935.0101 3.10 y17
2+ 
937.1672 937.1643 3.09 y26
3+ 
939.8212 939.8188 2.55 b27
3+ 
951.2535 951.2504 3.26 y35
4+ 
951.5247 951.5258 -1.16 c8 
953.4981 953.4952 3.04 y8 
958.5194 958.5185 0.94 y52
6+ 
962.5185 962.5193 -0.83 z18
2+ 
970.5274 970.5287 -1.34 y18
2+ 
970.5317 970.5287 3.09 y18
2+ 
974.0418 974.0386 3.29 b18
2+ 
974.5219 974.5231 -1.23 z27
3+ 
976.0200 976.0175 2.56 y36
4+ 
977.5158 977.5135 2.35 b28
3+ 
982.5508 982.5518 -1.02 c18
2+ 
993.5294 993.5302 -0.81 z28
3+ 
998.0369 998.0379 -1.00 z19
2+ 
998.6567 998.6525 4.21 y73
8+ 
998.8694 998.8698 -0.40 y28
3+ 
1003.8171 1003.8112 5.88 y64
7+ 
1006.0506 1006.0472 3.38 y19
2+ 
221 
 
1017.7029 1017.7010 1.87 y55
6+ 
1024.5355 1024.5323 3.12 y9 
1031.5562 1031.5540 2.13 y47
5+ 
1033.8495 1033.8482 1.26 y96
10+ 
1038.5573 1038.5580 -0.48 c9 
1042.5527 1042.5530 -0.29 z29
3+ 
1047.8922 1047.8930 -0.38 y29
3+ 
1062.0669 1062.0670 -0.28 z20
2+ 
1069.1642 1069.1595 4.40 b48
5+ 
1075.4652 1075.4672 -1.86 y100
10+ 
1088.2380 1088.2390 -1.19 z30
3+ 
1089.1049 1089.1080 -2.39 c20
2+ 
1093.5786 1093.5790 -0.27 y30
3+ 
1103.4852 1103.4837 1.36 y111
11+ 
1107.2625 1107.2728 -9.30 y132
13+ 
1108.7294 1108.7243 4.60 y143
14+ 
1111.5999 1111.6010 -1.35 z21
2+ 
1116.8035 1116.8017 1.61 y144
14+ 
1118.3070 1118.3076 -0.54 y112
11+ 
1123.9473 1123.9437 3.20 b32
3+ 
1134.2597 1134.2620 -1.68 z’31
3+ 
1148.6109 1148.6083 2.26 y96
9+ 
1156.9700 1156.9665 3.03 b33
3+ 
1159.8389 1159.8358 2.67 y97
9+ 
1168.1404 1168.1371 2.83 y22
2+ 
1169.5073 1169.5060 1.11 y98
9+ 
1174.1320 1174.1287 2.81 b42
4+ 
1180.6259 1180.6222 3.13 y11 
1185.4210 1185.4197 1.10 b109
10+ 
1189.9929 1189.9893 3.03 b34
3+ 
1190.3878 1190.3979 -8.48 b99 
9+ 
1194.8419 1194.8517 -8.20 y100
9+ 
1195.2989 1195.2990 -0.42 z33
3+ 
1195.6620 1195.6650 -2.34 c34
3+ 
1201.1810 1201.1874 -5.33 y101
9+ 
222 
 
1202.6324 1202.6290 2.83 b22
2+ 
1206.3935 1206.3893 3.48 b43
4+ 
1208.6629 1208.6630 -0.41 c11 
1211.1406 1211.1420 -1.40 c22
2+ 
1213.7300 1213.7313 -1.07 y111
10+ 
1216.6670 1216.6635 2.88 y23
2+ 
1221.5398 1221.5470 -5.89 b123
11+ 
1224.1496 1224.1435 4.98 b135 
12+ 
1228.1501 1228.1473 2.28 b44
4+ 
1230.0284 1230.0376 -7.48 y112
10+ 
1244.3470 1244.3437 2.65 b35
3+ 
1251.6635 1251.6593 3.36 y12 
1252.1667 1252.1632 2.80 b23
2+ 
1259.1778 1259.1780 -0.16 z24
2+ 
1264.9178 1264.9275 -7.67 y46
4+ 
1267.1902 1267.1873 2.29 y24
2+ 
1279.1728 1279.1698 2.35 b46
4+ 
1289.1933 1289.1907 2.02 y47
4+ 
1292.0563 1292.0584 -1.63 y96
8+ 
1307.9299 1307.9266 2.52 b47
4+ 
1309.7096 1309.7110 -1.07 c12 
1313.6757 1313.6886 -9.82 b73
6+ 
1314.1929 1314.1950 -1.37 z’48
4+ 
1336.2015 1336.1976 2.92 b48
4+ 
1338.7051 1338.7100 -3.59 z49
4+ 
1340.7291 1340.7215 5.67 y25
2+ 
1357.9581 1357.9556 1.84 b49
4+ 
1363.7257 1363.7216 3.01 b13 
1383.2212 1383.2175 2.67 b50
4+ 
1397.2328 1397.2340 -0.50 z26
2+ 
1449.7998 1449.7961 2.55 y14 
1476.8095 1476.8057 2.57 b14 
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Appendix 25. CID and ETD fragment ions of the α -globin chain in a previously 
undiagnosed (FAV6) neonatal sample. 
Meas m/z Calc m/z Δ ppm Fragment 
466.2797 466.2772 5.36 y3 
485.3082 485.3082 0.00 c5 
521.7981 521.7982 -0.19 c10
2+ 
527.7999 527.7982 3.22 y9
2+ 
553.3112 553.3093 3.43 y4 
583.3106 583.3086 3.43 b6 
585.8455 585.8457 -0.34 c11
2+ 
600.3350 600.3352 -0.33 c6 
612.8530 612.8510 3.26 b12
2+ 
621.3640 621.3642 -0.32 c12
2+ 
648.3718 648.3695 3.55 b13
2+ 
654.3590 654.3570 3.06 y5 
656.8826 656.8828 -0.30 c13
2+ 
677.7115 677.7114 0.15 b20
3+ 
701.3911 701.3884 3.85 b21
3+ 
707.0635 707.0639 -0.57 c21
3+ 
712.9114 712.9090 3.37 y13
2+ 
720.3969 720.3955 1.94 b22
3+ 
728.4299 728.4301 -0.27 c7 
741.7453 741.7426 3.64 y20
3+ 
749.9225 749.9225 0.00 c14
2+ 
759.6631 759.6605 3.42 y28
4+ 
763.4119 763.4097 2.88 b23
3+ 
767.4432 767.4410 2.87 y6 
769.0851 769.0852 -0.13 c23
3+ 
774.7675 774.7654 2.71 y21
3+ 
778.4332 778.4332 0.00 c15 
2+ 
778.4332 778.4339 -0.90 z14
2+ 
786.4431 786.4432 -0.13 y14
2+ 
786.4462 786.4432 3.81 y14
2+ 
787.9339 787.9315 3.05 y29
4+ 
795.1689 795.1665 3.02 b31
4+ 
224 
 
799.6741 799.6739 0.25 c+H31
4+ 
817.7667 817.7642 3.06 b24
3+ 
822.1983 822.1982 0.12 y30
4+ 
823.4392 823.4397 -0.61 c24
3+ 
827.9295 827.9266 3.50 b32
4+ 
829.4776 829.4778 -0.24 c8 
830.7980 830.7953 3.25 y23
3+ 
833.9703 833.9774 -8.51 b16
2+ 
842.4805 842.4807 -0.24 c16
2+ 
850.4911 850.4907 0.47 z7 
850.4934 850.4907 3.17 y15
2+ 
859.1374 859.1383 -1.05 z24
3+ 
860.4536 860.4503 3.84 b26
3+ 
864.4798 864.4779 2.20 y24
3+ 
866.1258 866.1259 -0.12 c26
3+ 
866.5122 866.5094 3.23 y7 
883.5052 883.5016 4.07 b17
2+ 
892.0148 892.0149 -0.11 c17
2+ 
892.9668 892.9647 2.35 b34
4+ 
897.2215 897.2213 0.22 c34
4+ 
903.2710 903.2701 1.00 c+H42
5+ 
903.4670 903.4645 2.77 b27
3+ 
908.0069 908.0042 2.97 y16
2+ 
908.1609 908.1611 -0.22 z25
3+ 
909.1392 909.1401 -0.99 c27
3+ 
911.2512 911.2477 3.84 y34
4+ 
913.5033 913.5007 2.85 y25
3+ 
914.7247 914.7227 2.19 b35
4+ 
918.6184 918.6136 5.23 b60
7+ 
918.9792 918.9793 -0.11 c35
4+ 
936.0181 936.0148 3.53 y35
4+ 
943.5208 943.5207 0.11 c9 
947.5341 947.5309 3.38 b19
2+ 
956.0441 956.0442 -0.10 c19
2+ 
956.5175 956.5149 2.72 y26
3+ 
225 
 
964.5502 964.5462 4.15 y17
2+ 
966.8305 966.8222 8.58 y62
7+ 
967.5602 967.5571 3.20 y8 
979.3057 979.3054 0.31 c45
5+ 
980.1967 980.1939 2.86 y27
3+ 
992.5588 992.5568 2.01 y37
4+ 
1000.0528 1000.0529 -0.10 z18
2+ 
1005.2718 1005.2715 0.30 c38
4+ 
1008.0614 1008.0622 -0.79 y18
2+ 
1008.0655 1008.0622 3.27 y18
2+ 
1008.7190 1008.7191 -0.10 c46
5+ 
1011.1864 1011.1862 0.20 c56
6+ 
1012.5477 1012.5449 2.77 y28
3+ 
1016.0639 1016.0603 3.54 b20
2+ 
1018.3123 1018.3091 3.14 y38
4+ 
1020.6903 1020.6898 0.49 c57
6+ 
1021.9691 1021.9661 2.94 y47
5+ 
1024.5736 1024.5736 0.00 c20
2+ 
1025.5658 1025.5626 3.12 b10 
1028.3235 1028.3192 4.18 b47
5+ 
1030.0774 1030.0754 1.94 y56
6+ 
1030.5339 1030.5335 0.39 c39
4+ 
1035.5715 1035.5714 0.10 z19
2+ 
1042.5892 1042.5891 0.10 c10  
1043.5343 1043.5330 1.25 c58
6+ 
1043.5843 1043.5808 3.35 y19
2+ 
1045.2344 1045.2359 -1.44 z' 29
3+ 
1045.5286 1045.5298 -1.15 b79
8+ 
1048.5688 1048.5692 -0.38 z39
4+ 
1050.2426 1050.2424 0.19 y29
3+ 
1052.5727 1052.5739 -1.14 y39
4+ 
1053.2021 1053.2038 -1.61 c+H59
6+ 
1054.3407 1054.3413 -0.57 c48
5+ 
1054.5925 1054.5891 3.22 y9 
1060.0921 1060.0922 -0.09 c21
2+ 
226 
 
1062.5563 1062.5572 -0.85 c40
4+ 
1065.5616 1065.5617 -0.09 c31
3+ 
1070.3276 1070.3272 0.37 z40
4+ 
1074.5513 1074.5529 -1.49 c+H60
6+ 
1087.8197 1087.8191 0.55 c41
4+ 
1088.6029 1088.6029 0.00 c22
2+ 
1089.1164 1089.1153 1.01 b112
11+ 
1094.4423 1094.4387 3.29 y60
6+ 
1095.9295 1095.9259 3.28 y30
3+ 
1099.1591 1099.1595 -0.36 c50
5+ 
1099.3986 1099.3957 2.64 b113
11+ 
1100.6758 1100.6754 0.36 y111
11+ 
1102.5823 1102.5880 -5.17 y102
10+ 
1108.9485 1108.9441 3.97 y61
6+ 
1109.2417 1109.2419 -0.18 c32
3+ 
1110.7648 1110.7645 0.27 c+H 51
5+ 
1112.1144 1112.1102 3.78 y20
2+ 
1113.4663 1113.4618 4.04 b94
9+ 
1126.8695 1126.8692 0.27 z42
4+ 
1128.5850 1128.5850 0.00 c42
4+ 
1130.8728 1130.8739 -0.97 y42
4+ 
1132.5100 1132.5028 6.36 y105
10+ 
1135.7265 1135.7226 3.43 b75
7+ 
1137.9442 1137.9444 -0.18 z32
3+ 
1140.8367 1140.8304 5.52 y138
13+ 
1143.4238 1143.4242 -0.35 c+H 64
6+ 
1147.5306 1147.5252 4.71 y139
13+ 
1153.1241 1153.1242 -0.09 c23
2+ 
1154.4465 1154.4426 3.38 b76
7+ 
1158.2641 1158.2647 -0.52 c33
3+ 
1158.8927 1158.8930 -0.26 z43
4+ 
1162.8967 1162.8976 -0.77 y43
4+ 
1170.6840 1170.6841 -0.09 c11 
1175.3709 1175.3681 2.38 y131
12+ 
1175.6386 1175.6390 -0.34 z33
3+ 
227 
 
1177.1170 1177.1165 0.42 b110
10+ 
1182.8570 1182.8582 -1.01 z' 54
5+ 
1184.2274 1184.2202 6.08 b111
10+ 
1189.8667 1189.8661 0.50 c+H44
4+ 
1194.7502 1194.7473 2.43 b79
7+ 
1195.6588 1195.6601 -1.09 z44
4+ 
1195.9593 1195.9593 0.00 c34
3+ 
1209.2327 1209.2345 -1.49 b113
10+ 
1209.3221 1209.3216 0.41 z34
3+ 
1210.6456 1210.6422 2.81 y111
10+ 
1213.2216 1213.2220 -0.33 c56
5+ 
1218.7900 1218.7940 -3.28 b69
6+ 
1224.9698 1224.9700 -0.16 c35
3+ 
1234.6549 1234.6559 -0.81 c24
2+ 
1240.6929 1240.6896 2.66 y11 
1241.7210 1241.7212 -0.16 c12 
1245.6927 1245.6894 2.65 y23
2+ 
1252.0363 1252.0381 -1.44 c58
5+ 
1267.2525 1267.2568 -3.39 z' 83
7+ 
1268.3202 1268.3173 2.29 b36
3+ 
1274.3544 1274.3505 3.06 y70
6+ 
1277.2086 1277.2058 2.19 y47
4+ 
1296.2164 1296.2132 2.47 y24
2+ 
1301.9573 1301.9578 -0.38 z48
4+ 
1307.7946 1307.7953 -0.54 b110
9+ 
1311.7301 1311.7267 2.59 y12 
1311.9267 1311.9265 0.15 c+H98
8+ 
1315.6942 1315.6883 4.48 b111
9+ 
1317.6745 1317.6748 -0.23 c48
4+ 
1325.0666 1325.0603 4.75 b137
11+ 
1330.5349 1330.5314 2.63 y61
5+ 
1340.0257 1340.0263 -0.45 c38
3+ 
1346.6837 1346.6819 1.34 b76
6+ 
1354.6977 1354.6932 3.32 b27
2+ 
1357.4116 1357.4098 1.33 y38
3+ 
228 
 
1361.7377 1361.7381 -0.29 z25
2+ 
1363.2063 1363.2065 -0.15 c27
2+ 
1368.0360 1368.0333 1.97 b39
3+ 
1369.7509 1369.7474 2.56 y25
2+ 
1387.9615 1387.9529 6.20 c51
4+ 
1393.7063 1393.7040 1.65 b79
6+ 
1397.7564 1397.7565 -0.07 z39
3+ 
1403.0944 1403.0961 -1.21 y39
3+ 
1416.4070 1416.4072 -0.14 c40
3+ 
1424.8141 1424.8108 2.32 y13 
1427.1010 1427.1031 -1.47 z'40
3+ 
1431.7590 1431.7579 0.77 z106
8+ 
1434.2722 1434.2687 2.44 y36
2+ 
1478.3180 1478.3209 -1.96 z' 54
4+ 
1544.8538 1544.8549 -0.71 z43
3+ 
1550.1930 1550.1944 -0.90 y43
3+ 
1564.8079 1564.7958 7.73 c58
4+ 
1566.8460 1566.8463 -0.19 z29
2+ 
1588.7244 1588.7209 2.20 z133
9+ 
1636.1598 1636.1508 5.50 z106
7+ 
1735.9409 1735.9440 -1.79 z'48
3+ 
1836.9481 1836.9514 -1.80 c35
2+ 
 
 
 
 
 
 
 
 
 
 
 
229 
 
Appendix 26. CID and ETD fragment ions of the  Gγ -globin chain in a previously 
undiagnosed (FAV6) neonatal sample. 
Meas m/z Calc m/z  Δ ppm  Fragment 
459.2211 459.2225 -3.05 z3 
558.7497 558.7515 -3.22 b10
2+ 
562.2715 562.2732 -3.02 y4 
615.2915 615.2935 -3.25 b11
2+ 
649.3032 649.3052 -3.08 y5 
665.8152 665.8173 -3.15 b12
2+ 
701.2866 701.2889 -3.28 b6 
705.6861 705.6884 -3.26 b19
3+ 
709.3310 709.3333 -3.24 b13
2+ 
738.7089 738.7112 -3.11 b20
3+ 
739.8730 739.8747 -2.30 y14
2+ 
762.3870 762.3893 -3.02 y6 
765.8730 765.8754 -3.13 b14
2+ 
769.3928 769.3952 -3.12 y21
3+ 
781.7229 781.7254 -3.20 b21
3+ 
800.6442 800.6468 -3.25 b30
4+ 
811.1557 811.1579 -2.71 y29
4+ 
816.3133 816.3159 -3.19 b7 
820.0652 820.0677 -3.05 b22
3+ 
828.9155 828.9178 -2.77 b31
4+ 
833.4237 833.4264 -3.24 y7 
843.7441 843.7467 -3.08 b23
3+ 
845.4267 845.4227 4.73 y30
4+ 
857.1863 857.1889 -3.03 b32
4+ 
858.9124 858.9150 -3.03 b15
2+ 
862.7511 862.7539 -3.25 b24
3+ 
867.4245 867.4283 -4.38 c15
2+ 
867.9483 867.9514 -3.57 y16
2+ 
873.6918 873.6957 -4.46 y31
4+ 
881.7581 881.7610 -3.29 b25
3+ 
881.9532 881.9560 -3.17 b33
4+ 
887.4231 887.4258 -3.04 b16
2+ 
230 
 
891.4502 891.4530 -3.14 y32
4+ 
897.9506 897.9537 -3.45 b48
6+ 
906.7201 906.7231 -3.31 b34
4+ 
917.7312 917.7349 -4.03 y66
8+ 
919.7210 919.7240 -3.26 y33
4+ 
920.4557 920.4585 -3.04 y8 
922.1215 922.1261 -4.99 z25
3+ 
924.7720 924.7752 -3.46 b26
3+ 
927.4633 927.4657 -2.59 y25
3+ 
944.4082 944.4108 -2.75 b8 
947.4857 947.4889 -3.38 b35
4+ 
951.4706 951.4732 -2.73 b17
2+ 
965.1366 965.1403 -3.83 z26
3+ 
966.1831 966.1858 -2.79 y52
6+ 
969.7499 969.7530 -3.20 y35
4+ 
977.7561 977.7595 -3.48 y70
8+ 
980.0719 980.0738 -1.94 y80
9+ 
991.4924 991.4956 -3.23 y9 
992.3272 992.3320 -4.84 z45
5+ 
994.5171 994.5201 -3.02 y36
4+ 
995.5321 995.5358 -3.72 y45
5+ 
1001.0045 1001.0074 -2.90 b18
2+ 
1004.5036 1004.5071 -3.48 y18
2+ 
1009.5163 1009.5207 -4.36 c18
2+ 
1016.7802 1016.7866 -6.29 y73
8+ 
1017.6123 1017.6180 -5.60 y111
12+ 
1022.7882 1022.7911 -2.84 y37
4+ 
1026.8408 1026.8458 -4.87 z28
3+ 
1032.0126 1032.0163 -3.59 z19
2+ 
1032.1814 1032.1853 -3.78 y28
3+ 
1032.1826 1032.1853 -2.62 y28
3+ 
1032.4703 1032.4745 -4.07 c9 
1040.7524 1040.7549 -2.40 y47
5+ 
1048.6934 1048.6960 -2.48 y66
7+ 
1072.0609 1072.0643 -3.17 z39
4+ 
231 
 
1075.8641 1075.8686 -4.18 z29
3+ 
1077.3396 1077.3430 -3.16 b48
5+ 
1079.6505 1079.6590 -7.87 b99
10+ 
1081.2042 1081.2081 -3.61 y29
3+ 
1082.4390 1082.4365 2.31 b80
8+ 
1086.3124 1086.3196 -6.63 z40
4+ 
1090.3207 1090.3243 -3.30 y40
4+ 
1098.6466 1098.6565 -9.01 y131
13+ 
1104.8847 1104.8880 -2.99 b31
3+ 
1110.0357 1110.0372 -1.35 y111
11+ 
1114.5860 1114.5906 -4.13 z41
4+ 
1121.5507 1121.5549 -3.74 z30
3+ 
1122.4368 1122.4270 8.73 y123
12+ 
1129.5839 1129.5883 -3.90 z61
6+ 
1139.6053 1139.6062 -0.79 z83
8+ 
1142.5782 1142.5827 -3.94 b32
3+ 
1147.4142 1147.4198 -4.88 c+H63 
6+ 
1148.6804 1148.6859 -4.79 y126
12+ 
1154.1005 1154.0997 0.69 z62
6+ 
1156.2134 1156.2193 -5.10 z52
5+ 
1156.9200 1156.9233 -2.85 c·64
6+ 
1159.2186 1159.2215 -2.50 y52 
5+ 
1159.2448 1159.2496 -4.14 z31
3+ 
1169.5120 1169.5122 -0.17 y97
9+ 
1170.9460 1170.9410 4.27 z63
6+ 
1174.8799 1174.8854 -4.68 z43
4+ 
1175.6011 1175.6055 -3.74 b33
3+ 
1178.8860 1178.8901 -3.48 y43
4+ 
1179.1788 1179.1825 -3.14 y98
9+ 
1180.5929 1180.5977 -4.07 c21
2+ 
1183.1108 1183.1143 -2.96 y86
8+ 
1188.1064 1188.1080 -1.35 b42
4+ 
1199.5144 1199.5092 4.34 b99
9+ 
1208.6241 1208.6283 -3.48 b34
3+ 
1211.6476 1211.6576 -8.25 z44
4+ 
232 
 
1216.8607 1216.8647 -3.29 b43
4+ 
1220.9337 1220.9402 -5.32 y111
10+ 
1221.1165 1221.1213 -3.93 c43
4+ 
1225.9683 1225.9629 4.40 y33
3+ 
1229.5933 1229.5979 -3.74 b22
2+ 
1236.9346 1236.9264 6.63 b80
7+ 
1238.1054 1238.1112 -4.68 c22
2+ 
1238.6193 1238.6227 -2.74 b44
4+ 
1240.1588 1240.1632 -3.55 z45
4+ 
1242.4822 1242.4820 0.16 y67
6+ 
1262.9788 1262.9828 -3.17 b35
3+ 
1266.6327 1266.6368 -3.24 y23
2+ 
1272.4184 1272.4239 -4.32 z46
4+ 
1273.6221 1273.6297 -5.97 c23
2+ 
1275.3875 1275.3898 -1.80 b45
4+ 
1289.6403 1289.6452 -3.80 b46
4+ 
1292.6629 1292.6682 -4.10 y35
3+ 
1300.6893 1300.6918 -1.92 y47
4+ 
1302.2606 1302.2632 -2.00 z83
7+ 
1303.3439 1303.3436 0.23 y70 
6+ 
1309.4570 1309.4640 -5.35 c+H60 
5+ 
1317.4054 1317.4040 1.06 c85 
7+ 
1318.1503 1318.1559 -4.25 b47
4+ 
1325.4372 1325.4438 -4.98 z48 
4+ 
1325.6866 1325.6910 -3.32 y36
3+ 
1335.0771 1335.0830 -4.42 c+H61 
5+ 
1341.2935 1341.2986 -3.80 z’60 
5+ 
1344.2918 1344.3008 -6.69 y60 
5+ 
1346.4234 1346.4269 -2.60 b48
4+ 
1347.6480 1347.6539 -4.38 c12  
1349.0844 1349.0898 -4.00 c62 
5+ 
1350.4564 1350.4629 -4.81 z’49 
4+ 
1354.2113 1354.2156 -3.18 y49
4+ 
1355.4970 1355.5060 -6.64 z' 61
5+ 
1363.3811 1363.3857 -3.37 y37
3+ 
233 
 
1376.4955 1376.5016 -4.43 c63
5+ 
1404.9173 1404.9277 -7.40 z63
5+ 
1426.7360 1426.7468 -7.57 c+H79
6+ 
1429.0774 1429.0833 -4.13 z39
3+ 
1434.4190 1434.4228 -2.65 y39
3+ 
1487.5829 1487.5732 6.52 z67
5+ 
1490.7643 1490.7769 -8.45 y67
5+ 
1490.9488 1490.9563 -5.03 y81
6+ 
1521.7979 1521.8090 -7.29 y83
6+ 
1523.4718 1523.4798 -5.25 z42
3+ 
1527.0099 1527.0135 -2.36 c+H56
4+ 
1536.8038 1536.8035 0.20 c85
6+ 
1553.8196 1553.8219 -1.48 z85
6+ 
1563.8011 1563.8109 -6.27 y70
5+ 
1566.1697 1566.1781 -5.36 z43
3+ 
1571.5126 1571.5177 -3.25 y43
3+ 
1576.8145 1576.8134 0.70 C+H101 
7+ 
1627.8185 1627.8160 1.54 c43
3+ 
1653.5431 1653.5412 1.15 z’45
3+ 
1658.5509 1658.5548 -2.35 y45
3+ 
1668.5962 1668.6020 -3.48 c+H61
4+ 
1686.3580 1686.3613 -1.96 c+H62 
4+ 
1697.8943 1697.8835 6.36 y61 
4+ 
1720.6194 1720.6294 -5.81 C+H63
4+ 
1756.1549 1756.1598 -2.79 z’63
4+ 
1822.9666 1822.9672 -0.33 z’83
5+ 
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Appendix 27. CID and ETD fragment ions of the  Aγ -globin chain in a previously 
undiagnosed (FAV6) neonatal sample. 
 
Meas m/z Calc m/z  Δ ppm  Fragment 
459.2211 459.2225 -3.05 z3 
558.7497 558.7515 -3.22 b10
2+ 
562.2715 562.2732 -3.02 y4 
615.2915 615.2935 -3.25 b11
2+ 
649.3032 649.3052 -3.08 y5 
665.8152 665.8173 -3.15 b12
2+ 
701.2866 701.2889 -3.28 b6 
705.6861 705.6884 -3.26 b19
3+ 
709.3310 709.3333 -3.24 b13
2+ 
738.7089 738.7112 -3.11 b20
3+ 
762.3870 762.3893 -3.02 y6 
765.8730 765.8754 -3.13 b14
2+ 
781.7229 781.7254 -3.20 b21
3+ 
800.6442 800.6468 -3.25 b30
4+ 
816.3133 816.3159 -3.19 b7 
820.0652 820.0677 -3.05 b22
3+ 
828.9155 828.9178 -2.77 b31
4+ 
833.4237 833.4264 -3.24 y7 
843.7441 843.7467 -3.08 b23
3+ 
849.4302 849.4322 -2.35 y23
3+ 
857.1863 857.1889 -3.03 b32
4+ 
858.9124 858.9150 -3.03 b15
2+ 
862.7511 862.7539 -3.25 b24
3+ 
867.4245 867.4283 -4.38 c15
2+ 
881.7581 881.7610 -3.29 b25
3+ 
881.9532 881.9560 -3.17 b33
4+ 
887.4231 887.4258 -3.04 b16
2+ 
897.9506 897.9537 -3.45 b48
6+ 
906.7201 906.7231 -3.31 b34
4+ 
235 
 
919.2262 919.2232 3.26 z33
4+ 
920.4557 920.4585 -3.04 y8 
923.2260 923.2279 -2.06 y33
4+ 
924.7720 924.7752 -3.46 b26
3+ 
932.1366 932.1376 -1.07 y25
3+ 
944.4082 944.4108 -2.75 b8 
947.4857 947.4889 -3.38 b35
4+ 
951.4706 951.4732 -2.73 b17
2+ 
973.2545 973.2569 -2.47 y35
4+ 
979.5071 979.5115 -4.49 y70
8+ 
991.4924 991.4956 -3.23 y9 
995.3303 995.3367 -6.43 z’ 45
5+ 
998.0214 998.0240 -2.61 y36
4+ 
1001.0045 1001.0074 -2.90 b18
2+ 
1009.5163 1009.5207 -4.36 c18
2+ 
1032.4703 1032.4745 -4.07 c9 
1043.5557 1043.5580 -2.20 y47
5+ 
1050.6944 1050.6983 -3.71 y66
7+ 
1077.3396 1077.3430 -3.16 b48
5+ 
1079.6505 1079.6590 -7.87 b99
10+ 
1080.5361 1080.5405 -4.07 z29
3+ 
1082.4390 1082.4365 2.31 b80
8+ 
1099.7307 1099.7346 -3.55 y131
13+ 
1104.8847 1104.8880 -2.99 b31
3+ 
1111.3095 1111.3113 -1.62 y111
11+ 
1114.0465 1114.0484 -1.71 y132
13+ 
1123.5937 1123.5950 -1.16 y123
12+ 
1142.5782 1142.5827 -3.94 b323+ 
1147.4142 1147.4198 -4.88 c+H63
6+ 
1156.9200 1156.9233 -2.85 c+H64
6+ 
1175.6011 1175.6055 -3.74 b33
3+ 
1178.3837 1178.3893 -4.75 z43
4+ 
1180.5929 1180.5977 -4.07 c21
2+ 
1188.1064 1188.1080 -1.35 b42
4+ 
1199.5144 1199.5092 4.34 b99
9+ 
236 
 
1208.6241 1208.6283 -3.48 b34
3+ 
1216.8607 1216.8647 -3.29 b43
4+ 
1221.1165 1221.1213 -3.93 c43
4+ 
1225.2998 1225.2952 3.75 z33
3+ 
1229.5933 1229.5979 -3.74 b22
2+ 
1236.9346 1236.9264 6.63 b80
7+ 
1238.1054 1238.1112 -4.68 c22
2+ 
1238.6193 1238.6227 -2.74 b44
4+ 
1262.9788 1262.9828 -3.17 b35
3+ 
1273.6221 1273.6297 -5.97 c23
2+ 
1275.3875 1275.3898 -1.80 b45
4+ 
1289.6403 1289.6452 -3.80 b46
4+ 
1309.4570 1309.4640 -5.35 c+H60
5+ 
1317.4054 1317.4040 1.06 c85
7+ 
1318.1503 1318.1559 -4.25 b47
4+ 
1335.0771 1335.0830 -4.42 c+H61
5+ 
1346.4234 1346.4269 -2.60 b48
4+ 
1347.6480 1347.6539 -4.38 c12  
1349.0844 1349.0898 -4.00 c62
5+ 
1354.7148 1354.7148 0.00 z49
4+ 
1376.4955 1376.5016 -4.43 c63
5+ 
1426.7360 1426.7468 -7.57 c+H79
6+ 
1527.0099 1527.0135 -2.36 c+H56
4+ 
1536.8038 1536.8035 0.20 c85
6+ 
1576.8145 1576.8134 0.70 c+H101
7+ 
1627.8185 1627.8160 1.54 c43
3+ 
1668.5962 1668.6020 -3.48 c+H61
4+ 
1686.3580 1686.3613 -1.96 c+H62
4+ 
1720.6194 1720.6294 -5.81 c+H63
4+ 
 
 
 
